癌抗原125在卵巢癌早期的表达诊断方法
摘要
目的：在过去20年,多种肿瘤标志物在临床的广泛应用使肿瘤的诊断和治疗取得了很大的进展,尤其是在指导卵巢癌的临床治疗和早期预防方面具有重要的意义。近3年,随着实验室基础设施的改善和诊断方法的进步,通过比较各种早期诊断卵巢癌的诊疗方法的数据发现对CA125系列标记物检测的需求明显增加。本论文回顾性研究的目的是评估单独应用生物标志物癌抗原CA125准确、早期的发现中国及几内亚早期卵巢癌患者。
方法：选择2005年3月1日-09年12月1日在中国吉林省长春市吉林大学白求恩医学部第二医院和西非几内亚科纳克里纳赛尔大学中央民族医院确诊为早期卵巢癌(Ⅰ-Ⅱ期)的患者度185例。应用生化ELISA技术,一种高分子量的糖蛋白,应用CA125试剂盒测定对照组和早期卵巢癌患者血清及手术切除标本中CA125值并对数据进行分析。我们应用酶联免疫吸附试验可以高效率的检测早期卵巢癌(Ⅰ-Ⅱ)患者外周血中CA125的水平。据文献报道检测早期卵巢癌患者外周血中CA125的水平已成为一个较优越的方法。统计分析方法：用SPSS15.0计算统计分析数据,评估患者的平均年龄(平均值±标准差)。P<0.05代表差异显著。本项研究围绕与CA125表达相关的关键因素展开,从而确定并规范诊断早期卵巢癌CA125的标准值。通过对早期卵巢癌患者外周血游离DNA的定性研究,探索可用于早期诊断、监测治疗卵巢癌的有效新方法。CA125被用于作为一种癌抗原,通过分析患者外周血肿瘤相关基因的表达以明确早期卵巢癌的诊断。
结果：
对无任何症状的早期卵巢癌患者,通过评估反应性抗原特异性的外周血CA125的值可有效诊断卵巢癌。检测外周血中卵巢细胞受抗原特异性早期反应产生的CA125可代表早期卵巢癌细胞内源性CA125的表达水平。本项研究证实在无症状的早期卵巢癌患者,卵巢癌细胞可引起CA125特异性地升高,从而可以进一步研究抗卵巢癌Ⅰ期和Ⅱ期的潜在抗体。因此,检测卵巢癌患者外周血中癌抗原CA125的表达可作为一个有前途的战略。有效的早期诊断无疑可以降低卵巢癌的死亡率,如果卵巢癌在出现临床表现多年前即被发现,如果对早期病变的有效诊断的准确率达80%或更高,则卵巢癌的死亡率将会减少一半。在227名早期卵巢癌患者中163名患者外周血中CA125表达呈阳性(>35 U/ml),二者相比其CA125的表达有差异(p<0.05)(患者年龄范围为18-77岁,中位数为49.89±14.96岁)。依据FIGO不同临床分期的患者CA125的表达水平是不同的。
A-依据FIGO分期确定肿瘤分期：
146例ⅡB期患者中64.31%的患者CA125表达呈阳性,其CA125的水平明显高于ⅠC和ⅡC的12例患者,CA125的表达与肿瘤的期别存在相关性。
IB-IIB IC-IIB相比,P=4.375E-05,#IIC与IC-IIB相比P=0.013
IB-IIB*与ⅠA相比,P=0.496,#IIC与ⅠA相比,P=0.431
ⅠB～ⅡB与ⅠC-ⅡB相比,P=4.375E-05,#ⅡC与ⅠC-ⅡB相比,P=0.013,其差别有统计学意义
Ⅰ期卵巢癌患者中22例CA125表达的水平升高,Ⅱ期卵巢癌患者中99例CA125表达水平升高,二者相比,Ⅱ期卵巢癌CA125表达的阳性率(11.95%)明显低于Ⅱ期卵巢癌阳性率(53.80%)
B-早期卵巢癌和对照组
检测227正常对照组,185例早期卵巢癌患者。其中185例早期卵巢患者中163例CA125的表达呈阳性,163例患者的血CA125呈高表达(>35 U/m1),12例CA125的表达呈阴性。163例早期卵巢癌患者与227例对照组相比,CA125的表达差异显著(P<0.05)。
肿瘤>4cm的卵巢癌患者的外周血中肿瘤生物标志物CA-125的水平高于肿瘤<4cm的卵巢癌患者,但细胞浆内的CA125的水平与肿瘤的大小无显著关系。(0.019,P<0.05)。
C CA125蛋白与早期卵巢癌患者临床病理特征的相关性。
对于通过分析CA125表达阳性的卵巢癌患者,发现家庭妇女的卵巢癌患者的进展速度低于城市妇女。
卵巢癌与其他肿瘤相比较,72.88%为单侧肿瘤,27.11%为双侧肿瘤。
CA125表达水平与职业、年龄和教育水平无显著的统计学差异。
18岁后结婚的患者的CA125表达阳性率(59.07%),分别要高于38-57岁结婚(57.62%)或18岁以前结婚的妇女(6.77%)。通过比较分析发现67.79%的已婚女性及76.27%的多产妇,CA125的表达也无显著差异。
D-早期病理诊断的多样性
卵巢癌患者CA125的表达比畸胎瘤,囊腺瘤,子宫内膜腺癌和非卵巢腺癌要高。
进一步分析我们过去5年的研究的肿瘤类型的数据发现,5年内子宫内膜癌共14例(6.16%),2005-2007年6例(占42.85%).2008-2009年8例(占57.14%)。
透明细胞癌4例,卵巢囊腺癌40例,浆液性卵巢癌26例,粘液性卵巢癌13例,卵巢布伦纳肿瘤和交界性卵巢肿瘤12例,卵巢腺癌5例,癌性腹水29例,卵巢良性畸胎瘤41例,卵巢恶性畸胎瘤20例,混合型25例。CA125表达水平在各肿瘤间表达无明显差异。
2005年的病例数量(25.06%)低于2007年的病例数量(37.62%),最近3年收集病例157例。
所有病例中,其中144例手术术后病理回报卵巢癌102例,不明来源的腺癌3例,良性卵巢肿瘤28例,子宫肌瘤8例,3例无异常。
应用ELISA正态分布曲线区分正常组织和癌变组织样本的敏感性和特异性分别达到81.49%、71.80%。此外,通过敏感性和特异性的获得,从而可以区分卵巢癌的高危人群或低危人群。本次博士论文的结果：可考虑应用CA125的酶联免疫吸附试验作为一种发现早期卵巢癌患者的战略,从而降低妇女的癌症死亡率。
结论：
卵巢是盆腔内一个很小的女性生殖器官。卵巢通过分泌激素支持女性生殖系统。早期诊断卵巢癌可降低中晚期卵巢癌的高死亡率。早期卵巢癌患者的外周血中CA125呈刺激性的高表达。这个系统的功能能力需要进一步检测方能考虑临床的监测使用。
BACKGROUND:Consultant gynecologic oncologists ELISA laboratory from the regional Register Cancer Center assisted community gynecologists’CA 125 test after diagnosis method for early ovarian cancer when they were invited. For this report, the study evaluated the performance CA125 effects of early stage on diagnosis outcome METHODS: The hospital files from 227 diagnosed for epithelial ovarian cancer between 2005-2009 of ConakryJilin2, ChinoGuineans, Africasia were abstracted. The diagnosis results were analyzed 4 for weak reaction ELISA; 154 for moderate; 27 for strong at the patients according to the clinicians examination by ELISA for diagnosis and SSP 15.00, Epi-Info6 analyses with univariate and multivariate Cox regression. RESULTS:Method was performed on 178 Bethune (BN) patients, and 7 Conakry (CY). ELISA Bethune followed diagnostically guidelines more strictly compared with Conakry,8CY(18.60%) vs.37BN(20.10%);[P=0.01]ⅠA-ⅠB stage; 8CY(18.20% vs. 30 BN(16.30%); [P=0.003]ⅡA-ⅡB stage,within 27 CY(62.79%) vs. 117 BN(63.58%); [P=0.02]ⅠC～ⅡC stage. Patients tumor were stratified according to early stageⅠwith 5-year overall survival rate was 96% versus 80%; (P=0.03) for patients disease and 76% versus 60%, (P=0.02) for stageⅡwho underwent peripheral blood ELISA CA125 Bethune and Conakry diagnosis. The hazards ratio was 0.79 (95% confidence interval [95%CI],0.61-1.03; adjusted for patient age, stage, type of hospital, when patients age 77 years were excluded, the hazards ratio fell to 0.71 (95% CI,0.54-0.94) in multivariate analysis. CONCLUSIONS:An early diagnosis ovarian cancers by ELISA CA125 occurred more often according to laboratory guidelines, tumor removal more often was complete, and survival improved.
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Jilin University Medical Center Normal Clinical, Bethune, The ChinoGuineans
CD 10183, ID 9200873101
Objective
In the past 20 years the diagnosis have made a great effort a variety of tumor makers in clinical widely used. The guide clinical laboratory with early prevention has effective important ovarian cancer significance. The recent past 3 years showing an improvement of infrastructure and methods of diagnosis that there was an increased demand on CA125 assay over the past 5-years, particularly in the last 3 years compared of data variety early diagnosis method clinic of patients of early ovarian cancer. The retrospective study was designed performance as assessed by the area under the receiver biomarker cancer antigen CA125 alone of panel to correctly identify women significantly greater and performance with early ovarian cancer chinoguineans.
Methods
The biochemical ELISA technique, a high molecular weight glycoprotein, was measured in sera from patients with the most common cause of cancer death among gynecologic tumors stages (ⅠandⅡ) in the benign worldwide. For biomarker panel Bethunedonka (BD) in surgical resection specimens and control group, blood sample with early ovarian cancer clinical data underwent respective examination monoclonal CA-125 albumins with ovarian cancer diagnosed kit blood from March 2005 January 1 to 2009 December 31, the Second Jilin hospital, Clinical Bethune of Medical Science (BN) of International Exchange Center Jilin University, Changchun, Jilin, China and Registered Cancer Center, National Hospitals Donka, Gamal Abdel Nasser University, Conakry(CY), West Africa. Guinea.
The ELISA data by In Vitro (protocol No.1820/ub90504A) kit sensitivity color reagent were purchased from a new biological Technology Co., Ltd, United States, and Alpha Diagnostic Intl.
We observed high CA125 efficiencies in the early ovarian cancer (stageⅠ-Ⅱ) and in ELISA using low peripheral blood concentrations with the absence of significant cell viability impairment. Early ovarian cancer has evolved as a superior method for CA125 into peripheral blood cells, CA125 was expressed in 4 for weak reaction ELISA; 154 for moderate; and 27 for strong at the patients as reported in the literature.
The expressing verified the results with the Gene Bank expression database analyzed cancer cells instability with this ELISA type, such as relevance of ovarian cancer stage I-II.
Statistical analysis Methods:Two independent statisticians from program Epi-Info and SPSS15.0 calculate statistic analyzed the data; the age average (mean±SE) of patients will be evaluated. Significant difference was that p<0.05 which represented all probability values lower than 0.05. The study was performed encompassing the critical issues associated with expression efficiency, to standardize a CA125 protocol for use in early ovarian cancer ELISA schedules. Through the peripheral blood of patients with early ovarian cancer free DNA for qualitative research to explore new treatment can be used early diagnosis stage and efficacy of the method of monitoring. CA125 was used as an antigen cancer to optimize peripheral blood by early ovarian cells by diagnosis the expression of the reporter tumor gene analysis for confirmation of the optimized loading parameters.
Results
The efficiency of this delivery system was assessed using CA125 peripheral blood in stimulating antigen specific peripheral blood cell responses in early ovarian stage of healthy individuals. The peripheral blood + antigen specific early ovarian cells responses were generated recognizing CA125 peripheral blood plasma and also early ovarian cancer cell lines endogenously expressing CA125. This study has identified CA125 specific early ovarian cells responses in healthy patients, allowing further investigation into the potential for its use as a stage I and II in ovarian cancer ELISA. Furthermore, the use of antigen cancer CA125 expressed with peripheral blood ovaries is a promising strategy for the delivery of CA125in the generation of antigen-specific early ovarian cell responses.
Early diagnostic efficiency are undoubtedly the major priorities for achieving long-term reduction of mortality due to ovarian cancer the hypothesis that early ovarian cancer may be detectable up to many years prior clinical presentation and that if effective diagnosis for early stage disease were achieved with an accuracy of 80% or more, mortality would be halved. The positivity of serum concentrations of CA125 expression are elevated (i.e.>35 U/ml) in 163 blood of patients with early stage disease. The CA125 expressions in patients with varied FIGO clinical stage were different. The data case cohort (overall and by disease stage) median age (range) of the (n=227) was 49.89(18-77) years (mean±SE,49.89±14.96) of age on plasma biomarker concentration identified (Spearman's rank correlation,0.0004. p< 0.05).
A- Tumor type was identified and FIGO clinical stage by FIGO nomenclature Rio de Janeiro 1998, ACS Cancer Facts & Figures,2007 presented of early stage cohorts:
⊥The CA125 expressions in patients with 146 cases (64.31%) IIB stage disease was much highest than in patients both with 12 (<35 U/ml) IC～IIC positive, the CA125 expression correlated the types, were significantly of IB to IIB, (0.496. p<0.05); and IIC (0.431,p<0.05).
⊥IB-IIB compared to IC-IIB, P= 4.375E-05,# IIC compared to IC-IIB, P= 0,013
⊥IB-IIB* compared to IA, P= 0,496,# IIC compared to IA, P= 0,431
Patient's commonly situation of early ovarian cancer, the significance difference was *IB～IIB compared to IC-IIB, P= 4.375E-05,# IIC compared to IC-IIB, P= 0,013.
⊥The CA-125 expressions elevated (i.e.□35 U/ml) in 22 cases (11.95%) in patients with I stage, was lowest than in 99(53.80%) of II stage.
B-The group Controls and early ovarian cancer
⊥In biomarker (n= 185{43.59±13.12} Cases) and (n=227{49.89±14.96}, Cases). The positives (n=175{40.87±11.48}, group compared falsies positives (n=6{27.09±10.14}). The significant differences biomarker plasma concentrations were significantly greater within 154(4CY+150BN) with 38.60±15.12 average (0.44, p< 0.05) moderate,27(1CY+26BN), 35.08±10.08 for strong,4 (2 CY and 2 BN)= 17.03±5.08 for weak reaction at patients and early ovarian cancer positively of date in Clinical patients 224(0.0003, p<0.05) of CA125 alone.
⊥High levels (<35 U/ ml) were found in 4 cases of 227 patients with active ovarian cancer but in 181 (79.73 %) Bethunedonka (BD) patients who had positive of cases.
⊥The tumor size on biomarker CA-125 plasma concentration was highly than in cells tumor>2 cm (177.24%) i.e 97.62% of the ovarian cells tumor<2 cm, plasma concentration was no significantly with tumor size, (0.019,p<0.05)
⊥Anatomical seat 18-37 ages were usually much affected,63 cases i.e.7 cases tumors associated, (0.299, p<0.05). Histological diagnosis by age and anatomical areas (0.299, p<0.05) compared to anatomical areas by age (0.0006, P<0.05).
C- Correlation between CA-125 protein and clinicopathological features of the patients of early ovarian cancer.
⊥The housewives are the most affected layer less than urban women to increase with processing,62.71%, with 142.37% of cases respectively. Compared with ovarian tumors unilateral or bilateral with other tumor,72.88%,27.11% of the cases registered. There were no statistical significantly difference correlates in profession (0.032, p<0.05) and age> 58 old (0,286, p<0.05) compared to education level (0.009, p< 0.05) with CA125A cancer antigen positively. CA125 positive expressing was seen in 17 of patients who get married before 18 old and 146(78.91%) after 18 years old; high than the age group 38 to 57 57.62%, and the age group below 18 years represents 6.77% respectively. Compared to married,67.79% and multiparous,76.27%patients. The CA125 expression were also no statistical significantly difference in
the parity (0.073, p<0.05), complaints (p=0.091, p<0.05) and in age marriage (>18 old years,0.106,p<0.05) for cohorts.
D-According to the variety histopathological diagnosis clinic in early stage
4-CA125 was expressing much than the teratoma (417.62%) with cystadenocarcinome, endometrial adenocarcinoma, and non ovarian adenocarcinomas.
4 In five (5) past years, the data in our study were further analyzed with types and detected in 14(6.16%) cases with endometrioid carcinoma with 5-year relative diagnosis estimates increasing from 6(42.85%) in 2005-2007 to 8(57.14%) in 2008-2009.
⊥We in 4(2.12%) clear cell carcinoma were diagnosed. The significant difference was in 2005, (0.03, P<0.05) and 2007, (0.02 p<0.05) diagnosis. In cystadenocarcinoma (n=40), serous,(n=26), mucinous(n=13), Brenner tumor and borderline(n=12), Adenocarcinoma(n 5), Leiomyoma et ascite carcinomatous(n =29). Cysts and teratoma tumors(n = 41) with carcinoma(n = 20), mixed type (mixed, n = 25). Tumor typing was no significantly with CA125.
⊥The greatest frequency was observed in 2005 which is lower than that in 2007 diagnosis 25.06% vs. (37.62%), respectively. Almost,157(145.92%) cases were detected in the recent past 3 years.
⊥Of those patients,144 cases underwent surgical procedures.5 had ovarian cancers,3 had adenocarcinoma of unknown origin,28 had benign tumors,8 had fibroids, and 3 had no abnormalities.
Using ELISA normal distribution statue to classify the measurements a sensitivity of 81.49 % and 71.80% specificity was achieved when classifying normal and cancerous samples. Also, a sensitivity of specificity was obtained when classifying patients as either being in a high risk group or low risk group of developing ovarian cancer. The results gained from this PhD thesis should be taken into consideration when designing future CA125 ELISA strategies, to combat one of the leading causes of cancer mortality in women, early ovarian cancer.
Conclusion
The ovaries are small female reproductive organs that reside in the pelvis. The ovary makes female hormones reproduction system. Diagnosis of disease in early stages can reduce the high mortality rate of ovarian cancer and treat of disease in advanced stages. CA125 is not a novel strategy to express peripheral blood and a strong expression simultaneously in ovaries cells earlier. The functional capacity of this system requires further monitoring before it can be considered for investigation clinical use.
方法：选择2005年3月1日-09年12月1日在中国吉林省长春市吉林大学白求恩医学部第二医院和西非几内亚科纳克里纳赛尔大学中央民族医院确诊为早期卵巢癌(Ⅰ-Ⅱ期)的患者度185例。应用生化ELISA技术,一种高分子量的糖蛋白,应用CA125试剂盒测定对照组和早期卵巢癌患者血清及手术切除标本中CA125值并对数据进行分析。我们应用酶联免疫吸附试验可以高效率的检测早期卵巢癌(Ⅰ-Ⅱ)患者外周血中CA125的水平。据文献报道检测早期卵巢癌患者外周血中CA125的水平已成为一个较优越的方法。统计分析方法：用SPSS15.0计算统计分析数据,评估患者的平均年龄(平均值±标准差)。P<0.05代表差异显著。本项研究围绕与CA125表达相关的关键因素展开,从而确定并规范诊断早期卵巢癌CA125的标准值。通过对早期卵巢癌患者外周血游离DNA的定性研究,探索可用于早期诊断、监测治疗卵巢癌的有效新方法。CA125被用于作为一种癌抗原,通过分析患者外周血肿瘤相关基因的表达以明确早期卵巢癌的诊断。
结果：
对无任何症状的早期卵巢癌患者,通过评估反应性抗原特异性的外周血CA125的值可有效诊断卵巢癌。检测外周血中卵巢细胞受抗原特异性早期反应产生的CA125可代表早期卵巢癌细胞内源性CA125的表达水平。本项研究证实在无症状的早期卵巢癌患者,卵巢癌细胞可引起CA125特异性地升高,从而可以进一步研究抗卵巢癌Ⅰ期和Ⅱ期的潜在抗体。因此,检测卵巢癌患者外周血中癌抗原CA125的表达可作为一个有前途的战略。有效的早期诊断无疑可以降低卵巢癌的死亡率,如果卵巢癌在出现临床表现多年前即被发现,如果对早期病变的有效诊断的准确率达80%或更高,则卵巢癌的死亡率将会减少一半。在227名早期卵巢癌患者中163名患者外周血中CA125表达呈阳性(>35 U/ml),二者相比其CA125的表达有差异(p<0.05)(患者年龄范围为18-77岁,中位数为49.89±14.96岁)。依据FIGO不同临床分期的患者CA125的表达水平是不同的。
A-依据FIGO分期确定肿瘤分期：
146例ⅡB期患者中64.31%的患者CA125表达呈阳性,其CA125的水平明显高于ⅠC和ⅡC的12例患者,CA125的表达与肿瘤的期别存在相关性。
IB-IIB IC-IIB相比,P=4.375E-05,#IIC与IC-IIB相比P=0.013
IB-IIB*与ⅠA相比,P=0.496,#IIC与ⅠA相比,P=0.431
ⅠB～ⅡB与ⅠC-ⅡB相比,P=4.375E-05,#ⅡC与ⅠC-ⅡB相比,P=0.013,其差别有统计学意义
Ⅰ期卵巢癌患者中22例CA125表达的水平升高,Ⅱ期卵巢癌患者中99例CA125表达水平升高,二者相比,Ⅱ期卵巢癌CA125表达的阳性率(11.95%)明显低于Ⅱ期卵巢癌阳性率(53.80%)
B-早期卵巢癌和对照组
检测227正常对照组,185例早期卵巢癌患者。其中185例早期卵巢患者中163例CA125的表达呈阳性,163例患者的血CA125呈高表达(>35 U/m1),12例CA125的表达呈阴性。163例早期卵巢癌患者与227例对照组相比,CA125的表达差异显著(P<0.05)。
肿瘤>4cm的卵巢癌患者的外周血中肿瘤生物标志物CA-125的水平高于肿瘤<4cm的卵巢癌患者,但细胞浆内的CA125的水平与肿瘤的大小无显著关系。(0.019,P<0.05)。
C CA125蛋白与早期卵巢癌患者临床病理特征的相关性。
对于通过分析CA125表达阳性的卵巢癌患者,发现家庭妇女的卵巢癌患者的进展速度低于城市妇女。
卵巢癌与其他肿瘤相比较,72.88%为单侧肿瘤,27.11%为双侧肿瘤。
CA125表达水平与职业、年龄和教育水平无显著的统计学差异。
18岁后结婚的患者的CA125表达阳性率(59.07%),分别要高于38-57岁结婚(57.62%)或18岁以前结婚的妇女(6.77%)。通过比较分析发现67.79%的已婚女性及76.27%的多产妇,CA125的表达也无显著差异。
D-早期病理诊断的多样性
卵巢癌患者CA125的表达比畸胎瘤,囊腺瘤,子宫内膜腺癌和非卵巢腺癌要高。
进一步分析我们过去5年的研究的肿瘤类型的数据发现,5年内子宫内膜癌共14例(6.16%),2005-2007年6例(占42.85%).2008-2009年8例(占57.14%)。
透明细胞癌4例,卵巢囊腺癌40例,浆液性卵巢癌26例,粘液性卵巢癌13例,卵巢布伦纳肿瘤和交界性卵巢肿瘤12例,卵巢腺癌5例,癌性腹水29例,卵巢良性畸胎瘤41例,卵巢恶性畸胎瘤20例,混合型25例。CA125表达水平在各肿瘤间表达无明显差异。
2005年的病例数量(25.06%)低于2007年的病例数量(37.62%),最近3年收集病例157例。
所有病例中,其中144例手术术后病理回报卵巢癌102例,不明来源的腺癌3例,良性卵巢肿瘤28例,子宫肌瘤8例,3例无异常。
应用ELISA正态分布曲线区分正常组织和癌变组织样本的敏感性和特异性分别达到81.49%、71.80%。此外,通过敏感性和特异性的获得,从而可以区分卵巢癌的高危人群或低危人群。本次博士论文的结果：可考虑应用CA125的酶联免疫吸附试验作为一种发现早期卵巢癌患者的战略,从而降低妇女的癌症死亡率。
结论：
卵巢是盆腔内一个很小的女性生殖器官。卵巢通过分泌激素支持女性生殖系统。早期诊断卵巢癌可降低中晚期卵巢癌的高死亡率。早期卵巢癌患者的外周血中CA125呈刺激性的高表达。这个系统的功能能力需要进一步检测方能考虑临床的监测使用。
BACKGROUND:Consultant gynecologic oncologists ELISA laboratory from the regional Register Cancer Center assisted community gynecologists’CA 125 test after diagnosis method for early ovarian cancer when they were invited. For this report, the study evaluated the performance CA125 effects of early stage on diagnosis outcome METHODS: The hospital files from 227 diagnosed for epithelial ovarian cancer between 2005-2009 of ConakryJilin2, ChinoGuineans, Africasia were abstracted. The diagnosis results were analyzed 4 for weak reaction ELISA; 154 for moderate; 27 for strong at the patients according to the clinicians examination by ELISA for diagnosis and SSP 15.00, Epi-Info6 analyses with univariate and multivariate Cox regression. RESULTS:Method was performed on 178 Bethune (BN) patients, and 7 Conakry (CY). ELISA Bethune followed diagnostically guidelines more strictly compared with Conakry,8CY(18.60%) vs.37BN(20.10%);[P=0.01]ⅠA-ⅠB stage; 8CY(18.20% vs. 30 BN(16.30%); [P=0.003]ⅡA-ⅡB stage,within 27 CY(62.79%) vs. 117 BN(63.58%); [P=0.02]ⅠC～ⅡC stage. Patients tumor were stratified according to early stageⅠwith 5-year overall survival rate was 96% versus 80%; (P=0.03) for patients disease and 76% versus 60%, (P=0.02) for stageⅡwho underwent peripheral blood ELISA CA125 Bethune and Conakry diagnosis. The hazards ratio was 0.79 (95% confidence interval [95%CI],0.61-1.03; adjusted for patient age, stage, type of hospital, when patients age 77 years were excluded, the hazards ratio fell to 0.71 (95% CI,0.54-0.94) in multivariate analysis. CONCLUSIONS:An early diagnosis ovarian cancers by ELISA CA125 occurred more often according to laboratory guidelines, tumor removal more often was complete, and survival improved.
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Jilin University Medical Center Normal Clinical, Bethune, The ChinoGuineans
CD 10183, ID 9200873101
Objective
In the past 20 years the diagnosis have made a great effort a variety of tumor makers in clinical widely used. The guide clinical laboratory with early prevention has effective important ovarian cancer significance. The recent past 3 years showing an improvement of infrastructure and methods of diagnosis that there was an increased demand on CA125 assay over the past 5-years, particularly in the last 3 years compared of data variety early diagnosis method clinic of patients of early ovarian cancer. The retrospective study was designed performance as assessed by the area under the receiver biomarker cancer antigen CA125 alone of panel to correctly identify women significantly greater and performance with early ovarian cancer chinoguineans.
Methods
The biochemical ELISA technique, a high molecular weight glycoprotein, was measured in sera from patients with the most common cause of cancer death among gynecologic tumors stages (ⅠandⅡ) in the benign worldwide. For biomarker panel Bethunedonka (BD) in surgical resection specimens and control group, blood sample with early ovarian cancer clinical data underwent respective examination monoclonal CA-125 albumins with ovarian cancer diagnosed kit blood from March 2005 January 1 to 2009 December 31, the Second Jilin hospital, Clinical Bethune of Medical Science (BN) of International Exchange Center Jilin University, Changchun, Jilin, China and Registered Cancer Center, National Hospitals Donka, Gamal Abdel Nasser University, Conakry(CY), West Africa. Guinea.
The ELISA data by In Vitro (protocol No.1820/ub90504A) kit sensitivity color reagent were purchased from a new biological Technology Co., Ltd, United States, and Alpha Diagnostic Intl.
We observed high CA125 efficiencies in the early ovarian cancer (stageⅠ-Ⅱ) and in ELISA using low peripheral blood concentrations with the absence of significant cell viability impairment. Early ovarian cancer has evolved as a superior method for CA125 into peripheral blood cells, CA125 was expressed in 4 for weak reaction ELISA; 154 for moderate; and 27 for strong at the patients as reported in the literature.
The expressing verified the results with the Gene Bank expression database analyzed cancer cells instability with this ELISA type, such as relevance of ovarian cancer stage I-II.
Statistical analysis Methods:Two independent statisticians from program Epi-Info and SPSS15.0 calculate statistic analyzed the data; the age average (mean±SE) of patients will be evaluated. Significant difference was that p<0.05 which represented all probability values lower than 0.05. The study was performed encompassing the critical issues associated with expression efficiency, to standardize a CA125 protocol for use in early ovarian cancer ELISA schedules. Through the peripheral blood of patients with early ovarian cancer free DNA for qualitative research to explore new treatment can be used early diagnosis stage and efficacy of the method of monitoring. CA125 was used as an antigen cancer to optimize peripheral blood by early ovarian cells by diagnosis the expression of the reporter tumor gene analysis for confirmation of the optimized loading parameters.
Results
The efficiency of this delivery system was assessed using CA125 peripheral blood in stimulating antigen specific peripheral blood cell responses in early ovarian stage of healthy individuals. The peripheral blood + antigen specific early ovarian cells responses were generated recognizing CA125 peripheral blood plasma and also early ovarian cancer cell lines endogenously expressing CA125. This study has identified CA125 specific early ovarian cells responses in healthy patients, allowing further investigation into the potential for its use as a stage I and II in ovarian cancer ELISA. Furthermore, the use of antigen cancer CA125 expressed with peripheral blood ovaries is a promising strategy for the delivery of CA125in the generation of antigen-specific early ovarian cell responses.
Early diagnostic efficiency are undoubtedly the major priorities for achieving long-term reduction of mortality due to ovarian cancer the hypothesis that early ovarian cancer may be detectable up to many years prior clinical presentation and that if effective diagnosis for early stage disease were achieved with an accuracy of 80% or more, mortality would be halved. The positivity of serum concentrations of CA125 expression are elevated (i.e.>35 U/ml) in 163 blood of patients with early stage disease. The CA125 expressions in patients with varied FIGO clinical stage were different. The data case cohort (overall and by disease stage) median age (range) of the (n=227) was 49.89(18-77) years (mean±SE,49.89±14.96) of age on plasma biomarker concentration identified (Spearman's rank correlation,0.0004. p< 0.05).
A- Tumor type was identified and FIGO clinical stage by FIGO nomenclature Rio de Janeiro 1998, ACS Cancer Facts & Figures,2007 presented of early stage cohorts:
⊥The CA125 expressions in patients with 146 cases (64.31%) IIB stage disease was much highest than in patients both with 12 (<35 U/ml) IC～IIC positive, the CA125 expression correlated the types, were significantly of IB to IIB, (0.496. p<0.05); and IIC (0.431,p<0.05).
⊥IB-IIB compared to IC-IIB, P= 4.375E-05,# IIC compared to IC-IIB, P= 0,013
⊥IB-IIB* compared to IA, P= 0,496,# IIC compared to IA, P= 0,431
Patient's commonly situation of early ovarian cancer, the significance difference was *IB～IIB compared to IC-IIB, P= 4.375E-05,# IIC compared to IC-IIB, P= 0,013.
⊥The CA-125 expressions elevated (i.e.□35 U/ml) in 22 cases (11.95%) in patients with I stage, was lowest than in 99(53.80%) of II stage.
B-The group Controls and early ovarian cancer
⊥In biomarker (n= 185{43.59±13.12} Cases) and (n=227{49.89±14.96}, Cases). The positives (n=175{40.87±11.48}, group compared falsies positives (n=6{27.09±10.14}). The significant differences biomarker plasma concentrations were significantly greater within 154(4CY+150BN) with 38.60±15.12 average (0.44, p< 0.05) moderate,27(1CY+26BN), 35.08±10.08 for strong,4 (2 CY and 2 BN)= 17.03±5.08 for weak reaction at patients and early ovarian cancer positively of date in Clinical patients 224(0.0003, p<0.05) of CA125 alone.
⊥High levels (<35 U/ ml) were found in 4 cases of 227 patients with active ovarian cancer but in 181 (79.73 %) Bethunedonka (BD) patients who had positive of cases.
⊥The tumor size on biomarker CA-125 plasma concentration was highly than in cells tumor>2 cm (177.24%) i.e 97.62% of the ovarian cells tumor<2 cm, plasma concentration was no significantly with tumor size, (0.019,p<0.05)
⊥Anatomical seat 18-37 ages were usually much affected,63 cases i.e.7 cases tumors associated, (0.299, p<0.05). Histological diagnosis by age and anatomical areas (0.299, p<0.05) compared to anatomical areas by age (0.0006, P<0.05).
C- Correlation between CA-125 protein and clinicopathological features of the patients of early ovarian cancer.
⊥The housewives are the most affected layer less than urban women to increase with processing,62.71%, with 142.37% of cases respectively. Compared with ovarian tumors unilateral or bilateral with other tumor,72.88%,27.11% of the cases registered. There were no statistical significantly difference correlates in profession (0.032, p<0.05) and age> 58 old (0,286, p<0.05) compared to education level (0.009, p< 0.05) with CA125A cancer antigen positively. CA125 positive expressing was seen in 17 of patients who get married before 18 old and 146(78.91%) after 18 years old; high than the age group 38 to 57 57.62%, and the age group below 18 years represents 6.77% respectively. Compared to married,67.79% and multiparous,76.27%patients. The CA125 expression were also no statistical significantly difference in
the parity (0.073, p<0.05), complaints (p=0.091, p<0.05) and in age marriage (>18 old years,0.106,p<0.05) for cohorts.
D-According to the variety histopathological diagnosis clinic in early stage
4-CA125 was expressing much than the teratoma (417.62%) with cystadenocarcinome, endometrial adenocarcinoma, and non ovarian adenocarcinomas.
4 In five (5) past years, the data in our study were further analyzed with types and detected in 14(6.16%) cases with endometrioid carcinoma with 5-year relative diagnosis estimates increasing from 6(42.85%) in 2005-2007 to 8(57.14%) in 2008-2009.
⊥We in 4(2.12%) clear cell carcinoma were diagnosed. The significant difference was in 2005, (0.03, P<0.05) and 2007, (0.02 p<0.05) diagnosis. In cystadenocarcinoma (n=40), serous,(n=26), mucinous(n=13), Brenner tumor and borderline(n=12), Adenocarcinoma(n 5), Leiomyoma et ascite carcinomatous(n =29). Cysts and teratoma tumors(n = 41) with carcinoma(n = 20), mixed type (mixed, n = 25). Tumor typing was no significantly with CA125.
⊥The greatest frequency was observed in 2005 which is lower than that in 2007 diagnosis 25.06% vs. (37.62%), respectively. Almost,157(145.92%) cases were detected in the recent past 3 years.
⊥Of those patients,144 cases underwent surgical procedures.5 had ovarian cancers,3 had adenocarcinoma of unknown origin,28 had benign tumors,8 had fibroids, and 3 had no abnormalities.
Using ELISA normal distribution statue to classify the measurements a sensitivity of 81.49 % and 71.80% specificity was achieved when classifying normal and cancerous samples. Also, a sensitivity of specificity was obtained when classifying patients as either being in a high risk group or low risk group of developing ovarian cancer. The results gained from this PhD thesis should be taken into consideration when designing future CA125 ELISA strategies, to combat one of the leading causes of cancer mortality in women, early ovarian cancer.
Conclusion
The ovaries are small female reproductive organs that reside in the pelvis. The ovary makes female hormones reproduction system. Diagnosis of disease in early stages can reduce the high mortality rate of ovarian cancer and treat of disease in advanced stages. CA125 is not a novel strategy to express peripheral blood and a strong expression simultaneously in ovaries cells earlier. The functional capacity of this system requires further monitoring before it can be considered for investigation clinical use.
引文
[1]Cancer Facts & Figures. In National Foundation for Cancer Research. American Cancer Society.2009; 1-3.
[2]Canadian Cancer Statistics. What is ovarian cancer? Canadian society cancer. In Canadian Cancer Society Public Health Agency logo.2009,3-13.
[3]Hoimes CJ, et al. JOP. J Panc0000000000000reas (Online). Cancer Facts & Figures. 2010; 10(4):352-356
[4]Cancer Care Center. What is ovarian cancer? Metro Health Drive Cleveland.2009, OH 44109(216)778-7800
[5]Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer:defining the target for early detection. PLoS Med.2009; 6(7),2-29
[6]Kurman RJ, Shih Ie-M:The origin and pathogenesis of epithelial ovarian cancer:a proposed unifying theory. Am. J. Surg. Pathol.2010,34(3),433-443
[7]Ferlay J, Bray F, Pisani P, and et al. GLOBOCAN 2002:cancer incidence, mortality and prevalence worldwide. IARC Press Cancer Base.2004(5) 2,4-18.
[8]American Joint Committee on Cancer. Ovary. In: AJCC Cancer Staging Manual. Springer.2002,6th ed,275-279.
[9]American Cancer Society Cancer Facts and Figures 2008. American Cancer Society. 2008.1-70
[10]Menon U, Gentry-Mahara J A, Mallett T and et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clin. Chem.2008,54(12): 11-79
[11]Ovarian Cancer Antigen(CA-125) Enzyme Immunassay Tests Kit. Enzyme Immunoassay for the Quantitative Measurement of Ovarian Cancer Antigen CA-12-5. 2008,2-5
[12]Chan JK, Cheung MK, Husain A, and et al. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 2006,108:521-528.
[13]Jemal A, Siegel R,Ward E, et al. Cancer statistics,2006. CA CancerJClin 2006; 56:106-130.
[14]Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol. Biol.2009, 472:413-437.
[15]Mabika B and et al. Cancers of the ovary in children in Gabon:A retrospective study over 20 years. Doctor of Black Africa.2004,51 (11):571-574
[16]Hoskins KF, Stopfer JE, Calzone KA, et al. Assessment and counseling for women with a family history of breast cancer:a guide for clinicians. JAMA.1995;273:577585.
[17]Australian Institute of Health and Welfare and National Breast and Ovarian Cancer Centre 2010 in Ovarian cancer in Australia: An overview. CAN. Canberra:AIHW. Cancer series.2010,48; 136
[18]Tracey Edgell, G. Martin-Roussety, G. Barker, D. J. Autelitano, D. Allen, P. Grant, and G. E. Rice Phase II biomarker trial of a multimarker diagnostic for ovarian cancer Cancer Res Clin Oncol.2010; 136(7):1079-1088.
[19]National Cancer Institute (NCI). Anatomy:the cervix and nearby organs, NCI visuals online. Bethesda, MD:National Institutes of Health, United States Department of Health and Human Services.2009,1-2
[20]American Cancer Society. Cancer Facts & Figures 2009. American Cancer Society.2010.1-8
[21]Kim K, Zang R, Choi SC, Ryu SY, Kim JW. Current status of gynecological cancer in China. J Gynecol Oncol.2009; 20(2):72-76.
[22]Body G et al, tumor and cyst of the ovary. B Hedon, PMadelnat in D. Dargent, S Fridman. Gynecology Ellipses.1998,3-16.
[23]Descamps Ph and neck, ultrasound screening of ovarian cancer is it possible in 1998? J. Gynecol. Midwifery, biol.1998,27 (5):76-480.
[24]Koulibaly M, Kabba IS, Cisse A et al. Cancer incidence in Conakrt. Guinea:Fist results from the cancer Registry. In Etiology of urethral discharge in West Africa:the role of Mycoplasma genitalium and Ghana (5 in Accra), Guinea (18 in Conakry and 1 in Kamsar). Bulletin of the World Health Organization - Etiology of urethral.1992-1995. Int J Cancer.1997; 70; 39-45.
[25]Kazadi Buanga J and neck surgery of ovarian cancer in a precarious situation. The observation at St John of God about 21 cases. Black African Medicine.2005,52 (2): 126-128.
[26]Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics,2002. CA Cancer J Clin.2005,55(2):74-108.
[27]American Joint Committee on Cancer. Ovary. In:AJCC Cancer Staging Manual. Springer; 6th Ed.2002:275-279.
[28]Landen CN, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008;26:995-1005.
[29]Karen A. Johnson. The Standard of Perfection:Thoughts about the Laying Hen Model of Ovarian Cancer. In Perspective on Hakim et al. Cancer Prevention Research,2009 2: 97,114
[30]Kathleen R. Cho. Ming Shih. Pathology:Mechanisms of Disease Annual Review.2009, (4)287-313
[31]Feng Su, Jennifer Lang, Ashutosh Kumar, Carey Ng, Brian Hsieh, Marc A. Suchard, Srinivasa T. Reddy, Robin Farias-Eisner. Validation of Candidate Serum Ovarian Cancer Biomarkers for Early Detection. Biomarker Insights 2007, (2)369-375
[32]Ries, LAG., Harkins, D., Krapcho, M. et al. SEER Cancer Statistics Review,1975-2003, National Cancer Institute.2008,3-4.
[33]Hermsen BBJ, von Mensdorff-Pouilly S, Berkhof J, et al:Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer. J Clin Oncol 2007,25:1383-1389
[34]Urban N, McIntosh MW, Andersen M, et al:Ovarian cancer screening. Hematol Oncol Clin North Am 2003.17,989-1005
[35]Skates SJ, Xu FJ, Yu YH, et al:Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 1995:2004-2010.76
[36]McIntosh MW, Urban N, Karlan B:Generating longitudinal screening algorithms using novel biomarkers for disease. Cancer Epidemiol Biomarkers Prev 2002,11,159-166
[37]Crump C, McIntosh MW, Urban N, et al:Ovarian cancer tumor marker behavior in asymptomatic healthy women:Implications for screening. Cancer Epidemiol Biomarkers Prev.2000.9,1107-1111,
[38]Santillan A, Garg R, Zahurak ML, et al:Risk of epithelial ovarian cancer recurrence in patients with rising serum CA125 levels within the normal range. J Clin Oncol 2005,23, 9338-9343
[39]Friedman LC, Kramer RM:Reproductive issues for women with BRCA mutations. J Natl Cancer Inst Monogr 2005,34,83-86
[40]Petricoin EF, Ardekani AM, Hitt BA, et al:Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002,359.572-577
[41]Ransohoff DF:Lessons from controversy:Ovarian cancer screening and serum proteomics. J Natl Cancer Inst 2005,97,315-319
[42]myDr, Ovarian cancer test (CA125). UBM Medica Australia,2000-2010.2008,2
[43]Carcangiu ML, Radice P, Manoukian S, et al:Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol 23:35-40,2004
[44]Colgan TJ, Murphy J, Cole DEC, et al:Occult carcinoma in prophylactic oophorectomy specimens. Am J Surg Pathol 25:1283-1289,2001
[45]Hermsen BBJ, van Diest PJ, Berkhof J, et al:Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and fallopian tube in women at hereditary high risk of breast and ovarian cancer. Int J Cancer 2006.119:1412-1418
[46]Crawford SM, Peace J:Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann Oncol 2005,16:47-50.
[47]Gynecologic Cancer Foundation, Society of Gynecologic Oncologists, American Cancer Society. Ovarian Cancer Symptoms Consensus Statement 2007
[48]Data interpretation in ovarian cancer in Australia, Australian Institute of Health and Welfare and National Breast and Ovarian Cancer, Centre Australian Institute of Health and Welfare Canberra CAN 48,2010,52,2
[49]Incidence of ovarian cancer in ovarian cancer in Australia, Australian Institute of Health and Welfare and National Breast and Ovarian Cancer, Centre Australian Institute of Health and Welfare Canberra CAN 48.2010.52,5
[50]Tang Taylor. Questions answers on the ovarian cancer test CA-125. Information inspiration & community.2003,1-4
[51]Rossing, M. A., Wicklund, K. G., Cushing-Haugen, K. L., Weiss, N. S. Predictive Value of Symptoms for Early Detection of Ovarian Cancer. J Natl Cancer Inst.2010.102: 222-229
[52]RUFFORD BD, JACOBS IJ, MENON U. Feasability of screening for ovarian cancer using symptoms as selection criteria. BJOG,2007; 114:59-64.
[53]Twombly R:Cancer killer may be'silent'no more. J. Natl Cancer Inst.2007,99(18), 1359-1361
[54]Dawn Dorsey. Ovarian Cancer Symptoms Are Not Silent. CancerWise.2007,1.
[55]Goff BA, Mandel LS, Melancon CH, et al. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA.2004; 291 (22):2705-2712.
[56]Andreson N & Y, Urinary levels of Bcl-2 are elevated in ovarian cancer patients. Gynecol Oncol,2009; 112:60-67.
[57]Chambers, A. F., Vanderhyden, B. C. Ovarian Cancer Biomarkers in Urine. Clin. Cancer Res.2006,12:323-327
[58]Winter-Roach BA, Kitchener HC, Dickinson HO. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev.2009; 21,2-10
[59]Chobanian N, Dietrich CS. Ovarian Cancer. Surgical Clinics of North America.2008; 88,285-99
[60]Cass, I., Karlan, B. Y. Ovarian Cancer Symptoms Speak Out--But What Are They Really Saying?. JNCI J Natl Cancer Ins.(2010).102:211-212.
[61]Ovarian Cancer. What is it? American Association for Clinical Chemistry,2010,1
[62]Goff BA, Matthews BJ, Larson EH et al.:Predictors of comprehensive surgical treatment in patients with ovarian cancer. Cancer 2007,109(10),2031-2042.
[63]Prognostic Significance of CA-125 in the Management of Patients with Recurrent Epithelial Ovarian Carcinoma Selected for Secondary Cytoreduction Anticancer Res. 2009,29(7):2817-2821
[64]Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels Ann Oncol (2009) 20(2):294-297
[65]Ovarian Cancer. Detection In early detection techniques. The National Ovarian Cancer Association (NOCA),2010,6-20.
[66]Kurian AW, Balise RR, McGuire V, Whittemore AS. Histologic types of epithelial ovarian cancer:have they different risk factors? Gynecol Oncol 2005; 96,520-530.
[67]Juretzka MM, Barakat RR, Chi DS et al. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol 2007; 104:176-180
[68]Ozols RF, Bundy BN, Greer BE et al. Phase Ⅲ trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage Ⅲ ovarian cancer:a Gynecologic Oncology Group Study. J Clin Oncol 2003; 21:3194-3200.
[69]The ICON Group. Paclitaxel plus carboplatin versus standard chemotherapy with single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer:the ICON3 randomised trial. Lancet 2002; 360:505-515.
[70]Tung CS, Wong KK, Mok SC. Biomarker discovery in ovarian cancer. Womens Health (Lond Engl).2008,4:27-40
[71]Markman M, Liu PY, Rothenberg ML et al. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol 2006; 24:1454-1458
[72]Liu P-Y Alberts DS, Monk BJ et al. An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol 2007; 25:3615-3620.
[73]Mann JR, Gray ES, Thornton C, Raafat F, Robinson K, Collins GS, Gornall P, Huddart SN, Hale JP, Oakhill A. Mature and immature extracranial teratomas in children:the UK Children's Cancer Study Group Experience. Journal of Clinical Oncology:Official Journal of the American Society of Clinical Oncology.2008,26 (21):3590-3597
[74]Pauler DK, Menon U, McIntosh M, et al:Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev 10:489-493,2001
[75]Tracey Edgell, G. Martin-Roussety, G. Barker, D. J. Autelitano, D. Allen, P. Grant, G. E. Rice. Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J Cancer Res Clin Oncol.2010,136:1079-1088
[76]Lo Curto M. D'Angelo P, Cecchetto G, and et al. Mature and immature teratomas: results of the first paediatric Italian study. Pediatric Surgery International 2007,23 (4): 315-322
[77]Ries LAG, Melbert D, Krapcho M, and et al. SEER cancer statistics review 1975-2005 Institute. NC, Bethesda, MD.2006,3-20
[78]Hess LM, Benham-Hutchins M, Herzog TJ, Hsu CH, Malone DC, Skrepnek GH. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer. May-Jun 2007;17(3):561-570.
[79]Elit L, Oliver TK, Covens A, Kwon J, Fung MF, Hirte HW. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer:a systematic review with metaanalyses. Cancer.2007;109(4):692-702
[80]Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer. Primary care clinics. JAMA. 2004;291(22):2705-2712.
[81]Riedinger JM, Bonnetain F, Basuyau JP et al. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. Ann Oncol 2007; 18:881-885.
[82]Riedinger JM, Wafflart J, Ricolleau G et al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome:results of a French multicentric studv. Ann Oncol 2006; 17:1234-1238.
[83]MEDEIROS LR, ROSA DD, DA ROSA MI. Accuracy of Ca 125 in the diagnosis of ovarian tumors:a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol, 2009; 142:99-105.
[84]Munkarah A, Chatterjee M, Yainski MA. Update on ovarian cancer sreening curr. Opin Obstet Gynecol,2007; 19:22-26
[85]Comparison of CA-125 and Standard Definitions of Progression of Ovarian Cancer in the Intergroup Trial of Cisplatin and Paclitaxel Versus Cisplatin and Cyclophosphamide JCO (2006) 24(1):45-51
[86]Coates RRJ, Kolor K, Stewart SL, Richardsonha LC. Diagnostic markers for ovarian cancer screening:not ready for routine clinical use. Clin Cancer Res,2008; 14,7 575-7576
[87]Moore, R. G., Bast, R. C. Jr. How Do You Distinguish a Malignant Pelvic Mass From a Benign Pelvic Mass? Imaging, Biomarkers, or None of the Above. JCO 2007,25: 4159-4161
[88]Symptoms of Ovarian Cancer in Gynecologic Cancer Symptoms. Facts About Gynecologic Cancer.2010,1-2
[89]Van Nagell JR, De Priest PD, Ueland FR. Ovarian cancer screening with annual transvaginal sosnography:findings of 25 000 women screened. Cancer,2007; 109:1 887-1896.
[90]Fleischer AC, Lyshchick A, Jones HW JR. Contrast enhanced transvaginal sonography of benign versus malignant ovarian masses:preliminar findings. J Ultrasound Med, 2008; 27,1011-1018.
[91]Basal E, Eghbali-Fatourechi GZ, Kalli KR, and et al. Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. PLoS One.2009,20;4(7):6292.
[92]Jacobs I, Davies AP, Ponts J, and et al. Prevalence de depistage pour le cancer de l'ovaire-chez les femmes menopausees par CA 125 de mesure et de l'echographie. BMJ. 1993; 306(6884):1030-1034.
[93]Jacobs IJ, patins S, Davies AP, RP Woolas, Jeyerajah A DH, Oram P Weidemann, K Sibley. Le risque de diagnostic de cancer de l'ovaire apres soulevees serum CA 125 concentration:une etude prospective de cohorte. BMJ.1996:313(7069):1355-1358]
[94]Jacobs IJ, Skates SJ, N MacDonald, and et al. Le depistage du cancer de l'ovaire:un pilote randomisee et controlee. Lancet.1999; 353(9160),1207-1210.
[95]Zurawski VR, Orjaseter H, Andersen A, Jellum E. elevation des taux seriques de CA-125 niveaux avant le diagnostic de la neoplasie-pertinence de l'ovaire pour la detection precoce de l'ovaire et le cancer. Int J Cancer.1988;42(5):677-680.
[96]Bast Jr RC, Klug TL, John St E, and et al. Un dosage radio-immunologique utilisant un anticorps monoclonal de surveiller l'evolution du cancer epithelial de l'ovaire. N Engl J Med.13 octobre 1983; 309 (15):883-7.
[97]Lan Jacobs et al. Ovarian cancer:early detection tests developer. Journal of Pathology 2009,1-2.
[98]H. Martelli[2003]and neck tumor of the gonads in children. Vol lo, (3) 246-250.
[99]Houlston RS, Boume TH, Davies A, Whitehead MI, Campbell S, Collins WP, et al. Use of family history in a screening clinic for familial ovarian cancer. Gynecol Oncol 1992;(42)247-252.
[100]Bell DA, Scully RE. Early de novo ovarian carcinoma. A study of fourteen cases. Cancer.1994, (73) 1859-1864.
[101]Olivier RI, Lubsen-Brandsma MA, Verhoef S, van BeurdenM. CA125 and transvaginal ultrasoundmonitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol.2006; (100)20-2 6.
[102]Mandic A, Nincic D, Vujkov T. Ovarian epithelial carcinoma--a malignant disease sparing no age group. Med Pregl.2003; 56(3-4),157-61.
[103]Coombes KR, Morris JS, Hu J, Edmonson SR, Baggerly KA. Serum proteomics profiling--a young technology begins to mature. Nat. Biotechnol.2005,(3) 291-292.
[104]Armstrong, D. Ovaries and fallopian tubes. In Abeloff MD ed. Abeloffs Clinical Oncology,4th ed. Philadelphia:Churchill Livingstone,2008,1827-1850.
[105]Nelson Guerreiro, Baltazar Gomez-Mancilla and Stephane Charmont. Optimization and evaluation of surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry for protein profiling of cerebrospinal fluid. Proteome Science.2006, (4)7. 1477-5956
[106]Zhang H, Kong B, Qu X, Jia L, Deng B, Yang Q.2006. Biomarker discovery for ovarian cancer using SELDI-TOF-MS. Gynecol. Oncol.2006, (1) 61-66.
[107]Whiteley GR, Colantonio S, Sacconi A, Saul RG. Analytical considerations for mass spectrometry profiling in serum biomarker discovery. Clin.2009, Lab. Med., (1)57-69.
[108]Keith AB, Jeffrey, SM, Sarah RE, Kevin RC. Signal in noise:evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J. Nat. Cancer Inst., 2005,(4) 307-309.
[109]Kristina G, Radomir P, Eva B, Lenka D, Radek L, Rostislav V. When one chip is not enough:augmenting the validity of SELDITOF proteomic profiles of clinical specimens. Lab. Chip.2009, (7) 1014- 1017.
[110]Josep Villanueva, David RS, John P. Differential exoprotease activities confer tumour-specific serum peptidome patterns. J. Clin. Invest.2006,1:271-284
[111]Sven B, Uta C, Georg MF, Jan L, Alexander L, Joachim T. Standardized approach to proteome profiling of human serum based on magnetic bead separation and Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry. Clin. Chem. 2005,(6) 973-980
[112]Cheng AJ, Chen LC, Chien KY, Chen YJ, Chang JT, Wang HM, Liao CT, Chen IH. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin. Chem.2005,12:2236-2244.
[113]Goreliket E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, Bigbee WL, Herberman RB, Lokshin AE. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol.2005,6-18
[114]Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE, Mor G. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res.2008,14(4):1065-1072.
[115]Park IS, Lee YS, Kim JC, Hwang SG. Serum neopterin levels in ovarian tumors. Int J Gynaecol Obstet.1995,51(3),229-234.
[116]Saraswathi A, Malait T. Superiority of CA 125 over CA 19-9 and CES for epithelial ovarian malignancies. Indian J Clin Biochem. (1995,10,23-28.
[117]Mandic A, Nincic D, Vujkov T. Ovarian epithelial carcinoma--a malignant disease sparing no age group. Med Pregl.2003; 56(3-4),157-61.
[118]Argueso P, Spurr-Michaud S, Russo CL, and et al. MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope. Invest Ophthalmol Vis Sci.2003;44(6):2487-95.
[119]Bhan V, Amso N, Whitehead MI, Campbell S, and et al. Characteristics of persistent ovarian masses in asymptomatic women. Br J Obstet Gynaecol.1989; 96:1384-91
[120]Vladimir Nossov,AffiliationDepartment of Obstetrics and Gynecology, University of California, Los Angeles, Medical Center, Los Angeles, CA Malaika Amneus, Feng Su, and et alAffiliations Department of Obstetrics and Gynecology, University of California, Los Angeles, Medical Center, Los Angeles, CA. Affiliation Atherosclerosis Research Unit, Department of Medicine/Cardiology, University of California, Los Angeles. CADepartment of Molecular and Medical Pharmacology. University of California. Los Angeles. CA Farias Robin-Eisner The early detection of ovarian cancer:from traditional methods to proteomics. Can we really do better than serum CA-125? American Journal of Obstetrics & Gynecology 2008(199),3,215-223Affiliations
[121]Berchuck A, Elbendary A, Havrilesky L, Rodriguez GC, Bast RC, Jr. Pathogenesis of ovarian cancers. J Soc Gynecol Investig 1994;(1)181-190.
[122]Karst AM, Drapkin R. Ovarian cancer pathogenesis:a model in evolution. J Oncol. 2010;(93)23-71.
[123]Nossov V, Amneus M, Su F, Lang J, Janco JMT, Reddy ST, Farias-Eisner R. The early detection of ovarian cancer:from traditional methods to proteomics. Can we really do better than serum CA-125? 2008, Am J Obstet Gynecol 199(3):215-223.
[124]Badgwell D, Bast RC Jr. Early detection of ovarian cancer. Dis Markers.2007,23(5-6)397-410
[125]Jackson D, Craven RA, Hutson RC, Graze I, Lueth P, Tonge RP. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin. Cancer Res.2007, 24:7370-7379.
[126]Fields MM, Chevlen E. Ovarian cancer screening:a look at the evidence. Clin. J. Oncol. Nurs.2006, (1)77-81.
[127]Best Evidence Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med.2006; 354(1):34-43.
[128]Dong-Mei Fan, Hui-Rong Shi, Zhi-Min Chen, and et al. Early detection of ovarian carcinoma by proteome profiling based on magnetic bead separation and matrix-assisted laser desorption/ionization time of flight mass spectrometry. African Journal of Microbiology Research.2010, Vol.4(10),940-951
[129]Ries LAG, Melbert D, Krapcho M, and et al. SEER Cancer Statistics Review,1975-2004. National Cancer Institute Bethesda, MD based on November 2006 SEER data submission, posted to the SEER web site,2007.
[130]Buamah P (2000) Benign Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol 75:264-265.
[131]Miralles C, Orea M, Espana P, Provencio M, Sanchez A, et al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol,2003,10: 150-154，
[132]Oei AL, Massuger LF, Bulten J, and et al. Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Br J Cancer,2006,94:814-819.
[133]Greene MH, Piedmonte M, Alberts D, and et al A Prospective Study of Risk-Reducing Salpingo-oophorectomy and Longitudinal CA-125 Screening among Women at Increased Genetic Risk of Ovarian Cancer:Design and Baseline Characteristics:A Gynecologic Oncology Group Study. Cancer Epidemiol Biomarkers Prev,2008,17: 594-604
[134]Skates SJ, Menon U, MacDonald N, Rosenthal AN, and et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol,2003,21:206s-210s.
[135]Fung ET, Hogdall C, EEngelholm SA, and et al. Novel biomarkers to aid in the differential diagnosis of a pelvic mass. Santa, Monica, CA.2006 14-18
[136]Skates SJ, Horick N, Yu Y and et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125Ⅱ, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol.2004.22:4059-4066.
[137]Lee-Jones L. Ovarian tumours:an overview. Atlas Genet Cytogenet Oncol Haematol. 2003
[138]Bast, Jr., R.C., Xu, and et al.. CA125:the past and the future. Int. J. Biol. Markers,1998, 13(4):179-187
[139]Amer K. Karam & Beth Y. Karlan. Ovarian cancer:the duplicity of CA125 measurement. Nature Reviews Clinical Oncology 2010(7).335-339.
[140]Bertenshaw GP, Yip P, Seshaiah P, and et al. (2008) Multi-Analyte Profiling of Serum Antigens, Autoimmune and Infectious Disease Molecules to Identify Biomarkers Dysregulated in Epithelial Ovarian Cancer. Cancer Epidemiol Biomarkers Prev 17: 2872-2881
[141]The above story is reprinted (with editorial adaptations by Science Daily staff) from materials provided by. New Blood Test shows promise as screening tool for Early Detection of Ovarian Cancer. ScienceDaily University of Texas M. D. Anderson Cancer Center. Science News.2010,1
[142]New Hope for Early Detection of Ovarian Cancer with CA-125 Protein Monitoring Over Time Health & Medicine for Senior Citizens.2010,2
[143]Lan Jacobs, Ann Prys Davies, Jane Bridges, and et al Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography BMJ 1993(306) 17
[144]Smith CA, Sinclair AH. Sex determination:insights from the chicken. BioEssays 2004;26:120-32
[145]Fredrickson TN. Ovarian tumors of the hen. Environ Health Perspect 1987;73:35-51.
[146]Piek JMJ, van Diest PJ, Zweemer RP, et al:Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001.195:451-456,
[147]Joyner AB, Runowicz CD. Ovarian cancer screening and early detection. In Carole & Ray Neag Comprehensive Cancer Center, University of Connecticut Health Center, Obstetrics & Gynecology, Farmington, CT 05030, USA. Womens Health (Lond Engl). 2009;5(6):693-696.
[148]Yin, B. W. T.; Lloyd, K. O. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J. Biol. Chem.2001,276(29),2732.
[149]Argueso, P.; Spurr-Michaud, S.; Russo, and et al. MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope. Invest. Ophthal. Vis. Sci.2003,44(6)::2485-2493
[150]Moszynski R, Szpurek D, Michalak S, and et al. The role of endothelin-1 and its correlation with CA125 levels, grayscale ultrasonography and doppler findings in differential diagnoses of ovarian tumors. In Division of Gynecological Surgery, Department of Gynecology, Obstetrics and Gynecological Oncology, University of Medical Sciences, Poznan, Poland. Eur J Gynaecol Oncol.2009;30(5):552-553.
[151]Rinker-Schaeffer C. W., O'Keefe J. P., Welch D. R., and et al. Theodorescu, Metastasis suppressor proteins:discovery, molecular mechanisms, and clinical application. Clinical Cancer Research,2006,(12)13,3882-3889.
[152]Julang Li, Qiang Feng, Jong-Min Kim, and et al. Human Ovarian Cancer and Cisplatin Resistance:Possible Role of Inhibitor of Apoptosis Proteins. Endocrinology.2001, 142(1),370
[153]Jinsong Liu, Gong Yang,l Jennifer A and et al. A Genetically Defined Model for Human Ovarian Cancer. CANCER RESEARCH,2004 64,1655.
[154]William G. Kaelin Jr The von Hippel-Lindau tumour suppressor protein:02 sensing and cancer Nature Reviews Cancer 2008,8,865-873
[155]Ingegerd Hellstro"m, John Raycraft, Martha Hayden-Ledbetter, Jeffrey A. Ledbetter, Miche, Schummer, Martin McIntosh, Charles Drescher, Nicole Urban, and Karl Erik Hellstro m
[156]I. H., J. R., M. H-L., and et al. Pacific Northwest Research Institute, Institute for Systems Biology[M. S.], Fred Hutchinson Cancer Research Center[M. M., C. D., N. U.]. and Swedish Hospital and Medical Center[C. D.], The HE4 (WFDC2) Protein Is a Biomarker for Ovarian Carcinoma. CANCER RESEARCH 2003,63,3695-3700
[157]Berek, J. S., Bast, R. C, and et al. Ovarian cancer screening The use of serial complementary tumor markers to improve sensitivity and specificity for early detection.Cancer,1995,76:2092-2089.
[158]Maggino, T., Gadducci, A., D'Addario, and et al. Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol. Oncol.,1994,54:117-119,
[159]Chang, K., Pai, L. H., Batra, J. K., and et al. Characterization of the antigen (CAK1) recognized by monoclonal antibody Kl present on ovarian cancers and normal mesothelium. Cancer Res.,1992,52:181-178.
[160]Scholler, N., Fu, N., Yang, and et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc. Natl. Acad. Sci. USA,1999,96:11531-11526,.
[161]Schummer, M., Ng, W., Bumgarner, R., and et al. Comparative hybridization of an array of 21500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene,1999,238:375-381.
[162]Ono, K., Tanaka, T., Tsunoda, T., and et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis Cancer Res.,2000,60:5007-5009.
[163]Welsh, J. B., Zarrinkar, P. P., Sapinoso, and et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Natl. Acad. Sci. USA,2001,98:1176-1178,
[164]Kirchhoff, C., Habben, I., Ivell, R., and et al. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol. Reprod.,1991,45:350-348.
[165]Kirchhoff, C. Molecular characterization of epididymal proteins. Rev. Reprod.,1998,3: 86-95.
[166]Dandekar, A. M., Robinson, E. A., Appellla, E., and et al. Complete sequence analysis of cDNA clones encoding rat whey phosphoprotein:homology to a protease inhibitor. Proc. Natl. Acad. Sci. USA,1982,79:3987-3989.
[167]Heinzel, R., Appelhans, H., Gassen, G., and et al. Molecular cloning and expression of cDNA for human antileukoprotease from cervix uterus. Eur. J. Biochem.,1986,160: 63-65.
[168]Wiedow, O., Schroder, J. M., Gregory, H., and et al. An elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J. Biol. Chem.,1990,265:14791-14792.
[169]Bingle, L., Singleton, V., and Bingle, C. D. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene,2002,21:2768-2773.
[170]Hayden, M. S., Gilliland, L. K., and Ledbetter, J. A. Antibody engineering. Curr. Opin. Immunol.,1997,9:201-212.
[171]Davidson NG, Khanna S, Kirwan PH, Bircumshaw D:Prechemotherapy serum CA125 level as a predictor of survival outcome in epithelial carcinoma of the ovary. Clin Oncol (R Coll Radiol) 1991,3:32-26.
[172]Rustin GJ, Gennings JN, Nelstrop AE, and et al. Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group. J Clin Oncol 1989, 7:1667-1667.
[173]Burger RA, Darcy KM, DiSaia PJ, and et al. Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy:a gynecologic oncology group study. Cancer 2004 101:106-109.
[174]Kim HS, Park NH, Chung HH, and et al. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer. Onkologie 2008,31:315-312.
[175]Juretzka MM, Barakat RR, Chi DS. and et al. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol 2007,104:176-178. [176]Riedinger JM, Bonnetain F, Basuyau JP, and et al. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. Ann Oncol 2007,18:881-875.
[177]Badulescu F, Badulescu A, Schenker M, Popescu CF, Stoica Z:The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma. Rom J Morphol Embryol 2005 46:329-328.
[178]Fisken J, Leonard RC, Stewart M, Beattie GJ, Sturgeon C, Aspinall L, Roulston JE:The prognostic value of early CA125 serum assay in epithelial ovarian carcinoma. Br J Cancer 1993,68:140-135.
[179]Redman CW, Blackledge GR, Kelly K, Powell J, Buxton EJ, Luesley DM:Early serum CA125 response and outcome in epithelial ovarian cancer. Eur J Cancer 1990,26:593- 586
[180]Colakovic S, Lukic V, Mitrovic L, Jelic S, Susnjar S, Marinkovic J:Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer. Int J Biol Markers 2000, 15:147-149.
[181]Yedema CA, Kenemans P, Voorhorst F, Bon G, Schijf C, Beex L, Verstraeten A, Hilgers J, Vermorken J:CA 125 half-life in ovarian cancer:a multivariate survival analysis. Br J Cancer 1993,67:1361-1357.
[182]Osman N, O'Leary N, Mulcahy E, Barrett N, Wallis F, Hickey K, Gupta R:Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre. Ir Med J 2008,101:245-237.
[183]Van Dalen A, Favier J, Burges A, and et al. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol 2000, 79:444-445.
[184]Cooper BC, Sood AK, Davis CS, and et al. Preoperative CA 125 levels:an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol 2002,100:59-54.
[185]Buller RE, Vasilev S, DiSaia PJ:CA 125 kinetics:a cost-effective clinical tool to evaluate clinical trial outcomes in the 1990. Am J Obstet Gynecol 1996,174:1241-1243.
[186]Nagele F, Petru E, Medl M, and et al. Preoperative CA 125:an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1995,86:259-264.
[187]Makar AP, Kristensen GB, Kaern J, and et al. Prognostic value of pre-and postoperative serum CA 125 levels in ovarian cancer:new aspects and multivariate analysis. Obstet Gynecol 1992,79:1002-1008.
[188]Sevelda P, Schemper M, Spona J:CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1989, 161:1213-1206.
[189]Moebus V:KRCGWHCHKH:Evaluation of CA125 as a prognostic and predictive factor in ovarian cancer. J Tumor Marker Oncol 1988,3:251-248.
[189]Cruickshank DJ, Fullerton WT, Klopper A:The clinical significance of pre-operative serum CA 125 in ovarian cancer. Br J Obstet Gynaecol 1987,94:692-685
[190]Hunter VJ, Daly L, Helms M, and et al. The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol 1990,163:1164-1157.
[191]Hawkins RE, Roberts K, Wiltshaw E, Mundy J, Fryatt IJ, McCready VR:The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol 1989,96:1395-1389.
[192]Gard GB, Houghton CR:An assessment of the value of serum CA 125 measurements in the management of epithelial ovarian carcinoma. Gynecol Oncol 1994,53:283-259.
[193]Frasci G, Conforti S, Zullo F, and et al. A risk model for ovarian carcinoma patients using CA 125:time to normalization renders second-look laparotomy redundant. Cancer 1996,77:1122-1120.
[194]Mano A, Falcao A, Godinho I, Santos J, Leitao F, de Oliveira C, Caramona M:CA-125 AUC as a predictor for epithelial ovarian cancer relapse. Cancer Biomark 2008,4:73-78.
[195]Mano A, Falcao A, Godinho I, and et al. CA-125 AUC as a new prognostic factor for patients with ovarian cancer. Gynecol Oncol 2005,97:529-524.
[196]Riman T, Persson I, Nilsson S:Hormonal aspects of epithelial ovarian cancer:review of epidemiological evidence. Clin Endocrinol (Oxf) 1998,49:695-702.
[197]Hermsen BBJ, von Mensdorff-Pouilly S, Berkhof J, et al:Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk ovarian cancer. J Clin Oncol 2007,25,1386
[198]Olsen CM, Green AC, Nagle CM, et al.; Australian Cancer Study Group (Ovarian Cancer) and the Australian Ovarian Cancer Study Group. Epithelial ovarian cancer: testing the'androgens hypothesis'. Endocr Relat Cancer.2008;15:1061-1060.
[199]Bidart JM, Thuillier F, Augereau C, Chalas J, Daver A, Jacob N, Labrousse F, Voitot H: Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 1999,45:1695-1701.
[200]Tamakoshi K, Kikkawa F, Hasegawa N, and et al. Clinical value of a new serum tumor marker, CA125II, in gynecologic disease:comparison with CA125. Gynecol Obstet Invest.1995; 39(2),125-129.
[201]Bets Davis, Ovarian cancer. Obstetrics and Gynecology,2009.
[202]Christine Wendt. Protein Diabetes Educator,2009
[203]U.S. Preventive Services Task Force. Screening for ovarian cancer,2004,6.
[204]Finegan J, Bartleman B, Wong PY:A window for the study of prenatal sex hormone influences on postnatal development. J Genet Psychol 1988; 150:101-112
[205]Rubinow DR, Schmidt PJ:Androgens, brain, and behavior. Am J Psychiatry 1996; 153:974-984
[206]Caswell H, Weeks DE:Two-sex models:chaos, extinction, and other dynamic consequences of sex. American Naturalist 1986; 128:707-735
[207]Bachman DL, Wolf PA, Linn R, and et al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology 1992; 42:115-119
[208]Finegan J, Bartleman B, Wong PY:A window for the study of prenatal sex hormone influences on postnatal development. J Genet Psychol 1988; 150:101-112
[209]Rubinow DR, Schmidt PJ:Androgens, brain, and behavior. Am J Psychiatry 1996; 153:974-984
[210]Caswell H, Weeks DE:Two-sex models:chaos, extinction, and other dynamic consequences of sex. American Naturalist 1986; 128:707-735
[211]Bachman DL, Wolf PA, Linn R, and et al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology 1992; 42:115-119
[212]Bachman DL, Wolf PA, Linn RT, and et al. Incidence of dementia and probable Alzheimer's disease in a general population:the Framingham Study. Neurology 1993; 43:515-519
[213]Canadian Study of Health and Aging Working Group:Canadian study of health and aging:study methods and prevalence of dementia. Can Med Assoc J 1994; 150:899-8913
[214]Tang MX, Jacobs D, Stern Y, and et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348:429-432
[215]Henderson VW, Buckwalter JG:Cognitive deficits of men and women with Alzheimer's disease. Neurology 1994; 44:90-96
[216]Hafner H, an der Heiden W:Epidemiology of schizophrenia. Can J Psychiatry 1997; 42:139-151
[217]Lewine RJR, Seeman MV. Gender, brain, and schizophrenia:anatomy of differences/differences of anatomy, in Gender and Psychopathology. Edited by Seeman MV. Washington, DC, American Psychiatric Press,1995
[218]Jablensky A, Cole SW:Is the earlier age at onset of schizophrenia in males a confounded finding? Br J Psychiatry 1997; 170:234-240
[219]Ciompi L The influence of aging on schizophrenia. Triangle 1993; 32:25-31
[220]Wong DF, Wagner HN Jr, Dannals RF and et al. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 1984; 226:1393-1396
[221]Seeman MV:Sex differences in predicting neuroleptic response, in The Prediction of Neuroleptic Response. Edited by Gaebel W, Awad AG. Vienna, Springer-Verlag,1995, pp 51-64
[222]Blum M, McEwen BS, Roberts JL:Transcriptional analysis of tyrosine hydroxylase gene expression in the tuberoinfundibular dopaminergic neurons of the rat arcuate nucleus after estrogen treatment. J Biol Chem 1987; 262:817-821
[223]DiPaolo T:Modulation of brain dopamine transmission by sex steroids. Rev Neurosci 1994; 5:27-42
[224]Toran-Allerand CD:The estrogen/neurotrophin connection during neural development: is co-localization of estrogen receptors with the neurotrophins and their receptors biologically relevant? Dev Neurosci 1996; 18:36-41
[225]Seeman MV, Lang M:The role of estrogens in schizophrenia gender differences. Schizophr Bull 1990; 16:185-194
[226]Bast RC Jr. Klug TL, St John E, and et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983 309:883-882.
[227]Nustad K, Bast RC Jr. Brien TJ, and et al. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen:first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumour Biol 1996,17:196-212.
[228]Markman M:Optimizing primary chemotherapy in ovarian cancer. Hematol Oncol Clin North Am 2003.17:957-958.
[229]Kenemans P. van Kamp GJ, Oehr P, Verstraeten RA:Heterologous double-determinant immunoradiometric assay CA 125 II:reliable second-generation immunoassay for determining CA 125 in serum. Clin Chem 1993,39:2509-2510.
[230]Hogdall EV, Christensen L, Kjaer SK, and et al. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. Gynecol Oncol 2007,104:508-509.
[231]Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE:Defining progression of ovarian carcinoma during follow-up according to CA 125:a North Thames Ovary Group Study. Ann Oncol 1996,7:361-344.
[232]Rustin GJ, Marples M, Nelstrop AE, Mahmoudi M, Meyer T:Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 2001,19:4054-4027.
[233]Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB:CA 125:the past and the future. Int J Biol Markers 1998,13:179-187.
[234]Menon U, Jacobs IJ:Ovarian cancer screening in the general population. Curr Opin Obstet Gynecol 2001,13:61-60.
[235]Verheijen RH, Mensdorff-Pouilly S, van Kamp GJ, Kenemans P:CA 125:fundamental and clinical aspects. Semin Cancer Biol 1999,9:117-114.
[236]Yin BW, Lloyd KO:Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001,276:27371-27370.
[237]Skates SJ, Menon U, MacDonald N, Rosenthal AN, Oram DH, Knapp RC, Jacobs IJ: Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003,21:206-205.
[238]Rustin GJ, Bast RC Jr, Kelloff GJ, and et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 2004,10:3919-3916.
[239]Gronlund B, Dehn H, Hogdall CK, and et al. Cancer-associated serum antigen level:a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma. Int J Gynecol Cancer 2005,15:836-833.
[240]Kang WD, Choi HS, Kim SM. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer. In Department of Obstetrics and Gynecology, Chonnam National University Medical School,8 Hakdong, Dong-gu, Gwangju, Republic of Korea. Gynecol Oncol.2010 Jan;116(1):57-55.
[241]Zurawski VR Jr, et al. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia:relevance for early detection of ovarian cancer. Int J Cancer 1988; (42)677-648.
[242]Agustin A Garcia, Samina Ahmed. Ovarian Cancer. Contributor Information and Disclosures.2010
[243]Kojima. T., Oh-eda, M., Hattori, and et al. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J. Biol. Chem.,1995,270:21984-21987.
[244]Chang, K.; Pastan, I.:Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Nat. Acad. Sci.93,1996, 138.
[245]Scholler, N.; Fu, N.; Yang, Y.; and et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from
[246]Bera, T. K.; Pastan, I. Mesothelin is not required for normal mouse development or reproduction. Molec. Cell. Biol.2000,20,2905.
[247]Campbell, I. G.; Nicolai, H. M.; Foulkes, W. D.; and et al. A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1. Hum. Molec. Genet.3:1994,589-579.
[248]Lange, S.; Xiang, F.; Yakovenko, A.; and et al. The kinase domain of titin controls muscle gene expression and protein turnover. Science,2005,308,1599-1601.
[249]Brown, M. A.; Nicolai, H.; Xu, C.-F.; and et al. Regulation of BRCA1. (Letter) Nature 1994,372,730.
[250]Brown, M. A.; Xu, C.-F.; et al. The 5-prime end of the BRCA1 gene lies within a duplicated region of human chromosome 17q21. Oncogene 1996,12,2511.
[251]Santillan A, Garg R, Zahurak ML, et al Risk of epithelial ovarian cancerrecurrence in patients with rising serum CA125 levels within the normal range.J Clin Oncol 2005, 23:9338-9339
[252]Friedman LC, Kramer RM:Reproductive issues for women with BRCA mutations. J Natl Cancer Inst Monogr 2005,34,85
[253]Ransohoff DF:Lessons from controversy:Ovarian cancer screening and serum proteomics. J Natl Cancer Inst 2005,97:315-317
[254]Hermsen BBJ, van Diest PJ, Berkhof J, et al:Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and fallopian tube in women at hereditary high risk of breast and ovarian cancer. Int J Cancer.2006 119:1412-1409
[255]Kirtly Jones, Female reproductive system. Obstetrics and Gynecology Medicine.2008
[256]Maria Essig. DNA (deoxyribonucleic acid). Reproductive Genetics,2009
[257]Sandy Jocoy, A pelvic exam Obstetrics and Gynecology.2009
[258]Monica Rhodes. Biopsy Medical Toxicology.2009
[259]Ovarian cancer. NCCN Practice Guidelines in Oncology, National Comprehensive Cancer Network.2009.
[260]Sendahl M, Ernst E, Rasmussen PE, Yding Andersen C.2008.
[261]Fertil. Steril. True ovarian volume is underestimated by two-dimensional transvaginal ultrasound measurement.2008
[262]Steven Vasilev, M.D., Ovarian Cancer Stage & Grade:Two Critical Factors. Health's Disease and Condition content.2008.
[263]Berchuck A, Elbendary A, Havrilesky L, and et al. Pathogenesis of ovarian cancers. J Soc Gynecol Investig 1994;(1)181-190.
[264]Karst AM, Drapkin R. Ovarian cancer pathogenesis:a model in evolution. J Oncol. 2010;(93)23-71.
[265]Markman M, Liu PY, Rothenberg ML et al. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer J Clin Oncol 2006; 24:1454-1458
[266]Liu P-Y, Alberts DS, Monk BJ et al An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy J Clin Oncol 2007; 25:3615-3620
[267]Medeiros LR, Rosa DD, DA Rosa MI. Accuracy of Ca 125 in the diagnosis of ovarian tumors:a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol,2009; 142:99-105.
[268]Comparison of CA-125 and Standard Definitions of Progression of Ovarian Cancer in the Intergroup Trial of Cisplatin and Paclitaxel Versus Cisplatin and Cyclophosphamide JCO (2006) 24(1):45-51
[269]Coates RRJ, Kolor K, Stewart SL, and et al. Diagnostic markers for ovarian cancer screening:not ready for routine clinical use. Clin Cancer Res,2008; 14,7575-7576
[270]Pauler DK, Menon U, McIntosh M, et al:Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev 10:489-493,2001
[271]Lo Curto M, D'Angelo P, Cecchetto G, and et al. Mature and immature teratomas: results of the first paediatric Italian study. Pediatric Surgery International.2007,23 (4): 315-322
[272]Ries LAG, Melbert D, Krapcho M, and et al. SEER cancer statistics review 1975-2005 Institute. NC, Bethesda. MD.2006,3-20
[273]Hess LM, Benham-Hutchins M, Herzog TJ, and et al. A meta-analysis of the efficacy of intrapexitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer.2007;17(3):561-570.
[274]Elit L, Oliver TK, Covens A, and et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer:a systematic review with metaanalyses. Cancer.2007;109(4):692-702
[275]Goff BA, Mandel LS, Melancon CH, and et al Frequency of symptoms of ovarian cancer. Primary care clinics. JAMA.2004;291(22):2705-2712.
[276]Riedinger JM, Wafflart J, Ricolleau G et al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome:results of a French multicentric study. Ann Oncol 2006; 17:1234-1238.
[277]Vladimir Nossov, AffiliationDepartment of Obstetrics and Gynecology, University of California, Los Angeles, Medical Center, Los Angeles, CA Malaika Amneus, and et al. The early detection of ovarian cancer:from traditional methods to proteomics. Can we really do better than serum CA-125? American Journal of Obstetrics & Gynecology 2008(199),3,215-223 Affiliations
[278]Amer K. Karam & Beth Y. Karlan. Ovarian cancer:the duplicity of CA125 measurement. Nature Reviews Clinical Oncology,2010,7,335-339
[279]Louis Dubeau MD The cell of origin of ovarian epithelial tumors. The Lancet Oncology. 2008, (9)12,1191-1197
[280]Victorian, Brande. Questioning the Role of CA125 as a Biomarker in Ovarian Cancer. Oncology Times,2010, (32)24,9-10
[281]Jankovic M.M, Milutinovic. B S. Pregnancy-associated CA125 antigen associated CA125 antigen as mucin:evaluation of ferning morphology. Mol Hum Reprod,2007 (13)405-408
[282]McLemore MR, Aouizerat B. Introducing the MUC16 gene:implications for prevention and early detection in epithelial ovarian cancer. Biol Res Nurs.2005 6(4):262-7.
[283]Monica R. McLemore, Bradley Aouizerat. Introducing the MUC16 Gene:Implications for Prevention and Early Detection in Epithelial Ovarian Cancer. Biol Res Nurs April 2005,(6)4,262-267
[284]Jankovic M.M, Milutinovic. B S.Pregnancy-associated CA125 antigen associated CA125 antigen as mucin:evaluation of ferning morphology. Mol Hum Reprod,2007, (13)405-408
[285]McGuire WP. CA-125 and Early Ovarian Cancer. J Natl Cancer Inst,2005,95,105-112
[286]Richard R. Barakat, Maurie Markman, Marcus E. Randall. Principles and Practice of Gynecologic Oncology.-2009-Medical-1072
[287]James L. Wilder, Edward Pavlik, John M. Straughn and et al. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecologic Oncology,2003, (89) 2,233-235
[288]Victorian, Brande. Questioning the Role of CA125 as a Biomarker in Ovarian Cancer. Oncology Times,2010, (32)24,9-10
[289]Louis Dubeau MD The cell of origin of ovarian epithelial tumors. The Lancet Oncology. 2008, (9)12,1191-1197
[290]Tiss, Ali, Timms, John F and et al. Highly Accurate Detection of Ovarian Cancer Using CA125 but Limited Improvement With Serum Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Profiling. International Journal of Gynecological Cancer:2010, (20) 9,1518-1524
[291]Merrill Goozner. Personalizing Ovarian Cancer Screening. JNCI J Natl Cancer Inst (2010) doi:10.1093/jnci/djq296
[292]Digant Gupta, Christopher G Lis. Role of CA125 in predicting ovarian cancer survival-a review of the epidemiological literature. Journal of Ovarian Research 2009, (2),13,1757-2215
[293]Menon, U., Gentry-Maharaj, A., Ryan, and et al. Recruitment to multicentre trials lessons from UKCTOCS:descriptive study. BMJ.2008,337,2079-2079
[294]Fang CY, Cherry C, Devarajnk. A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynaecologic screening for ovarian cancer. Gynecol Oncol,2009; 112:594-600.
[295]Jacobs I, Bast RC Jr:The CA 125 tumour-associated antigen:a review of the literature. Hum Reprod 1989,4(1):1-12.
[296]Kurman R. Malignant germ cell ovarian cancer. Hum Pathol.1997,8.5; 551-564
[297]Odicino F, Pecorelli S. Zigliani L & Creasman WT. History of the FIGO cancer staging system. International Journal of Gynecology and Obstetrics.2008;(101)205-210.
[298]Pecorelli S, Ngan HY & Hacker NF (eds). Staging classification and clinical practice guidelines for gynaecological cancers. International Journal of Gynecology & Obstetrics.2000,10(2),207-312.
[299]Survival rates for ovarian cancer in Early Detection, Diagnosis, and Staging. ACS Cancer Facts & Figures,2007
[300]Rio de Janeiro. Survival rates for ovarian cancer in Familial aggregation of breast/ovarian cancer:age of onset along subsequent generations in Brazil. Cadernos de Saude Publica.14(3),1998
[301]Abenhaim, H. A., Titus-Ernstoff, L., Cramer, D. W. Ovarian cancer risk in relation to medical visits, pelvic examinations and type of health care provider. CMAJ.2007,176: 941-947
[302]National Cancer Institute. Anatomy:the cervix and nearby organs, NCI visuals online. Bethesda, MD:National Institutes of Health, United States Department of Health and Human Services.2009,1-2
[303]Mor QVisintin I, Lai Y, et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci US A.2005; 102,7677-768236.
[304]Ovarian Cancer, CA-125 Addiction, and Informed Confusion:Much Ado About Less JCO (2007) 25(24):3570-3571
[305]Agarwal R, Alvero A, Visintin I, et al. Macrophage migration inhibitory factor expression in ovarian cancer. Am J Obstet Gynecol 2007; 196,348,1-537
[306]Kruskal WH, Wallis WA. Use of ranks in one-criterion variance analysis. J Am Stat Assoc.1952,47:583-621
[307]Kindelberger DW, Lee Y, Miron A, and et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma:Evidence for a causal relationship. Am J Surg Pathol. 2007,31:161-169
[308]Huhtinen K, Suvitie P, Hiissa J, and et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. In.Br J Cancer.2009,100(8):1315-1319.
[309]Tanaka YO, Okada S, Yagi T, and et al. MRI of endometriotic cysts in association with ovarian carcinoma. AJR Am J Roentgenol.2010;194(2):355-361
[310]Kane Gueye SM, in retrospective analysis of 93 cases of 018. ML.SD. L 5115 Ovarian tumors in Julio Curie Institute in Dakar (Senegal) results and therapeutic implications. Medicine in Africa. Black.2003 50 (12):556-560
[311]Paw C a Paw. C and neck malignant germinal tumors of the ovary in girls and adolescent:about 82 cases treated in protocols of the French society of pediatric oncology. Ann. Pediatr.1998,(45) 4.210-217
[312]Bast RC Jr, Badgwell D, Lu Z, and et al. New tumor markers:CA125 and beyond. Int J Gynecol Cancer 2005,15(Suppl 3):274-81
[313]Arioz DT, Tokyol C, Sahin FK, et al. Squamous cell carcinoma arising in a mature cystic teratoma of the ovary in young patient with elevated carbohydrate antigen 19-9. Eur. J. Gynaecol. Oncol.2008,29 (3):282-284.
[314]Muscatello L, Giudice M, Feltri M (2005). "Malignant cervical teratoma:report of a case in a newborn". European archives of oto-rhino-laryngology:official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS):affiliated with the German Society for Oto-Rhino-Laryngology-Head and Neck Surgery 262 (11): 899-904
[315]Arlikar JD, Mane SB, Dhende NP, and et al. Fetus in fetus:two case reports and review of literature. Pediatric Surgery International.2009,25 (3):289-292.
[316]Ukiyama E, Endo M, Yoshida F, and et al., Hata Recurrent yolk sac tumor following resection of a neonatal immature gastric teratoma. Pediatr. Surg. J,2005. Int.21 (7): 585-8.
[317]Tumor in baby's brain contained tiny foot.2008,1.
[318]Talmadge (Ted) Cooper. Orbital dermoid cyst at eMedicine.2010,1-5.
[319]Heintz APM, Odicino F, Maisonneuve P, and et al. Carcinoma of the ovary. International Journal of Gynecology & Obstetrics 2006,95(0):161-192.
[320]National Breast and Ovarian Cancer Centre (NBOCC). Population screening and early detection of ovarian cancer in asymptomatic women:NBOCC position statement. Surry Hills, NSW:NBOCC.2009
[321]Malkasian GD Jr, Knapp RC, Lavin PTand et al. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988, 159(2):341-346.
[322]Dixia Chen DX, Schwartz PE, Li XG, Yang Z:Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol 1988,72(1):23-27.
[323]Nolen B, et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol in press.[321]Skates SJ, Singer DE. Quantifying the potential benefit of CA 125 screening for ovarian cancer. J Clin Epidemiol.1991;44(4-5):365.
[324]Ruibal A, Encabo G, Martinez-Miralles E, and et al. CA 125 seric levels in non malignant pathologies. Bull Cancer 1984,71(2):145-146.
[325]Einthorn. N, MD, R. C. and et al. Prospective evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer.1986.67(3),414-416
[326]Stenman UH, Seppala M:Ovarian cancer antigen CA 125 levels in pelvic inflammaroy disease and pregnancy. Cancer 1986,57(7):1327-1329.
[327]Irene Visintin, Ziding Feng, Gary Longton,and et al. Diagnostic Markers for Detection of Ovarian Cancer 2007 Clin Cancer Res.2008; 14(4),1065
[328]Paavonen J, Miettinen A, Heinonen PK, and et al. Serum CA 125 in (?) inflammatory disease Br J Obstet Gynaecol 1989,96(5):574-579
[329]Saito K, Katsumata Y, Hirabuki T, and et al. Fetus-in-fetus:parasite or (?) study of two cases. Fetal. Diagn. Ther.2007,22 (5):383-388. [330]Chua JH, Chui CH, Sai Prasad TR, Jabcobsen AS. Meenakshi A. Hwang W5.(?) in-fetu in the pelvis:report of a case and literature review. Ann. Acad. Med. Singap. 2005,34 (10):646-649
[331]Kajbafzadeh AM, Baharnoori M. Fetus in fetu. Teratoma also occurs, rarely, in non-human animals.Can J Urol.2006,13 (5):3277-8.
[332]Harms D, Zahn S, Gobel U, and et al. Pathology and molecular biology of teratomas in childhood and adolescence. Klinische Padiatrie.2006,218 (6):296-302.
[333]Utsuki S, Oka H, Sagiuchi T, and et al.Malignant transformation of intracranial mature teratoma to yolk sac tumor after late relapse. Case report. J. Neurosurg.2007,106 (6): 1067-1069.
[334]Chen YH. Chang CH, Chen KC, and et al. Malignant transformation of a well-organized sacrococcygeal fetiform teratoma in a newborn male. J. Formos. Med. Assoc.2007.106 (5):400-402
[335]Biskup W, Calaminus G, Schneider DT, and et al. Teratoma with malignant transformation:experiences of the cooperative GPOH protocols MAKEI.2006,1.
[336]Diallo Ramatoulaye and associated and ovarian teratoma:Etude anatomo-clinical pathology department of the National Hospital Donka. Thesis of doctorate in medicine. 2008,1108,41-43.
[337]Chechia Abdellatif[2002]and et al, Struma ovarii, about a case a smart and Benin:Tunis Med.2002, (80) 1,53-56.
[338]Kocaoglu M, Frush DP (2006). Pediatric presacral masses Radiographics 26 (3):833-857.
[339]Lefebvre R, Theoret C, Dore M, and et al. Ovarian teratoma and endometritis in a mare Can. Vet. J.2005,46 (11):1029-1033.
[340]Chan JK, Urban R, Cheung MK, and et al. Ovarian cancer in younger vs older women: a population-based analysis. British Journal of Cancer 2006, (95)1314-1320.
[341]Maas HAAM, Kruitwagen RFPM, Lemmens VEPP, and et al. The influence of age and co-morbidity on treatment and prognosis of ovarian cancer:a population-based study. Gynecologic Oncology 2005,97:104-109.
[342]McMurdo ME, Witham MD & Gillespie ND. Including older people in clinical research. British Medical Journal.2005, (331)1036-1037.
[343]Petignat P, Fioretta G, Verkooijen HM, and et al.2004. Poorer survival of elderly patients with ovarian cancer:a population-based study. Surgical Oncology 2004, (13)181-186.
[344]South Australia Cancer Registry. Epidemiology of cancer in South Australia. Incidence, mortality and survival 1977 to 1999. Incidence and mortality 1999 analysed by type and geographical location. Twenty-three years of data. Adelaide:South Australia Cancer Registry, Epidemiology Branch, Statewide Division, Department of Human Services.2000,2-4
[345]Uyar D, Frasure HE, Markman M and et al. Treatment patterns by decade of life in elderly women (≥ 70 years of age) with ovarian cancer. Gynecologic Oncology.2005, (98),403-408.
[346]Iyer VR, Lee SI, MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization. AJR Am J Roentgenol.2010; 194(2):311-21
[347]Clare Turnbull, Elizabeth A Rapley, Sheila Seal, and et al. Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer. Nature Genetics.2010,42, 604-607
[348]Cancer Research[http://info.cancerresearchuk.org]. United Kingdom(2005)
[349]DeVita VTHS, Rosenberg SA:Principles and Practice of Oncology.1982 edition. Edited by:KR Perez CA. Young RC. Philadelphia:JB Lippioncott; 1982.
[350]Westhoff C:Ovarian cancer. Annu Rev Public Health 1996,17:85-96.
[351]Culton LK, Deavers MT, Silva EG, and et al. Endometrioid Carcinoma Simultaneously Involving the Uterus and the Fallopian Tube:A Clinicopathologic Study of 13 Cases. Uterine Carcinoma. Am J Surg Pathol.2006,30(7):844-849.
[352]Incidence of ovarian cancer, Incidence in 2006. In An overview. Ovarian cancer, Australia. Australian Institute of Health and Welfare and National Breast and Ovarian Cancer Centre, Australian Institute of Health and Welfare Canberra 2010,48,136
[353]An overview. In Ovarian cancer, Australia. Australian Institute of Health and Welfare and National Breast and Ovarian Cancer Centre, Australian Institute of Health and Welfare Canberra 2010,48,5
[354]AIHW & CA. Cancer Australia. Non-melanoma skin cancer: general practiceconsultations, hospitalisation and mortality. Cancer series. Canberra: AIHW.2008, (43), Cat. (39).
[355]Incidence in 2006 in Introduction Ovarian cancer, Australia. Australian Institute of Health and Welfare and National Breast and Ovarian Cancer Centre, Australian Institute of Health and Welfare Canberra 2010,48,1-65
[356]Ahmedin Jemal, Rebecca Siegel, Elizabeth Ward, Yongping Hao, Jiaquan Xu and Michael J. Thun. Cancer Statistics,2009. CA Cancer J Clin 2009;59;225
[357]Tracey EA, Roder D, Francis J, Zorbas HM, Hacker NF & Bishop J. Reasons for improved survival from ovarian cancer in New South Wales, Australia, between 1980 and 2003:implication for cancer control. International Journal of Gynecological Cancer 2009,19(4),591-599.
[358]Morris CR, Rodriquez AO, Epstein J & Cress RD. Declining trends of epithelial ovarian cancer in California. Gynecologic Oncology 2008, (108),207-213.
[359]FDH (Florida Department of Health). Ovarian cancer in Florida. Tallahassee:Bureau of Epidemiology.2009,1.
[360]Kjaerbye-Thygesen A, Huusom LD, Frederiksen K & Kjaer SK. Trends in the incidence and mortality of ovarian cancer in Denmark 1978-2002:comparison with other Nordic countries. Acta Obstetricia et Gynecologica Scandinavica 2005, (84),1006-1012
[361]Grossi M. Quinn MA. Thursfield VJ. Francis PA, Rome RM, Planner RS et al. Ovarian cancer:patterns of care in Victoria during 1993-1995. Medical Journal of Australia. 2002,177(1),11-16.
[361]Kosary CL. Cancer of the ovary. In:Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD & Horner MJ (eds). SEER survival monograph:cancer survival among adults:US SEER Program,1998-2001, patient and tumour characteristics. NIH pub. Bethesda, MD:National Cancer Institute.2007,(07).6215.
[363]WHC (Women's Health Council) & NCRI (National Cancer Registry Ireland). Women and cancer in Ireland 1994-2001. Dublin:The Women's Health Council,2006,7
[364]Bast RC Jr, Feeney M, Lazarus H. Nadler LM, Colvin RB, Knapp RC:Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981,68(5):1331-1337.
[365]Bast RC Jr, Klug TL, St John E, and et al:A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983, 309(15):883-887.
[366]Alice Park. Ovarian Cancer Screening:Hope for Early Detection. Health & Science. 2010,1-9
[367]Dolson Laura. The Truth About CA 125 Have you seen the Infamous Email? Here's the Whole Story. CA125 Test Facts and Myth.2001,1,5
[368]Granberg S., Wikland M, Friberg L.-G. Tumor marker CA 125 level and ovarian volume at different cycle day periods and in postmenopause. International Journal of Gynecology & Obstetrics.,1990, (33)2,149-152
[369]Ferlay, J, Bray, F, Psiani, P,and et al. Cancer Incidence, Mortality and Prevalence Worldwide IARC Cancer Base. IARCH Press; 2004,5(2),3
[370]Duffy M.J., Bonfrer J.M, Kulpa J., and et al. CA125 in ovarian cancer:European Group on Tumor Markers guidelines for clinical use.2005,15(5),679-691
[371]Louis Dubeau MD The cell of origin of ovarian epithelial tumours. The Lancet Oncology.2008, (9)12,1191-1197
[372]Daniel G. Rosen, Lin Wang, J. Neeley Atkinson, and et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecologic Oncology, 2005(99),267-277
[373]Robert C Past. Early Detection of Ovarian Cancer:New Technologies in Pursuit of a Disease that is Neither Common nor Rare. Trans Am Clin Climatol Assoc. Transactions of the American Clinical and Climatological Association.2004; 115,115-233
[374]Jacobs I, Bast RC, Jr. L'antigene CA 125 associe a la tumeur:une revue de la litterature. Hum Reprod,1989,4,1-9
[375]McIntosh M.W., Drescher C., Karlan B., and et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma Gynecol Oncol 2004 October; 95(1):9-15
[376]Yang L, Klint A, Lambe M, Bellocco R, Riman T, Bergfeldt K et al. Predictors of ovarian cancer survival:a population-based prospective study in Sweden. International Journal of Cancer 2008,(123),672-679
[377]Stany MP, Maxwell GL, Rose GS. Clinical decision making using ovarian cancer risk assessment. AJR Am J Roentgenol. Feb 2010;194(2):337-42
[378]Fourati H. et al. Goitre ovarian aspects anatomo-clinical and therapeutic About 6 cases: Tunis. Med.1998, (76)3,42-45
[379]Aggarwal A, Lucco KL, Lacy J, and et al. Ovarian epithelial tumors of low malignant potential:a case series of 5 adolescent patients. J Pediatr Surg.2009; 44(10):2023.
[380]Kurman R[1997], malignant germ cell ovarian cancer. Hum Pathol.1997,8(5); 551-564
[381]Caroline Munzer, Florence Menegaux, Brigitte Lacour, and et al. Birth-related characteristics, congenital malformation, maternal reproductive history and neuroblastoma:the ESCALE study (SFCE) Int J Cancer.2008; 122(10):2315.
[382]Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N et al. (ed. SEER cancer statistics review,1975-2006. Bethesda, MD:National Cancer Institute. 2009,1-4
[383]Cancer Research UK 2006. Cancer Stats:ovarian cancer survival statistics. London: Cancer Research UK.2009.
[384]WCRF (World Cancer Research Fund) & AICR (American Institute for Cancer Research) Food, nutrition, physical activity and the prevention of cancer:a global perspective. Washington:AIRC.2007,2-4.
[385]Yin BW, Lloyd KO Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001,276:27371-27375
[386]O'Brien TJ, Beard JB, Underwood LJ, and et al. The CA 125 gene:an extracellular superstructure dominated by repeat sequences. Tumour Biol 2001,22:348-366.
[387]Burger RA, Darcy KM, DiSaia PJ, and et al. Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy:a gynecologic oncology group study. Cancer 2004, 101:106-115
[388]Tuxen MK, Soletormos G, Dombernowsky P:Serum tumour marker CA 125 in monitoring of ovarian cancer during firstline chemotherapy. Br J Cancer 2001, 84:1301-1307.
[389]Franco Odicino, Sergio Pecorelli, Lucia Zigliani,William T. Creasman. History of the FIGO cancer staging system. International Journal of Gynecology and Obstetrics (2008) 101,205-210
[390]Makar AP, Kristensen GB, Kaern J, Bormer OP, Abeler VM, Trope CG:Prognostic value of pre-and postoperative serum CA 125 levels in ovarian cancer:new aspects and multivariate analysis. Obstet Gynecol 1992,79:1002-1010
[391]Gadducci A, Zola P, Landoni F, and et al. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer:results of a multicentric Italian study. Gynecol Oncol 1995, 58:42-47.
[392]Burg ME van der, Lammes FB, van Putten WL, and et al. Ovarian cancer:the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecol Oncol 1988,30:307-312.
[393]Colakovic S, Lukic V, Mitrovic L, and et al. Prognostic alue of CA125 kinetics and half-life in advanced ovarian cancer. Int J Biol Markers 2000,15:147-152.
[394]Hunter VJ, Daly L, Helms M, and et al The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction Am J Obstet Gynecol 1990,163:1164-1167.
[394]Hawkins RE, Roberts K, Wiltshaw E, and et al The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol 1989,96:1395-1399.
[395]Mano A, Falcao A, Godinho I, Santos J, Leitao F, Oliveira C, Caramona M:CA-125 AUC as a new prognostic factor for patients with ovarian cancer. Gynecol Oncol 2005, 97:529-534.
[396]Van Dalen A, Favier J, Burges A, and et al Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol 2000, 79:441-448.
[397]Peters-Engl C, Obermair A, Heinzl H, and et al. CA 125 regression after two completed cycles of chemotherapy:lack of prediction for long-term survival in patients with advanced ovarian cancer. Br J Cancer 1999,81:662-666
[398]Badgwell D, Bast RC Jr. Early detection of ovarian cancer. Dis Markers.2007; 23(5-6):397.
[399]Das PM, Bast RC Jr. Early detection of ovarian cancer. Biomark Med.2008 Jun:2(3):291
[400]Zhen Zhang, Robert C. Bast Jr., Yinhua Yu, and et al. Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer. Cancer Res.2004.64; 5882-5890
[401]Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer Mol Cell Proteomics 2004; 3,355-366.
[402]Yu B, Xu PZ, Wang QW, and et al. Clinical value of tumour specific growth factor (TSGF) and carbohydrate antigen-125 (CA-125) in carcinoma of the endometrium. J Int Med Res.2009,37(3):878-883.
[403]Kolwijck E, Thomas CM, Bulten J,and et al. Preoperative CA-125 levels in 123 patients with borderline ovarian tumors:a retrospective analysis and review of the literature. Int J Gynecol Cancer.2009; 19(8):1335-1336.
[404]Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, and et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer. 2005;15(5):679-689.
[405]Huhtinen K, Suvitie P, Hiissa J, and et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. In.Br J Cancer.2009 4(101),3
[406]Parera M, Adamo B, Peralta S, and et al. Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels. Ann Oncol.2009,20(2):294-297.
[407]Camlica H, Duranyildiz D, Tas F, Yasasever V. Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer. Am J Clin Oncol.2008, 31(6),585-588.
[408]Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem.2004,5; 279(10),9190-9198.
[409]Khan Y, Haq AN, Nasar R. Primary fallopian tube carcinoma presenting with a sinus in the posterior portion of cervix. Int J Gynecol Cancer.2004;14(1):166-168.
[410]Pardeshi SP, Kulkarni MM, Hishikar VA. Primary fallopian tube carcinoma. J Postgrad Med.1996; 42(2),59-61.
[411]Ovarian cancer. How is ovarian cancer staged? in Early Detection, Diagnosis, and Staging Topic. American Cancer Society.2010,20-27
[412]Asher et al., Pelvic mass associated with raised CA 125 for benign condition:a case report World Journal of Surgical Oncology 2010,8:28
[413]Ron IG, Inbar M, Gelernter I, and et al. Use of CA-125 response to predict survival parameters of patients with advanced ovarian carcinoma. Acta Obstet Gynecol Scand 1994,73:658-662.
[414]Cruickshank DJ. Fullerton WT, Klopper A. The clinical significance of pre-operative serum Cancer antigen 125 and prognosis. Curr Opin Obstet Gynecol 2008,20:4-6
[415]Kurman RJ, Visvanathan K, Roden R, and et al. Early detection and treatment of ovarian cancer:shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am. J. Obstet. Gynecol.2008,198(4):351-354.
[416]Goonewardene TI, Hall MR, Rustin GJS. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol 2007; 8: 813-821
[417]Ryerson AB, Eheman C, Burton J, et al. Symptoms, diagnoses, and time to key diagnostic procedures among older U.S. women with ovarian cancer. Obstet Gynecol. 2007 109(5):1053-1059.
[418]Bankhead CR, Kehoe ST, Austoker J. Symptoms associated with diagnosis of ovarian cancer:a systematic review. BJOG.2005,112 (7):857-65
[419]Hogdall E:Cancer antigen 125 and prognosis. Curr Opin Obstet Gynecol 2008,20,4-8.
[420]Gadducci A, Cosio S, Tana R, Genazzani AR:Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol 2009.69(1):12-27
[421]Liu J, Xu Y, Wang J:Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis of ovarian carcinoma. Eur J Radiol 2007,62(3):328-334
[422]Consesus Development Program. Ovarian Cancer:Screening, Treatment, and Followup. National Institutes of Health Consensus Development Conference Statement,1994 in OvarianCancer.2005,2.
[423]Togashi K:Ovarian cancer:the clinical role of US, CT, and MRI. Eur Radiol.2003, 13(4):87-104.
[424]Jeong YY, Outwater EK, Kang HK:Imaging evaluation of ovarian masses. Radiographics 2000,20(5):1445-1470.
[425]Balan P:Ultrasonography, computed tomography and magnetic resonance imaging in the assessment of pelvic pathology. Eur J Radiol 2006,58(1):147-1455.
[426]Risum S, Hφgdall C, Loft A, and et al. The diagnostic value of PET/CT for primary ovarian cancer--a prospective study Gynecol Oncol 2007,105(1):145-149
[427]Boubacar Siddi Diallo FB[1997]and neck, ovarian tumor, incidence, pathology and therapy at the Clinic for Gynecology and Obstetrics University Hospital of Donka. Thesis of doctor of medicine. University of Conakry.1997,46,54-57
[428]Chambers, A. F., Vanderhyden, B. C. Ovarian Cancer Biomarkers in Urine. Clin. Cancer Res.2006,12:323-327
[429]Cancer Council Victoria. Canstat:ovarian cancer. Carlton:Cancer Council Victoria. 2007,1.
[430]Katsumata N, Yasuda M, Takahashi F, and et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer:a phase 3, open-label, randomised controlled trial. Lancet.2009;374(9698):1331-1336.
[431]Markman M, Liu PY, Moon J, and et al. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel:follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol.2009;114(2):195-197.
[432]Riman T, Persson I, Nilsson S:Hormonal aspects of epithelial ovarian cancer:review of epidemiological evidence. Clin Endocrinol (Oxf) 1998,49:695-704
[433]Survival by stage at diagnosis. Australia. Australian Institute of Health and Welfare and National Breast and Ovarian Cancer Centre, Australian Institute of Health and Welfare Canberra 2010,48,38
[434]Emily Jackson, Ken Anderson, Chris Ashwell, James Petitte and Paul E. Mozdziak CA125 expression in spontaneous ovarian adenocarcinomas from laying hens. Gynecologic Oncology.2007, (104) 1,192-198
[435]Jacobs IJ, Skates S, Davies AP, Woolas RP, Jeyerajah A, Weidemann P, Sibley K, Oram DH:Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration:a prospective cohort study. BMJ 1996.313(7069):1355-1358.
[436]Bast RC, Brewer M, Zou C, et al. Prevention and early detection of ovarian cancer: mission impossible?. Recent Results Cancer Res.2007,174:91-98
[437]Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N. Engl. J. Med. 2009,361 (2):170-174
[438]Wylam Fought and et al. Journal of Obstetrics Gynecology/Cancer.2009,31(4),300-302
[439]Piek JM, van Diest PJ, Verheijen RH. Ovarian carcinogenesis:an alternative hypothesis. Adv. Exp. Med. Biol.2008,622:79-87
[440]Fazal Hussain, MBBS, Hamed Homoud Al Husainia Gynecologic Tumor Marker Contributor Information and Disclosures.2010,1-6
[441]Liu YN, Ye X, Cheng HY, and et al. Measurement of serum human epididymis secretory protein 4 combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian benign and malignant tumors. Zhonghua Fu Chan Ke Za Zhi. 2010;45(5):363-364.
[442]Barbosa CP, Souza AM, Bianco B, and et al. Frequency of endometriotic lesions in peritoneum samples from asymptomatic fertile women and correlation with CA125 values. Sao Paulo Med J.2009 Nov;127(6):342-5.
[443]Nabeta M, Abe Y, Haraguchi R, and et al. Serum anti-PDIKIL autoantibody as a novel marker for endometriosis. Fertil Steril.2010,2
[444]Penninx J, Brandes M, de Bruin JP, and et al. Prediction of pelvic pathology in subfertile women with combined Chlamydia antibody and CA-125 tests. Eur J Obstet Gynecol Reprod Biol.2009; 147(2):178-82.
[445]Pfisterer J, Plante M, Vergote I, and et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer:an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol.2006;24(29):4699-707.
[446]Evans, J., Ziebland, S., McPherson, A. Minimizing delays in ovarian cancer diagnosis: an expansion of Andersen's model of total patient delay. Fam Pract.2007,24:48-53
[447]Hydzik C. Treatment of ovarian cancer with intraperitoneal chemotherapy. Oncology. 2009;23(11):15-18.
[448]Jemal A, Siegel R, Ward E, and et al. Cancer statistics J. CA Cancer J Clin,2009,59: 225-238.
[449]Duan ZF, Ames RY, Ryan M, et al. CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells J. Cancer Chemoth Pharm,2009,63(4):681-684.
[450]Odening KE, Li W, Rutz R, et al. Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells J. Clin Exp Immunol,2009,155(2):239-244.
[451]Vandersickel V, Mancini M, Marras E, et al. Lentivirus-mediated RNA interference of Ku70 to enhance radiosensitivity of human mammary epithelial cells. J. Int J Radiat Biol,2010,86(2):114-120.
[452]Sankpal NV, Fleming TP, Gillanders, WE. Dual Expression Lentiviral Vectors for Concurrent RNA Interference and Rescue. J Surg Res,2009,156(1):50-56.
[453]Greenlee RT, Hill-Harmon MB, Murray T, and et al. Cancer statistics,2001.CA Cancer J Clin 2001:51:15-29.
[454]Oehler VG, Yeung KY, Choi YE. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data J. Blood,2009,114(15):3292-3295.
[455]Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med.2006; 354,34-35.
[456]Christine S. Walsh and Beth Y. Karlan Contemporary progress in ovarian cancer screening Current Oncology Reports.2007,(9) 6,484
[1]Joyner AB. Runowicz CD. Ovarian cancer screening and early detection. In Carole & Ray Neag Comprehensive Cancer Center, University of Connecticut Health Center, Obstetrics & Gynecology, Farmington, CT 05030, USA. Womens Health (Lond Engl). 2009;5(6):693-696.
[2]Yin, B. W. T.; Lloyd, K.O. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J. Biol. Chem.2001,276(29),2732.
[3]Argueso, P.; Spurr-Michaud, S.; Russo, and et al. MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope. Invest. Ophthal. Vis. Sci.2003,44(6)::2485-2493
[4]Moszynski R, Szpurek D, Michalak S, and et al. The role of endothelin-1 and its correlation with CA125 levels, grayscale ultrasonography and doppler findings in differential diagnoses of ovarian tumors. In Division of Gynecological Surgery, Department of Gynecology, Obstetrics and Gynecological Oncology, University of Medical Sciences, Poznan, Poland. Eur J Gynaecol Oncol.2009;30(5):552-553.
[5]Rinker-Schaeffer C. W., O'Keefe J. P., Welch D. R., and et al. Theodorescu, Metastasis suppressor proteins:discovery, molecular mechanisms, and clinical application. Clinical Cancer Research,2006,(12)13,3882-3889.
[6]Julang Li, Qiang Feng, Jong-Min Kim, and et al. Human Ovarian Cancer and Cisplatin Resistance:Possible Role of Inhibitor of Apoptosis Proteins. Endocrinology.2001, 142(1),370
[7]Jinsong Liu, Gong Yang.1 Jennifer A and et al. A Genetically Defined Model for Human Ovarian Cancer. CANCER RESEARCH,2004 64,1655.
[8]William G. Kaelin Jr The von Hippel-Lindau tumour suppressor protein:O2 sensing and cancer Nature Reviews Cancer 2008,8,865-873
[9]Ingegerd Hellstrom, John Raycraft, Martha Hayden-Ledbetter, Jeffrey A. Ledbetter, Miche, Schummer, Martin McIntosh, Charles Drescher, Nicole Urban, and Karl Erik Hellstrom
[10]I. H., J. R., M. H-L., and et al. Pacific Northwest Research Institute, Institute for Systems Biology [M. S., Fred Hutchinson Cancer Research Center [M. M., C. D.,N. U., and Swedish Hospital and Medical Center [C. D., The HE4 (WFDC2) Protein Is a Biomarker for Ovarian Carcinoma. CANCER RESEARCH.2003,63,3695-3700
[11]Berek, J. S., Bast, R. C, and et al. Ovarian cancer screening The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer,1995.76:2092-2089.
[12]Maggino, T., Gadducci, A., D'Addario, and et al. Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol. Oncol.,1994,54:117-119,
[13]Chang, K., Pai, L. H., Batra, J. K., Pastan, I., and Willingham, M. C. Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res.,1992,52:181-178.
[14]Scholler, N., Fu, N., Yang, and et al. Soluble member(s) of the mesothelin/ megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc. Natl. Acad. Sci. USA,1999,96:11531-11526,.
[15]Schummer, M., Ng, W., Bumgarner, R., and et al. Comparative hybridization of an array of 21 500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene,1999,238:375-381.
[16]Ono, K., Tanaka, T., Tsunoda, T., and et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis Cancer Res.,2000,60:5007-5009.
[17]Welsh, J. B., Zarrinkar, P. P., Sapinoso, and et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Natl. Acad. Sci. USA,2001,98:1176-1178,
[18]Kirchhoff, C, Habben, I., Ivell, R., and et al. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol. Reprod.,1991,45:350-348.
[19]Kirchhoff, C. Molecular characterization of epididymal proteins. Rev. Reprod.,1998, 3:86-95.
[20]Dandekar, A. M., Robinson, E. A., Appellla, E., and et al. Complete sequence analysis of cDNA clones encoding rat whey phosphoprotein:homology to a protease inhibitor. Proc. Natl. Acad. Sci. USA,1982,79:3987-3989.
[21]Heinzel, R., Appelhans, H., Gassen, G., and et al. Molecular cloning and expression of cDNA for human antileukoprotease from cervix uterus. Eur. J. Biochem.,1986,160: 63-65.
[22]Wiedow, O., Schroder, J. M., Gregory, H., and et al. An elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J. Biol. Chem.,1990,265:14791-14792.
[23]Bingle, L., Singleton, V., and Bingle, C. D. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene,2002,21:2768-2773.
[24]Hayden, M. S., Gilliland, L. K., and Ledbetter, J. A. Antibody engineering. Curr. Opin. Immunol.,1997,9:201-212.
[25]Davidson NG, Khanna S, Kirwan PH. Bircumshaw D:Prechemotherapy serum CA125 level as a predictor of survival outcome in epithelial carcinoma of the ovary. Clin Oncol (R Coll Radiol) 1991,3:32-26.
[26]Rustin GJ, Gennings JN, Nelstrop AE, and et al. Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group. J Clin Oncol 1989,7:1667-1667.
[27]Burger RA, Darcy KM, DiSaia PJ, and et al. Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy:a gynecologic oncology group study. Cancer 2004, 101:106-109.
[28]Kim HS, Park NH, Chung HH, and et al. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer. Onkologie 2008,31:315-312.
[29]Juretzka MM, Barakat RR, Chi DS, and et al. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol 2007,104:176-178.6 Riedinger JM, Bonnetain F, Basuyau JP, and et al. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. Ann Oncol 2007,18:881-875.
[30]Badulescu F, Badulescu A, Schenker M, Popescu CF, Stoica Z:The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma. Rom J Morphol Embryol 2005 46:329-328.
[31]Fisken J, Leonard RC, Stewart M, Beattie GJ, Sturgeon C, Aspinall L, Roulston JE: The prognostic value of early C A125 serum assay in epithelial ovarian carcinoma. Br J Cancer 1993,68:140-135.
[32]Redman CW, Blackledge GR, Kelly K, Powell J, Buxton EJ, Luesley DM:Early serum CA125 response and outcome in epithelial ovarian cancer. Eur J Cancer 1990. 26:593-586
[33]Colakovic S, Lukic V, Mitrovic L, Jelic S, Susnjar S, Marinkovic J:Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer. Int J Biol Markers 2000, 15:147-149.
[34]Yedema CA, Kenemans P, Voorhorst F, Bon G, Schijf C, Beex L, Verstraeten A, Hilgers J, Vermorken J:CA 125 half-life in ovarian cancer: a multivariate survival analysis. Br J Cancer 1993,67:1361-1357.
[35]Osman N, O'Leary N, Mulcahy E, Barrett N, Wallis F, Hickey K, Gupta R:Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre. Ir Med J 2008,101:245-237.
[36]Van Dal en A, Favier J, Burges A, and et al. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol 2000,79:444-445.
[37]Cooper BC, Sood AK, Davis CS, and et al. Preoperative CA 125 levels:an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol 2002 100:59-54.
[38]Buller RE, Vasilev S, DiSaia PJ:CA 125 kinetics:a cost-effective clinical tool to evaluate clinical trial outcomes in the 1990. Am J Obstet Gynecol 1996,174:1241-1243.
[39]Nagele F, Petru E, Medl M, and et al. Preoperative CA 125:an independent prognostic factor in patients with stage Ⅰ epithelial ovarian cancer. Obstet Gynecol 1995,86:259-264.
[40]Makar AP, Kristensen GB, Kaern J, and et al. Prognostic value of pre-and postoperative serum CA 125 levels in ovarian cancer:new aspects and multivariate analysis. Obstet Gynecol 1992.79:1002-1008.
[41]Sevelda P, Schemper M, Spona J:CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1989 161:1213-1206.
[42]Moebus V:KRCGWHCHKH:Evaluation of CA125 as a prognostic and predictive factor in ovarian cancer. J Tumor Marker Oncol 1988,3:251-248.
[43]Cruickshank DJ. Fullerton WT. Klopper A:The clinical significance of pre-operative serum CA 125 in ovarian cancer. Br J Obstet Gynaecol 1987,94:692-685
[44]Hunter VJ, Daly L, Helms M, and et al. The prognostic significance of CA 125 half- life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol 1990,163:1164-1157.
[45]Hawkins RE, Roberts K, Wiltshaw E, Mundy J, Fryatt IJ, McCready VR:The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol 1989,96:1395-1389.
[46]Gard GB, Houghton CR:An assessment of the value of serum CA 125 measurements in the management of epithelial ovarian carcinoma. Gynecol Oncol 1994,53:283-259.
[47]Frasci G, Conforti S, Zullo F, and et al. A risk model for ovarian carcinoma patients using CA 125:time to normalization renders second-look laparotomy redundant. Cancer 1996,77:1122-1120.
[48]Mano A, Falcao A, Godinho I, Santos J, Leitao F, de Oliveira C, Caramona M:CA-125 AUC as a predictor for epithelial ovarian cancer relapse. Cancer Biomark 2008, 4:73-78.
[49]Mano A, Falcao A, Godinho I, and et al. CA-125 AUC as a new prognostic factor for patients with ovarian cancer. Gynecol Oncol 2005,97:529-524.
[50]Riman T, Persson I, Nilsson S:Hormonal aspects of epithelial ovarian cancer:review of epidemiological evidence. Clin Endocrinol (Oxf) 1998,49:695-702.
[51]Hermsen BBJ. von Mensdorff-Pouilly S, Berkhof J, et al:Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk ovarian cancer. J Clin Oncol 2007,25,1386
[52]Olsen CM, Green AC, Nagle CM, et al.; Australian Cancer Study Group (Ovarian Cancer) and the Australian Ovarian Cancer Study Group. Epithelial ovarian cancer: testing the'androgens hypothesis'. Endocr Relat Cancer.2008;15:1061-1060.
[53]Bidart JM, Thuillier F, Augereau C, Chalas J, Daver A, Jacob N, Labrousse F, Voitot H:Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 1999,45:1695-1701.
[54]Tamakoshi K, Kikkawa F, Hasegawa N, and et al. Clinical value of a new serum tumor marker, CA125II, in gynecologic disease:comparison with CA125. Gynecol Obstet Invest.1995; 39(2),125-129.
[55]Bets Davis, Ovarian cancer. Obstetrics and Gynecology,2009.
[56]Christine Wendt. Protein Diabetes Educator.2009
[57]U.S. Preventive Services Task Force. Screening for ovarian cancer,2004.6.
[58]Finegan J, Bartleman B, Wong PY:A window for the study of prenatal sex hormone influences on postnatal development. J Genet Psychol 1988; 150:101-112
[59]Rubinow DR, Schmidt PJ:Androgens, brain, and behavior. Am J Psychiatry 1996; 153:974-984
[60]Caswell H, Weeks DE:Two-sex models:chaos, extinction, and other dynamic consequences of sex. American Naturalist 1986; 128:707-735
[61]Bachman DL, Wolf PA, Linn R, and et al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology 1992; 42:115-119
[62]Finegan J, Bartleman B, Wong PY:A window for the study of prenatal sex hormone influences on postnatal development. J Genet Psychol 1988; 150:101-112
[63]Rubinow DR, Schmidt PJ:Androgens, brain, and behavior. Am J Psychiatry 1996; 153:974-984
[64]Caswell H, Weeks DE:Two-sex models:chaos, extinction, and other dynamic consequences of sex. American Naturalist 1986; 128:707-735
[65]Bachman DL, Wolf PA, Linn R, and et al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology 1992; 42:115-119
[66]Bachman DL, Wolf PA, Linn RT, and et al. Incidence of dementia and probable Alzheimer's disease in a general population:the Framingham Study. Neurology 1993; 43:515-519
[67]Canadian Study of Health and Aging Working Group:Canadian study of health and aging:study methods and prevalence of dementia. Can Med Assoc J 1994; 150:899-8913
[68]Tang MX, Jacobs D, Stern Y, and et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348:429-432
[69]Henderson VW, Buckwalter JG:Cognitive deficits of men and women with Alzheimer's disease. Neurology 1994; 44:90-96
[70]Hafner H, an der Heiden W:Epidemiology of schizophrenia. Can J Psychiatry 1997; 42:139-151
[71]Lewine RJR, Seeman MV. Gender, brain, and schizophrenia:anatomy of differences/differences of anatomy, in Gender and Psychopathology. Edited by Seeman MV. Washington, DC, American Psychiatric Press,1995
[72]Jablensky A, Cole SW:Is the earlier age at onset of schizophrenia in males a confounded finding? Br J Psychiatry 1997; 170:234-240
[73]Ciompi L The influence of aging on schizophrenia. Triangle 1993; 32:25-31
[74]Wong DF, Wagner HN Jr, Dannals RF and et al. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 1984; 226:1393-1396
[75]Seeman MV:Sex differences in predicting neuroleptic response, in The Prediction of Neuroleptic Response. Edited by Gaebel W, Awad AG. Vienna, Springer-Verlag,1995, pp 51-64
[76]Blum M, McEwen BS, Roberts JL:Transcriptional analysis of tyrosine hydroxylase gene expression in the tuberoinfundibular dopaminergic neurons of the rat arcuate nucleus after estrogen treatment. J Biol Chem 1987; 262:817-821
[77]DiPaolo T:Modulation of brain dopamine transmission by sex steroids. Rev Neurosci 1994; 5:27-42
[78]Toran-Allerand CD:The estrogen/neurotrophin connection during neural development: is co-localization of estrogen receptors with the neurotrophins and their receptors biologically relevant? Dev Neurosci 1996; 18:36-41
[79]Seeman MV, Lang M:The role of estrogens in schizophrenia gender differences. Schizophr Bull 1990; 16:185-194
[80]Bast RC Jr, Klug TL, St John E, and et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983 309:883-882.
[81]Nustad K, Bast RC Jr, Brien TJ, and et al. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen:first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumour Biol 1996,17:196-212.
[82]Markman M:Optimizing primary chemotherapy in ovarian cancer. Hematol Oncol Clin North Am 2003,17:957-958.
[83]Kenemans P, van Kamp GJ, Oehr P, Verstraeten RA:Heterologous double-determinant immunoradiometric assay CA 125 II:reliable second-generation immunoassay for determining CA 125 in serum. Clin Chem 1993,39:2509-2510.
[84]Hogdall EV, Christensen L., Kjaer SK, and et al. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. Gynecol Oncol 2007,104:508-509.
[85]Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE:Defining progression of ovarian carcinoma during follow-up according to CA 125:a North Thames Ovary Group Study. Ann Oncol 1996,7:361-344.
[86]Rustin GJ, Marples M, Nelstrop AE. Mahmoudi M, Meyer T:Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 2001,19:4054-4027.
[87]Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB:CA 125:the past and the future. Int J Biol Markers 1998,13:179-187.
[88]Menon U, Jacobs IJ:Ovarian cancer screening in the general population. Curr Opin Obstet Gynecol 2001,13:61-60.
[89]Verheijen RH, Mensdorff-Pouilly S, van Kamp GJ, Kenemans P:CA 125: fundamental and clinical aspects. Semin Cancer Biol 1999,9:117-114.
[90]Yin BW, Lloyd KO:Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001,276:27371-27370.
[91]Skates SJ, Menon U, MacDonald N, Rosenthal AN, Oram DH, Knapp RC, Jacobs IJ: Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003,21:206-205.
[92]Rustin GJ, Bast RC Jr, Kelloff GJ, Barrett JC, Carter SK, Nisen PD, Sigman CC, Parkinson DR, Ruddon RW:Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 2004,10:3919-3916.
[93]Gronlund B, Dehn H, Hogdall CK, Engelholm SA, Jorgensen M, Norgaard-Pedersen B, Hogdall EV:Cancer-associated serum antigen level:a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma. Int J Gynecol Cancer 2005, 15:836-833.
[94]Kang WD, Choi HS, Kim SM. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer. In Department of Obstetrics and Gynecology, Chonnam National University Medical School,8 Hakdong, Dong-gu, Gwangju, Republic of Korea. Gynecol Oncol.2010 Jan;116(1):57-55.
[95]Zurawski VR Jr, et al. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia:relevance for early detection of ovarian cancer. Int J Cancer 1988; (42)677-648
[96]Agustin A Garcia, Samina Ahmed. Ovarian Cancer. Contributor Information and Disclosures.2010
[97]3 Kojima, T., Oh-eda, M., Hattori, and et al. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J. Biol. Chem.,1995,270:21984-21987.
[98]4 Chang, K.; Pastan, I.:Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas. and ovarian cancers. Proc. Nat. Acad. Sci.93, 1996,138.
[99]Scholler, N.; Fu, N.; Yang, Y.; and et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc. Nat. Acad. Sci.1999,96:11531-11535.
[100]Bera, T. K.; Pastan, I. Mesothelin is not required for normal mouse development or reproduction. Molec. Cell. Biol.2000,20,2905.
[101]Campbell, I. G.; Nicolai, H. M.; Foulkes, W. D.; and et al. A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1. Hum. Molec. Genet.3:1994,589-579.
[102]Lange, S.; Xiang, F.; Yakovenko, A.; and et al. The kinase domain of titin controls muscle gene expression and protein turnover. Science,2005,308,1599-1601.
[103]Brown, M. A.; Nicolai, H.; Xu, C.-F.; and et al. Regulation of BRCA1. (Letter) Nature 1994,372,730.
[104]Brown, M. A.; Xu, C.-F.; et al. The 5-prime end of the BRCA1 gene lies within a duplicated region of human chromosome 17q21. Oncogene 1996,12,2511.
[105]Santillan A, Garg R, Zahurak ML, et al:Risk of epithelial ovarian cancerrecurrence in patients with rising serum CA125 levels within the normal range.J Clin Oncol 2005, 23:9338-9339
[106]Friedman LC, Kramer RM:Reproductive issues for women with BRCA mutations. J Natl Cancer Inst Monogr 2005,34,85
[107]Ransohoff DF:Lessons from controversy:Ovarian cancer screening and serum proteomics. J Natl Cancer Inst 2005,97:315-317
[108]Hermsen BBJ, van Diest PJ, Berkhof J, et al:Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and fallopian tube in women at hereditary high risk of breast and ovarian cancer. Int J Cancer.2006 119:1412-1409
[109]Kirtly Jones, Female reproductive system. Obstetrics and Gynecology Medicine.2008
[110]Maria Essig. DNA (deoxyribonucleic acid). Reproductive Genetics,2009
[111]Sandy Jocoy, A pelvic exam Obstetrics and Gynecology.2009
[112]Monica Rhodes. Biopsy Medical Toxicology.2009
[113]Ovarian cancer. NCCN Practice Guidelines in Oncology, National Comprehensive Cancer Network.2009.
[114]Sendahl M, Ernst E, Rasmussen PE, Yding Andersen C.2008.
[115]Fertil. Steril. True ovarian volume is underestimated by two-dimensional transvaginal ultrasound measurement.2008
[116]Steven Vasilev, M.D., Ovarian Cancer Stage & Grade:Two Critical Factors. Health's Disease and Condition content.2008.
[117]Berchuck A, Elbendary A, Havrilesky L, and et al. Pathogenesis of ovarian cancers. J Soc Gynecol Investig 1994;(1)181-190.
[118]Karst AM, Drapkin R. Ovarian cancer pathogenesis:a model in evolution. J Oncol. 2010; (93)23-71.
[119]Markman M, Liu PY, Rothenberg ML et al. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer J Clin Oncol 2006; 24:1454-1458
[120]Liu P-Y, Alberts DS, Monk BJ et al An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy J Clin Oncol 2007; 25:3615-3620
[121]Medeiros LR, Rosa DD, DA Rosa MI. Accuracy of Ca 125 in the diagnosis of ovarian tumors:a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol,2009; 142:99-105.
[122]Comparison of CA-125 and Standard Definitions of Progression of Ovarian Cancer in the Intergroup Trial of Cisplatin and Paclitaxel Versus Cisplatin and Cyclophosphamide JCO (2006) 24(1):45-51
[123]Coates RRJ, Kolor K, Stewart SL, Richardsonha LC. Diagnostic markers for ovarian cancer screening:not ready for routine clinical use. Clin Cancer Res,2008; 14,7 575-7576
[124]Pauler DK, Menon U, McIntosh M, et al:Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev 10:489-493,2001
[125]Lo Curto M, DA'ngelo P, Cecchetto G, and et al. Mature and immature teratomas: results of the first paediatric Italian study. Pediatric Surgery International.2007,23 (4): 315-322
[126]Ries LAG, Melbert D, Krapcho M, and et al. SEER cancer statistics review 1975-2005 Institute. NC, Bethesda, MD.2006,3-20
[127]Hess LM, Benham-Hutchins M, Herzog TJ. and et al. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer.2007;17(3):561-570.
[128]Elit L, Oliver TK, Covens A, and et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer:a systematic review with metaanalyses. Cancer.2007;109(4):692-702
[129]Goff BA, Mandel LS, Melancon CH. Muntz HG. Frequency of symptoms of ovarian cancer. Primary care clinics. JAMA.2004;291(22):2705-2712.
[130]Riedinger JM, Wafflart J, Ricolleau G et al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome:results of a French multicentric study. Ann Oncol 2006; 17:1234-1238.
[131]Vladimir Nossov, AffiliationDepartment of Obstetrics and Gynecology, University of California, Los Angeles, Medical Center, Los Angeles, CA Malaika Amneus, and et al. The early detection of ovarian cancer:from traditional methods to proteomics. Can we really do better than serum CA-125? American Journal of Obstetrics & Gynecology 2008(199),3,215-223Affiliations
[132]Amer K. Karam & Beth Y. Karlan. Ovarian cancer:the duplicity of CA125 measurement. Nature Reviews Clinical Oncology,2010,7,335-339
[133]Louis Dubeau MD The cell of origin of ovarian epithelial tumors. The Lancet Oncology.2008, (9)12,1191-1197
[134]Victorian. Brande. Questioning the Role of CA125 as a Biomarker in Ovarian Cancer. Oncology Times,2010, (32)24,9-10
[135]Jankovic M.M, Milutinovic. B S. Pregnancy-associated CA125 antigen associated CA125 antigen as mucin:evaluation of ferning morphology. Mol Hum Reprod,2007, (13)405-408
[136]McLemore MR, Aouizerat B. Introducing the MUC16 gene:implications for prevention and early detection in epithelial ovarian cancer. Biol Res Nurs.2005 6(4):262-7.
[137]Monica R. McLemore, Bradley Aouizerat . Introducing the MUC16 Gene: Implications for Prevention and Early Detection in Epithelial Ovarian Cancer. Biol Res Nurs April 2005, (6) 4,262-267
[138]Jankovic M.M, Milutinovic. B S.Pregnancy-associated CA125 antigen associated CA125 antigen as mucin:evaluation of ferning morphology. Mol Hum Reprod,2007, (13)405-408
[139]WP McGuire. CA-125 and Early Ovarian Cancer. J Natl Cancer Inst,2005,95.105- 112
[140]Richard R. Barakat, Maurie Markman, Marcus E. Randall. Principles and Practice of Gynecologic Oncology.-2009-Medical-1072
[141]James L. Wilder, Edward Pavlik, John M. Straughn and et al. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer:a preliminary investigation. Gynecologic Oncology,2003, (89) 2,233-235
[142]Victorian, Brande. Questioning the Role of CA125 as a Biomarker in Ovarian Cancer. Oncology Times,2010, (32)24,9-10
[143]Louis Dubeau MD The cell of origin of ovarian epithelial tumors. The Lancet Oncology.2008, (9)12,1191-1197
[144]Tiss, Ali, Timms, John F and et al. Highly Accurate Detection of Ovarian Cancer Using CA125 but Limited Improvement With Serum Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Profiling. International Journal of Gynecological Cancer:2010, (20) 9,1518-1524
[145]Merrill Goozner. Personalizing Ovarian Cancer Screening. JNCI J Natl Cancer Inst (2010) doi:10.1093/jnci/djq296
[146]Digant Gupta, Christopher G Lis. Role of CA125 in predicting ovarian cancer survival a review of the epidemiological literature. Journal of Ovarian Research 2009, (2),13,1757-2215
[1]Parkin DM et al. (2005) Global cancer statistics,2002. CA Cancer J Clin 55:74-108
[2]Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin M.GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide:IARC CancerBase No.10 [Internet].Lyon, France:International Agency for Research on Cancer; 2010.
[3]Office for National Statistics. Cancer Statistics registrations:Registrations of cancer diagnosed in 2007, England. Series MB1 no.38.2010
[4]Cancer Intelligence and Surveillance Unit. Cancer Incidence in Wales.2010.
[5]Stirling D et al. (2005) Screening for familial ovarian cancer:failure of current protocols to detect ovarian cancer at an early stage according to the International Federation of Gynecology and Obstetrics system. J Clin Oncol 23:5588-5596
[6]Evans, J., Ziebland, S., McPherson, A. Minimizing delays in ovarian cancer diagnosis: an expansion of Andersen's model of total patient delay. Fam Pract.2007,24:48-55
[7]Hydzik C. Treatment of ovarian cancer with intraperitoneal chemotherapy. Oncology. 2009; 23(11):15-20.
[8]Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics [J]. CA Cancer J Clin,2009,59:225-249.
[9]Duan ZF, Ames RY, Ryan M, et al. CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells [J]. Cancer Chemoth Pharm,2009.63(4):681-689.
[10]Odening KE, Li W, Rutz R, et al. Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells [J]. Clin Exp Immunol,2009,155(2):239-248.
[11]Vandersickel V, Mancini M, Marras E, et al. Lentivirus-mediated RNA interference of Ku70 to enhance radiosensitivity of human mammary epithelial cells [J]. Int J Radiat Biol,2010,86(2):114-124.
[12]Sankpal NV. Fleming TP, Gillanders, WE. Dual Expression Lentiviral Vectors for Concurrent RNA Interference and Rescue [J]. J Surg Res,2009,156(1):50-56.
[13]Greenlee RT, Hill-Harmon MB, Murray T, Thum M. Cancer statistics,2001.CA Cancer J Clin 2001:51:15-36.
[14]Oehler VG, Yeung KY, Choi YE. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data [J]. Blood,2009,114(15):3292-3298.
[15]Gynecologic Cancer Foundation, Society of Gynecologic Oncologists, American Cancer Society. Ovarian Cancer Symptoms Consensus Statement 2007
[16]Odicino F, Pecorelli S, Zigliani L & Creasman WT. History of the FIGO cancer staging system. International Journal of Gynecology and Obstetrics.2008;(101)205-210.
[17]Menon, U., Gentry-Maharaj, A., Ryan, A. and et al. Recruitment to multicentre trials lessons from UKCTOCS:descriptive study. BMJ.2008,337,2079-2079
[18]Ries LAG, Melbert D, Krapcho M, and et al (eds). SEER cancer statistics review 1975-2005 Institute. NC, Bethesda, MD.2006,3-20
[19]Tracey Edgell, G. Martin-Roussety, G. Barker, and et al. Phase Ⅱ biomarker trial of a multimarker diagnostic for ovarian cancer. J Cancer Res Clin Oncol.2010,136:1079-1088
[20]Mann JR, Gray ES, Thornton C, Raafat F, and et al. Mature and immature extracranial teratomas in children:the UK Children's Cancer Study Group Experience. Journal of Clinical Oncology:Official Journal of the American Society of Clinical Oncology.2008, 26 (21):3590-3597
[21]Moore, R. G., Bast, R. C. Jr. How Do You Distinguish a Malignant Pelvic Mass From a Benign Pelvic Mass? Imaging, Biomarkers, or None of the Above. JCO 2007,25:4159-4161
[22]Kurman RJ. Shih Ie-M:The origin and pathogenesis of epithelial ovarian cancer:a proposed unifying theory. Am. J. Surg. Pathol.2010,34(3),433-443
[23]American Cancer Society Cancer Facts and Figures 2008 American Cancer Society. 2008,1-70
[24]Prof Louis Dubeau MD The cell of origin of ovarian epithelial tumors. The Lancet Oncology.2008, (9)12,1191-1197
[25]Jemal A, Siegel R,Ward E, et al. Cancer statistics,2006. CA CancerJClin 2006; 56:106-130.
[26]Winter-Roach BA, Kitchener HC, Dickinson HO. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev.2009; 21,2-10
[27]myDr, Ovarian cancer test (CA125). UBM Medica Australia,2000-2010.2008,2
[28]Nossov V, Amneus M, Su F, Lang J, and et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? 2008, Am J Obstet Gynecol 199(3):215-223.
[29]Tung CS, Wong KK, Mok SC. Biomarker discovery in ovarian cancer. Womens Health (Lond Engl).2008,4:27-40
[30]Abenhaim, H. A., Titus-Ernstoff. L., Cramer, D. W. Ovarian cancer risk in relation to medical visits, pelvic examinations and type of health care provider. CMAJ.2007,176: 941-947
[31]Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer:defining the target for early detection. PLoS Med.2009; 6(7),2-29
[32]Markman M, Liu PY, Rothenberg ML et al. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol 2006; 24:1454-1458
[33]Dong-Mei Fan, Hui-Rong Shi, Zhi-Min Chen, Qing-Hua Wu, Hui-Na Liu and Rui-Tao Zhang. Early detection of ovarian carcinoma by proteome profiling based on magnetic bead separation and matrix-assisted laser desorption/ionization time of flight mass spectrometry. African Journal of Microbiology Research.2010, Vol.4(10),940-951
[34]Hess LM, Benham-Hutchins M, Herzog TJ, and et al. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer. May-Jun 2007; 17(3):561-570.
[35]Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer:an intergroup trial of the AGO-OVAR, the NCIC CTG and the EORTC GCG. J Clin Oncol.2006;24(29):4699-7070
[36]Bookman M (2006) GOG0182-ICON5:5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs. combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma [abstract#5002]. J Clin Onco
[37]Elit L, Oliver TK, Covens A, and et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer:a systematic review with metaanalyses. Cancer.2007;109(4):692-702
[38]Riedinger JM, Bonnetain F, Basuyau JP et al. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. Ann Oncol 2007; 18:881-885.
[39]Emily Jackson, Ken Anderson, Chris Ashwell, James Petitte and Paul E. Mozdziak CA125 expression in spontaneous ovarian adenocarcinomas from laying hens. Gynecologic Oncology.2007, (104) 1,192-198
[40]American Cancer Society of Gynecologic Oncologists. Ovarian Cancer Symptoms, Cancer Facts & Figures, Consensus Statement 2007
[41]Agustin A Garcia (2007). Ovarian cancer in eMedecine specialties. Gynecologic oncology
[42]Karen A. Johnson. The Standard of Perfection:Thoughts about the Laying Hen Model of Ovarian Cancer. In Perspective on Hakim et al. Cancer Prevention Research,2009 2: 97,114
[43]Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih Ie M. Early detection and treatment of ovarian cancer:shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am. J. Obstet. Gynecol.2008,198(4):351-356.
[44]Asher et al., Pelvic mass associated with raised CA 125 for benign condition:a case report World Journal of Surgical Oncology 2010,8:28
[45]Kathleen R. Cho, Ming Shih. Pathology:Mechanisms of Disease Annual Review.2009, (4)287-313
[46]Hermsen BBJ, von Mensdorff-Pouilly S, Berkhof J, et al:Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer. J Clin Oncol 2007.25:1383-1389
[47]Ries, LAG, Harkins, D., Krapcho, M. et al. SEER Cancer Statistics Review,1975-2003, National Cancer Institute.2008,3-4.
[48]Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer Methods Mol. Biol.2009, 472:413-437.
[49]Fang CY, Cherry C, Devarajnk. A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynaecologic screening for ovarian cancer. Gynecol Oncol,2009; 112:594-600
[50]Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem.2001;20:27371-27375
[51]Chan, Tian, Monk, et al. Prognostic factors for high-risk early-stage epithelial ovarian cancer:a Gynecologic Oncology Group study. Cancer.2008;112:2202-2210
[52]Peter W. Kujtan. Why Did You Not Do the CA-125 Test? Health & Wellness, Doctor's Corner.2003,22,27-28.2003
[53]Tiss, Ali, Timms, John F and et al. Highly Accurate Detection of Ovarian Cancer Using CA125 but Limited Improvement With Serum Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Profiling. International Journal of Gynecological Cancer:2010, (20) 9,1518-1524
[54]Merrill Goozner. Personalizing Ovarian Cancer Screening. JNCI J Natl Cancer Inst (2010) doi:10.1093/jnci/djq296
[55]Van Dalen A, Favier J, Burges A, Hasholzner U, de Bruijn HW, Dobler-Girdziunaite D, Dombi VH, Fink D, Giai M, McGing P, Harlozinska A, Kainz C, Markowska J, Molina R, Sturgeon C, Bowman A, Einarsson R:Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol 2000, 79:444.450
[56]Gadducci A, Cosio S, Tana R, Genazzani AR:Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol 2009,69(1):12-27
[57]Digant Gupta, Christopher G Lis. Role of CA125 in predicting ovarian cancer survival-a review of the epidemiological literature. Journal of Ovarian Research 2009, (2),13.1757-2215
[58]William P. McGuire. CA-125 and Early Ovarian Cancer:Does This Help the Clinician or Further Muddy the Water? Journal of Clinical Oncology,2005, (23) 25,5862-586
[59]Hydzik C. Treatment of ovarian cancer with intraperitoneal chemotherapy. Oncology. 2009;23(11):15-18.
[60]Jemal A. Siegel R, Ward E, and et al. Cancer statistics J. CA Cancer J Clin,2009,59: 225-238.
[61]Duan ZF, Ames RY, Ryan M, et al. CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells J. Cancer Chemoth Pharm,2009,63(4):681-684.
[62]Odening KE, Li W, Rutz R, et al. Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells J. Clin Exp Immunol,2009,155(2):239-244.
[63]Vandersickel V, Mancini M, Marras E, et al. Lentivirus-mediated RNA interference of Ku70 to enhance radiosensitivity of human mammary epithelial cells. J. Int J Radiat Biol,2010,86(2):114-120.
[64]Sankpal NV, Fleming TP, Gillanders, WE. Dual Expression Lentiviral Vectors for Concurrent RNA Interference and Rescue. J Surg Res,2009,156(1):50-56.
[65]Greenlee RT, Hill-Harmon MB, Murray T, and et al. Cancer statistics,2001.CA Cancer J Clin 2001:51:15-29.
[66]Oehler VG, Yeung KY, Choi YE. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data J. Blood,2009.114(15):3292-3295.
[67]Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med.2006; 354,34-35.
[68]Jacobs I, Bast RC, Jr. L'antigene CA 125 associe a la tumeur:une revue de la litterature. Hum Reprod,1989,4,1-12
[69]The electronic version of this article is the complete one and can be found online at: http://www.ovarianresearch.com/content/2/1/13
[70]http://creativecommons.org/licenses/by/2.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
A.REFERENCES in Journal Medical of Guinea
1. Importance of hematoxylin-eosin in diagnosis of cervical neoplasia
REFERENCES
Adenomyosis with severe inflammation in the uterine cervix in a dog. Hiromichi Tamada, Noritoshi Kawate, Toshio Inaba, Mitsuru Kuwamura, Masaya Maeda, Taketsugu Kajikawa, and Tsutomu Sawada.2005. Can Vet J. April; 46(4):333-334.
Agosti JM, Goldie SJ.2007. Introducing HPV vaccine in developing countries. Key challenges and issues [archive], New Eng J Med,356:1908-1910.
Boyle P, Ferlay J.2004. Cancer incidence et de mortalite en Europe. Ann Oncol 2005; 16:481-488.
Castapeda-Ipiguez MS, Toledo-R Cisneros, Aguilera-Delgadillo M.1998. Facteurs de risque de cancer de l'uterus cervico-vaginales chez les femmes dans Zacalecos. Salud Publica de Mexico 40:330-8
Danielle MARTEL (IFTAB-PARIS. Hemalun, Eosine (HE).2005, Fiches techniques Bioimage His-Image.1-2
da Silva Cardeal LB, Brohem CA, Correa TC, et al.2006. Higher expression and activity of metalloproteinases in human cervical carcinoma cell lines is associated with HPV presence[J]. Biochem Cell Biol.84(5):713-719.
Fonn S, B Bloch, Mabina M, S Carpenter, Cronje H, Maise C. et al.2002. Prevalence des lesions precancereuses et le cancer du col de l'uterus en Afrique du Sud:Une etude multicentrique. Afr Med S.92:148-156
Lawson JSHW, R Henson, Bobo JK, MK Kaeser.2000. Application de la recommandation pour la detection precoce du cancer du sein et du col uterin chez le groupe a faible revenu. Rep Recomm MMWR 49:37-55
Llewellyn BD. Nuclear staining with alum-hematoxylin. Biotech. Histochem.2009,84:159-177.
Misra JS, K Das, Chandrawati.1998. Resultats de la clinique downstaging cancer du col uterin dans un programme de depistage cytologique. Diag Cytopathol.19:344-348
Misra JS, Gupta HP, Das V.2004. Evaluation de la faisabilite devaluation du temps de vie de celibataire frottis entre 41-50 ans de la strategic de l'age pour le controle du cancer du col dans les pays en developpement de nos 32 annees d'experience de 1'hopital en fonction de routine de depistage cytologique. Diag Cytopathol; 31:376-379.
Mitkas P, Koutkias V, Symeonidis A, et al.2008. Association studies on cervical cancer facilitated by inference and semantic technologies:the assist approach [J].Stud Health Technol Inform,136:241-246.
Murthy NS, Chaudhary K, Saxena Tendances S.2005. L'incidence du cancer du col uterin: scenario indien. Eur J Cancer Prev 14:513-8
Organisation mondiale de la Sante, de la cytologie du tractus genital feminin.1995. Geneve: OMS; 1973 8- Systeme de Bethesda pour la declaration col de l'uterus/diagnostic cytologique vaginal:Acta cytologie 37:115-120
Peko J.F; Buambo S.; Diafouka M; Nsonde-Malanda J.2009. LESIONS PRECANCEREUSES DU COL UTERIN ET INFECTION A VIH A BRAZZAVILLE (56)10,532-536
Rauvala M, Aglund K, Puistola U, et al.2006. Matrix metalloproteinases-2 and -9 in cervical cancer:different roles in tumor progression[J].Int J Gynecol Cancer,16(3):1297-1302COL
Roberts CC, Tadesse AS, Sands J, et al.2006. Detection of HPV in Norwegian cervical biopsy specimens with type-specific PCR and reverse line blot assays. J Clin.36 (4):277-282.
Schiffman M, Castle PE, Jeronimo J, Rodriguez AC,Wacholder S.2007. Human Papilloma virus and cervical cancer. Lancet.370:890-907.
Shanta V, S Krishnamurthi, Gajalakshmi CK, Swaminathan R, Ravichandran K.2000. Epidemiologie du cancer du col de l'uterus:perspective mondiale et nationale. Indian J Med Assoc; 98:49-52
Wei YC, Chou YS, Chu TY.2007. Detection and typing of minimal human Papilloma virus DNAin plasma. Int J Gynaecol Obstet; 96 (2):112-116.
Woodman CB, Collins SI, Young LS.2007. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 7(1):11-22.
Wu RF, Dai M, Qiao YL, Clifford GM, Liu ZH, Arslan A, Li N, Shi JF, Snijders PJ, Meijer CJ, Franceschi S.2007. Human papillomavirus infection in women in Shenzhen City, People's Republic of China, a population typical of recent Chinese urbanisation Int J Cancer 121:1306-1311
2. Importance of hematoxylin-eosin in diagnosis of cervical neoplasia
REFERENCES
Aglund Kl, Rauvala Ml. Puistola U, Angstrom T, Turpeenniemi-Hujanen T.Zackrisson B & Stendahl U. Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer MMP-9 correlates to the grade and the stage. Gynecol Rauvala, Marita. Matrix metalloproteinases-2 and-9 and tissue inhibitors of metalloproteinases-1 and-2 in gynaecological cancers. Acta Univ. Oul.2006,4,12,1-90,
Bor-Ching Sheu, Huang-Chun Lien, Hong-Nerng Ho, Ho-Hsiung Lin, Song-Nan Chow, Su-Cheng Huang, and Su-Ming Hsu. Increased Expresomie sion and Activation of Gelatinolytic Matrix Metalloproteinases Is Associated with the Progression and Recurrence of Human Cervical CancerCancer Res,2003 63; 6537
Brooks R, Kizer N, Nguyen L, Jaishuen A, Wanat K, Nugent E, Grigsby P, Allsworth JE, Rader JS. Polymorphisms in MMP9 and SIPA1 are associated with increased risk of nodal metastases in early-stage cervical cancer. Gynecol Oncol.2010 Mar; 116(3):539-43.
Coussens L. M., Fingleton B., Matrisian L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (Wash. DC),295:2387-2392,2002.
Cuzick J, M Arbyn, Sankaranarayanan R, V Tsu, Ronco G, MH Mayrand, et al. Vue d'ensemble des ressources humaines en fonction et d'autres nouvelles options-papillomavirus pour le depistage du cancer du col uterin dans les pays developpes et en developpement. Vaccine 2008; 26:29-41
Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev. (Lond.),2:163-176,2002.
Garzetti G. G, Ciavattini A., Lucarini G., Goteri G., Nictolis M. D., Biagini G Microinvasive cervical carcinoma and cervical intraepithelial neoplasia:biologic significance and clinical implications of 72-kDa metalloproteinase immunostaining. Gynecol. Oncol., 61:97-203,1999.
Gilles C.. Polette M., Piette J., Munaut C., Thompson E. W., Birembaut P., Foidart J-M. High level of MT-MMP expression is associated with invasiveness of cervical cancer cells. Int. J. Cancer,65:209-213,1996.Liotta L. A.. Kohn E. C. The microenvironment of the tumor-host interface. Nature (Lond.),411:375-379,2001.
Hantz S, Alain S, Denis F. Human papillomavirus prophylactic vaccines:stakes and perspectives. Gynecol Obstet Fertil 2006 Jul:34(78):647-55.
Johansson N., Vaalamo M., Grenman S., Hietanen S., Klemi P., Saarialho-Kere U., Kahari V-M. Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas. Am. J. Pathol.,154:469-480,1999.
Kato Y, T Yamashita, Ishikawa Entre ce qui concerne l'expression de M. de la metalloproteinase matricielle-2 et la matrice metalloproteinase-9 et la Capacite d'invasion des Cellules cancereuses du col uterin. Oncol Rep 2002; 9:565-569
Lin LF, Chuang CH, Li CF, Liao CC, Cheng CF, Cheng TL, Shen MR, Tseng JT, Chang WC, Lee WH, Wang JM. ZBRK1 acts as a metastatic suppressor by directly regulating MMP9 in cervical cancer. Cancer Res.2010 Jan 1; 70(1):192-201.
Li Sheng Lei, Liu Zongwen, Zhaoqiu Min, et al. Esophageal squamous cell carcinoma RECKmRNA and protein expression and its significance. Chinese Journal of Clinical Oncology,2007,34:1280-1286.
McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Histoire naturelle des neoplasies cervicales intraepitheliales et risque de cancer invasif chez les femmes presentant une neoplasie intraepitheliale cervicale 3:une etude de cohorte retrospective. Lancet Oncol 2008; 9:425-434
M Iwasaki, Nishikawa A, T Fujimoto, N Akutagawa, K Manase, T Endo, et al. Effet anti-invasive du L'MMI-166 Selectif inhibiteur de metalloproteinase matrice nouvelle, col uterin Dans Le lignees de carcinome CELLULAIRES. Gynecol Oncol.2002; 85:103-107.
Moss M. L., Jin S-L. C., Milla M. E., Burkhart W., Carter H. L., Chen W-J., Clay W. C. Didsbury J. R., Hassler D., Hoffman C. R., Kost T. A., Lambert M. H., Leesnitzer M. A., McCauley P., McGeehan G., Mitchell J., Moyer M., Pahel G., Rocque W., Overton L. K., Schoenen F., Seaton T., Su J-L., Warner J., Willard D., Becherer J. D. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-a. Nature (Lond.),385:733-736,1997.
Nakamura H., Ueno H., Yamashita K., Shimada T., Yamamoto E., Noguchi M., Fujimoto N., Sato H., Seiki M., Okada Y. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res.,59:467-473,1999.
Noriyuki M, Sumi T, Zhi X, et al.Vascular endothelial growth factor, matrix metalloproteinases, and cyclooxygenase-2 influence prognosis of uterine cervical cancer in young women[J].Int J Oncol,2007.31(3):531-6.
Nuovo G. J., MacConnell P. B., Simsir A., Valea F., French D. L. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res.,55: 267-275,1995.
Rauvala,Marita. Matrix metalloproteinases-2 and-9 and tissue inhibitors of metalloproteinases-1 and-2 in gynaecological cancers. Acta Univ. Oul.2006,4.12, 1-90,
Rundhaug JE Matrix metalloproteinases and angiogenesis. J Cell Mol Med,2005,9:267-285
Sang-Hyuk Chung and Paul F. Lambert Prevention and treatment of cervical cancer in mice using estrogen receptor antagonists. Medical Science, November 17,2009, vol.106, no.46,19467-19472
Sheu B-C., Hsu S-M., Ho H-N., Lien H-C., Huang S-C., Lin R-H. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res.,61:237-242, 2001
Schiffman M, S. Wacholder De l'Inde au monde:une meilleure facon de prevenir le cancer du col de 1'uterus. N Engl J Med 2009;360:1453-512.
Ueno H., Yamashita K., Azumano I., Inoue M., Okada Y. Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas. Int. J. Cancer (Pred. Oncol.),84:470-477,1999.
Yamashita K., Azumano I., Mai M., Okada Y. Expression and tissue localization of matrix metalloproteinase-7 (matrilysin) in human gastric carcinomas.Implications for vessel invasion and metastasis. Int. J. Cancer (Pred. Oncol.),79:187-194,1998.
Yang SF, Wang PH, Lin LY, et al.A significant elevation of plasma A significant elevation of plasma level of matrix metalloproteinase-9 in patients with high-grade intraepithelial neoplasia and early squamous cell carcinoma of the uterine cervix [J].Reprod Sci, 2007,14(7):710-718.
Yoshida S, Kajitani N, Satsuka A, Nakamura H, Sakai H. Ras modifies proliferation and invasiveness of cells expressing human papillomavirus oncoproteins. J Virol.2008 Sep; 82(17):8820-7.
Yu J, Qian H, Li Y, et al.Arsenic trioxide (As2O3) reduces the invasive and metastatic properties of cervical cancer cells in vitro and in vivo[J].Gynecol Oncol, 2007,106(2):400-6.
Wang, Qin Tianjie, Ruan Zhi-ping, Ma Jinlu. Expressions and significance of PCNA and MMP9 in cervix cancer tissueExpressions and significance of PCNA and MMP-9 in cervix cancer tissue.journal.shouxi.net,13:15:42,2006,364
Wang PH, Yang SF, Chen GD, et al. Human non metastatic clone 23 type 1 gene suppresses migration of cervical cancer cells and enhances the migration inhibition of fungal immunomodulatory protein from Ganoderma tsugae[J].Reprod Sci,2007,14(5):475-485.
3. Colposcopic aspects of cervix vaginal lesions condylomatosis of the Center Donka Hospital University
REFERENCES
Almonte M, Ferreccio C, Winkler JL. Cuzick J, Tsu V, Robles S, Takahashi R, Sasieni P Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. Int J Cancer 2007,121:796-802
CEDEF. Item 149-Tumeurs cutanees epitheliales et melaniques:tumeurs a papillomavirus humain (HPV). Annales de dermatologie et de venereologie 2008,135S,141-14
Derrien J. les papillomavirus dans la genese des cancers du col Uterin. Concours medical 2000,165-172
Ferlay J, Bray F, DM Parkin P Pisani,. GLOBOCAN 2002:l'incidence du cancer, de mortalite et de prevalence dans le monde. Base de cancer du CIRC N°5, Version 2.0. IARC Press,2004:Lyon
Goldie S, Gaffikin L, Goldhaber-Fiebert J, Gordillo-Tobar A, Levin C. Mahe C, Wright T. Cost effectiveness of cervical screening in five developing countries. The New England Journal of Medicine.2005; 353:2158-2168.
Isabelle Navarria. Martine Jacot-Guillarmod. Depistage, traitement et surveillance. In Recommandations pour la prise en charge des pathologies cervicales. Societe Suisse de Gyn Obst,,6-17,2010
Koulibaly M. Ibrahim Sidiki, Amara Cisse, Sory Baillo, Diallo, Mamadou Diallo，Mamadou Bobo Diallo, Namory Keita, Naby Daouda Camara, cancer Indicence in conakry, Guinea:First Results From the cancer Registry. Int. Cancer.1997,70,39-45
Kurman RJ, Malkasian GD Jr，Sedlis A, Salomon D. De Papanicolaou a Bethesda:La justification d'une classification cytologique du col de nouvelles. Obstet Gynecol 1991; 77:779-82
LS Massad, YC Collins. Resistance des correlations entre l'impression colposcopique et histologie de la biopsie. Gynecol Oncol 2003; 89:424-8
Li. J-F Shi, S Franceschi, W-H Zhang M Dai, B Liu, Y-Z Zhang, L-K Li, R-F Wu, H De Vuyst1, M Plummer. Y-L Qiao, and G Clifford. Different cervical cancer screening approaches in a Chinese multicentre study. British Journal of Cancer 2009,100,532-537
Lynette Denny, Rengaswamy Sankaranarayanan. Secondary prevention of cervical cancer. International Journal of Gynecology and Obstetrics.2006,94 (Supplement 1),6.
Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutle'e F, Franco EL. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.2007, N Engl J Med 357:1579-1588
Mitchell MF, Schottenfeld D, Tortolero-Luna D, Cantor SB, Richrds-Kortum R. Colposcopie Pour le diagnostic des lesions intra-epithieles:Une meta-analyse. Obstet Gynecol 1998; 91:626-31
Pimple S, Muwonge R, Amin G, Goswami S, Sankaranarayanan R, Shastri SS. Cytology versus HPV testing for the detection of high-grade cervical lesions in women found positive on visual inspection in Mumbai, India. Int J Gynaecol Obstet.; 2010, 108(3):236-239.
Pretorius RG, Bao YP, Belinson JL, Burchette RJ, Smith JS, Qiao YL Inappropriate gold standard bias in cervical cancer screening studies. Int J Cancer 2007,121:2218— 2224cervical cancer.2007, N Engl J Med 357:1579-1588
Rauvala M, Aglund K, Puistola U, et al. Matrix metalloproteinases-2 and-9 in cervical cancer: different roles in tumor progression[J].Int J Gynecol Cancer,2006,16(3):1297-1302
Reid R, P. Scalzi verrues genitales et le cancer du col de l'uterus:VII:un meilleur indice pour differencier les infections colposcopique papillomc benin virale de haut grade neoplasie intraepitheliale cervicale. Am J Obstet Gynecol 1985; 153:611-8
Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, Fayette JM, Cherian J Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India:a cluster-randomised trial.2007, Lancet 370:398-406
Sangwa-Lugoma G, Mahmud S, Nasr SH, Liaras J, Kayembe PK, Tozin RR, Drouin P, Lorincz A, Ferenczy A, Franco EL Visual inspection as a cervical cancer screening method in a primary health care setting in Africa. Int J Cancer 2006,119:1389-1395
Sellors J, Sankaranarayanan R. Colposcopie et traitement des neoplasies cervicales intraepitheliales:manuel pour debutants. Lyon:IARC Press,2003
B. REFERENCES in International Journal of Advanced Studies and Research in Africa
4. Interest of the successive application of acetic acid and lugol in identification lesion
Papilloma virus Cervical
References
Almonte M. Ferreccio C, Winkler JL, Cuzick J, Tsu V, Robles S, Takahashi R, Sasieni P. 2007. Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. Int J Cancer.121:796-802.
Arbyn M, Sankaranarayanan R, Muwonge R, Keita N, Dolo A, Mbalawa CG, et al. 2008;Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer 123:153-158
Aynaud O, Piron D, Barrasso R, Poveda JD.1998. Comparison of clinical, histological, and virological symptoms of HPV in HIV-1 infected men and immunocompetent subjects. Sex Transm Infect.74(1):32-34.
Basu P, Sankaranarayanan R, Mandal R, Roy C, Das P, Choudhury D, et al.2003. The Calcutta Cervical Cancer Early Detection Group. Visual inspection with acetic acid and cytology in the early detection of cervical neoplasia in Kolkata, India. International Journal of Gynecological Cancer; 13:626-632.
Belinson J, Qiao YL, Pretorius R, Zhang WH, Elson P, Li L, Pan QJ, Fischer C, Lorincz A, Zahniser D.2001. Shanxi Province Cervical Cancer Screening Study:a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol.83:439-444
Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV.2002. The causal relation between human papillomavirus and cervical cancer. Journal of Clinical Pathology;55:244-65.
Blumenthal PD, Gaffikin L, Chirenje ZM, McGrath J, Womack S, Shah K.2001. Adjunctive testing for cervical cancer in low resource settings with visual inspection, HPV, and the Pap smear. International Journal of Gynaecology and Obstetrics;72:47-53.
Castellsague X.2008. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol.110:4-.7
CEDEF.2008. Item 149-Tumeurs cutanees epitheliales et melaniques:tumeurs a papillomavirus humain (HPV). Annales de dermatologie et de venereologie 135,141
Cuzick J. Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P. Iftner T.2006. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer.119:1095-1101
Dai M, Bao YP, Li N. Clifford GM, Vaccarella S. Snijders PJF, Huang RD, Sun LX, Meijer CJLM, Qiao YL, Franceschi S.2006. Human papillomavirus infection in Shanxi Province, People's Republic of China:a population-based study. Br J Cancer.95:96-101
da Silva Cardeal LB, Brohem CA, Correa TC, and et al.2006. Higher expression and activity of metalloproteinases in human cervical carcinoma cell lines is associated with HPV presence. J. Biochem Cell Biol,84(5):713-719.
De Vuyst H, Claeys P, Njiru S, Muchiri L, Steyaert S, De Sutter P. Van Marck E, Bwayo J, Temmerman M.2005. Comparison of pap smear, visual inspection with acetic acid, human papillomavirus DNA-PCR testing and cervicography. Int J Gynaecol Obstet.;89:120-126.
Denny L, Kuhn L, De Souza M, Pollack AE, Dupree W, Wright TC., Jr.2005. Screen-and-treat approaches for cervical cancer prevention in low-resource settings:a randomized controlled trial. JAMA.294:2173-2181
Denny L, Kuhn L, Pollack A, Wainwright H, Wright TC, Jr Evaluation of alternative methods of cervical cancer screening for resource-poor settings. Cancer. 2000;89:826-833
Denny L, Kuhn L, Pollack A, Wright TC Jr.2002. Direct visual inspection for cervical cancer screening:an analysis of factors influencing test performance. Cancer; 94:1699-707.
Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2004. Cancer Incidence, Mortality and Prevalence Worldwide. International Agency for Research on Cancer (IARC) Cancer Base.5(2)
Ferreccio C, Bratti MC, Sherman ME, Herrero R, Wacholder S, Hildesheim A, Burk RD, Hutchinson M, Alfaro M, Greenberg MD, Morales J, Rodriguez AC, Schussler J, Eklund C, Marshall G, Schiffman M.2003. A comparison of single and combined visual, cytologic, and virologic tests as screening strategies in a region at high risk of cervical cancer. Cancer Epidemiol Biomarkers Prev.;12:815-823.
Giustranti C.2006. Cancer du col de 1'uterus:MYC, un gene sous influence. J. Inst Curie.68:4
Goldie S, Gaffikin L, Goldhaber-Fiebert J, Gordillo-Tobar A, Levin C, Mahe C, Wright T. 2005. Cost effectiveness of cervical screening in five developing countries. The New England Journal of Medicine.353:2158-2168
IARC IARC.2005. Handbooks of Cancer Prevention Volume 10:Cervix Cancer Screening. IARC Press,311.
International Agency for Research on Cancer Working Group on the Evaluation of Carcinogenic Risks to Humans.1995. Human Papillomaviruses. Lyon:IARCPress; (IARC monographs on the Evaluation of Carcinogenic Risks to Humans.64.
IARC Working Group on Cervical Cancer Screening.1986. Summary chapter. In:Hakama M, Miller AB, Day NE, editors. Screening for cancer of the uterine cervix. Lyon: IARCPress; (IARC Scientific Publications),76,133-142
Jean-Philippe Spano, Anne-Genevieve Marcelin, Guislaine Carcelin,2005. HPV and cancer. Bulletin du Cance.92 (1):59-64
Jeronimo J, Schiffman M.2006. Colposcopy at a crossroads. Am J Obstet Gynecol.,195: 349-353
Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E.2007. Diagnostic accuracy of human papillomavirus testing in primary cervical screening:a systematic review and meta analysis of non-randomized studies. Gynecol Oncol,104: 232-246
Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC.2000. Human papillomavirus testing for cervical cancer screening in low-resource settings. Journal of the National Cancer Institute;92:818-25
Kulasingham SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, et al.2002. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities:comparison of sensitivity, specificity, and frequency of referral. JAMA;288:1749-57.
Li LK, Dai M, Clifford GM, Yao WQ, Arslan A, Li N, Shi JF, Snijders PJ, Meijer CJ, Qiao YL, Franceschi S.2006. Human papillomavirus infection in Shenyang City, People's Republic of China:a population-based study. Br J Cancer.95:1593-1597.
Li N, J-F Shi, S Franceschi, W-H Zhang M Dai, B Liu, Y-Z Zhang, L-K Li, R-F Wu, H De Vuystl, M Plummer, Y-L Qiao, and G Clifford.2009. Different cervical cancer screening approaches in a Chinese multicentre study. British Journal of Cancer 100: 532-537
Lynette Denny 2006. Rengaswamy Sankaranarayanan. Secondary prevention of cervical cancer. International Journal of Gynecology and Obstetrics.,94 (Supplement 1),65-70
Mahboobeh Safaeian, Mohammad Kiddugavu,Patti E. Gravitt,Stephen J. Gange, Joseph Ssekasanvu. Dan Murokora.Marc Sklar, David Serwadda, Maria J. Wawer.Keerti V. Shah and Ron Gray.2008. Determinants of Incidence and Clearance of High-Risk Human Papillomavirus Infections in Rural Rakai, Uganda. Cancer Epidemiol Biomarkers Prev;17(6). June 2008
Massad LS, Collins YC.2003; Strength of correlations between colposcopic impression and biopsy histology. Gynecol Oncol 89:424-424
Mayaud P, Gill DK, Weiss HA, Uledi E. Kopwe L, Todd J. ka-Gina G Grosskurth H, Hayes RJ, Mabey DC, Lacey CJ.2001. The interrelation of HIV, cervical human papillomavirus, and neoplasia among antenatal clinic attenders in Tanzania. Sex Transm Infect.77(4):248-254.
Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlee F, Franco EL.2007. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med,357:1579-1588.
Mitchell MF, Schottenfeld D, Tortolero-Luna G Cantor SB, Richards-Kortum R. 1998;Colposcopy for the diagnosis of squamous intraepithelial lesions:A meta-analysis. Obstet Gynecol 91:626-631
Mitkas P, Koutkias V, Symeonidis A, et al.2008. Association studies on cervical cancer facilitated by inference and semantic technologies:the assist approach. J. Stud Health Technol Inform.136:241-246.
Monk BJ, Tewari KS.2007. The spectrum and clinical sequelae of human papillomavirus infection. Gynecol Oncol.107:6-13
Morris BJ.2007. Why circumcision is a biomedical imperative for the 21 (st) century. Bioessays.29(11):1147-58.
Nicolas Duport.2008. Donnees epidemiologiques sur le cancer du col de Tuterus-Etat des connaissanccs-Actualisation In Maladies chroniques et traumatismes. Institut de veille sanitaire:5-27
Ng'andwe C, Lowe JJ, Richards PJ, Hause L, Wood C, Angeletti PC.2007. The distribution of sexually-transmitted Human Papillomaviruses in HIV positive and negative patients in Zambia, Africa. BMC Infect Dis.7:77.
Organisation mondiale de la Sante, de la cytologie du tractus genital feminin.1973, Geneve: OMS
Parkin D, Whelan S, Ferlay J, et al., editors.2002. Cancer Incidence in Five Continents.. IARC Scientific Publications.155(8):418-499
Peto J, Gilham C, Fletcher O, Matthews FE.2004. The cervical cancer epidemic that screening has prevented in the UK. Lancet.364:249—256.
Philip E. Castle, Mark Schiffman, Cosette M. Wheeler, Nicolas Wentzensen and Parti E. Gravitt.2009. Impact of Improved Classification on the Association of Human Papillomavirus With Cervical Vrecancer.Am.Epidemiol. J.172(1):390
Pimple S, Muwonge R, Amin G, Goswami S, Sankaranarayanan R, Shastri SS.2010. Cytology versus HPV testing for the detection of high-grade cervical lesions in women found positive on visual inspection in Mumbai, India. Int J Gynaecol Obstet. 108(3):236-239Expand+
Pretorius RG, Bao YP, Belinson JL, Burchette RJ, Smith JS, Qiao YL.2007. Inappropriate gold standard bias in cervical cancer screening studies. Int J Cancer.121:2218-2224.
Rengaswamy Sankaranarayanan, Ketayun Dinshaw, BhagwanMNene, Kunnambath Ramadas, Pulikattil Okkaru Esmy, Kasturi Jayant, Thara Somanathan, Surendra Shastri.2006. Cervical and oral cancer screening in India. J Med Screen. (Suppl 1):35-38
Safaeian M, Kiddugavu M, Gravitt PE, et al.2007. Comparability of self-collected vaginal swabs and physician-collected cervical swabs for detection of human papillomavirus infections in Rakai, Uganda. Sex Transm Dis;34:429-36.
Safaeian M, Kiddugavu M, Gravitt PE, Gange SJ, Ssekasanvu J, Murokora D, Sklar M, Serwadda D, Wawer MJ, Shah KV, Gray R.2008. Prevalence and risk factors for carcinogenic human papillomavirus infections in rural Rakai, Uganda. Sex Transm Infect.84(4):306-311.
Sangwa-Lugoma G, Mahmud S, Nasr SH, Liaras J, Kayembe PK, Tozin RR, Drouin P. Lorincz A, Ferenczy A, Franco EL.2006. Visual inspection as a cervical cancer screening method in a primary health care setting in Africa. Int J Cancer.;119:1389-1395.
Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, Fayette JM, Cherian J.2007. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India:a cluster-randomised trial. Lancet.370:398-406.
Sankaranarayanan R, Wesley R, Thara S, Dhakad N, Chandralekha B, Sebastian P, et al. 2003;Test characteristics of visual inspection with 4% acetic acid (VIA) and Lugol's iodine (VILI) in cervical cancer screening in Kerala, India. Int J Cancer 106:404-408.
Sankaranarayanan R, Chatterji R, Shastri SS, Wesley RS, Basu P, Mahe C, Muwonge R, Seigneurin D, Somanathan T, Roy C, Kelkar R, Chinoy R, Dinshaw K, Mandal R, Amin G, Goswami S, Pal S, Patil S, Dhakad N, Frappart L, Fontaniere B.2004b. Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: results from a multicenter study in India. Int J Cancer.112:341-347.
Sankaranarayanan R, Wesley R. A Practical Manual on Visual Screening for Cervical Neoplasia 2003. IARC Press:Lyon; IARC technical publication no.41
Sankaranarayanan R, Shastri S, Basu P, Mahe C, Mandal R, Amin G, et al.2004. The role of low-level magnification in visual inspection with acetic acid for the early detection of cervical neoplasia. Cancer Detection and Prevention; 28:245-251.
Sankaranarayanan R, Wesley R, Somanathan T, Dhakad N, Shyamalakumary B, Amma NS, et al.1998. Visual inspection of the uterine cervix after the application of acetic acid in the detection of cervical carcinoma and its precursors, Cancer;83:2150-256
Sankaranarayanan R, et al.,2005;. A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. International Journal of Cancer,116(4):617—623
Sankaranarayanan R et al.2005. A critical assessment of screening methods for cervical neoplasia. International Journal of Gynecology and Obstetrics.(89) 2:4-12
Sankaranarayanan R, Basu P, Wesley R, Mahe C, Keita N, Gombe C, et al.2004. Accuracy of visual screening for cervical neoplasia: Results from an IARC multicentre study in India
and Africa. International Journal of Cancer; 110,907-913
Sankaranarayanan R. Royal Society of Tropical Medicine and Hygiene meeting at Manson House,2002. Cervical cancer in developing countries. Trans R Soc Trop Med Hyg. 96:580-582.
Sankaranarayanan R, Budukh A, Rajkumar R. Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bulletin of the World Health Organization 2001;79:954-962.
Sarian LO, Derchain SF, Naud P, Roteli-Martins C, Longatto-Filho A. Tatti S, Branca M, Erzen M, Serpa-Hammes L, Matos J, Gontijo R, Braganca JF, Lima TP, Maeda MY, Lorincz A, Dores GB, Costa S, Syrjanen S, Syrjanen K.2005. Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) study. J Med Screen.; 12:142-149
Schiffman M.2007. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer; 111:145-53
Sellors JW, Sankaranarayanan R. Colposcopy and Treatment of Cervical Intraepithelial Neoplasia:A Beginner's Manual. International Agency for Research on Cancer:Lyon; 2003.
Sepulveda C, Prado R.2005. Effective cervical cytology screening in middle-income countries:The Chilean experience. Cancer Detect Prev.29:405-411
Shastri SS, Dinshaw K, Amin G, Goswami S, Patil S, Chinoy R, et al.2005;Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical Neoplasia in Mumbai, India. Bull World Health Organ 83:186-191
Steward BW. Kleihues P.2003. World Cancer Report. IARC Press.145-166
Surendra S Shastri.2010. Cervical cancer screening and vaccination in India. Indian Journal of Medical Ethics.7(1):41
Surendra S. Shastri, Ketayun Dinshaw, Geetanjali Amin, Smriti Goswami, Sharmila Patil, Roshini Chinoy, S. Kane, Rohini Kelkar, Richard Muwonge, Cedric Mahe, Dulhan Ajit, & R. Sankaranarayanan.2005. Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India. Bulletin of the World Health Organization.83:186-194.
Systeme de Bethesda pour la declaration col de l'uterus / diagnostic cytologique vaginal. 1995. Acta cytologie.37:115-120
University of Zimbabwe/JHPIEGO Cervical Cancer Project.1999. Visual inspection with acetic acid for cervical cancer screening:test qualities in a primary-care setting. Lancet 353:869-873.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N.1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol.189(1):12-29
Wu R.F., Dai M., Qiao Y.L., Clifford G.M., Liu Z.H., Arslan A., Li N., Shi J.F., Snijders P.J., Meijer C.J., Franceschi S.2007. Human papillomavirus infection in women in Shenzhen City, People's Republic of China, a population typical of recent Chinese urbanisation. Int J Cancer,121:1306- 1311.
5. Interest of CA 125 antigens dosing for the assessment of premature ovarian cancer
REFERENCES
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ:Cancer statistics. CA Cancer J Clin 2008, no 58,71-96.
Edwards BK, Brown ML, Wingo PA, et col:Annual report to the nation on the status of cancer,1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005, no97,1407-1427.
Hartge P, Whittemore AS, Itnyre J, McGowan L. Cramer D:Rates and risks of ovarian cancer in subgroups of white women in the United States The Collaborative Ovarian Cancer Group Obstet Gynecol 1994, no84,760-764.
Lu KH, Patterson AP, Wang L, et col:Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004, no 10,3291-3300
Averette HE, Janicek MF, Menck HR:The National Cancer Data Base report on ovarian cancer. American College of Surgeons Commission on Cancer and the American Cancer Society Cancer 1995, no76,1096-1103
Kosary CL:FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system:an analysis of 1973-1987 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 1994, no 10,31-46.
Fishman DA, Bozorgi K:The scientific basis of early detection of epithelial ovarian cancer: the National Ovarian Cancer Early Detection Program (NOCEDP). Cancer Treat Res 2002, no107,3-28.
Jemal A, Siegel R, Ward E, et al:Cancer statistics,2009. CA Cancer J Clin 2009, vol 4, no 59, 225-249.
van Dalen A, Favier J, Burges A, et col:Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol 2000, no 79, 444-450
Bast RC Jr, Badgwell D, Lu Z, Marquez R, et col:New tumor markers:CA125 and beyond. Int J Gynecol Cancer 2005, no15(Suppl 3),274-281.
Landen CN, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008; no26,995-1005.
Kurman RJ, Visvanathan K, Roden R, et al. Early detection and treatment of ovarian cancer; shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 2008; n o198,351-356.
Heerlein Meinhold-1, Bauerschlag D, Zhou Y, et al. An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. Clin Cancer Res.2007; no13(2 Pt 1),458-466
Abstracts of the first scientific workshop of the Early Detection Research Network Dis Markers 2001,17:3-38
Hogdall E:Cancer antigen 125 and prognosis. Curr Opin Obstet Gynecol 2008, no 20,4-8.
Tuxen MK, Soletormos G, Dombernowsky P:Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev 1995, no 21,215-245.
Karen A. Johnson. The Standard of Perfection:Thoughts about the Laying Hen Model of Ovarian Cancer. In Perspective on Hakim et al. Cancer Prevention Research,2009, vol 2,n o 97,114
Gynecologic Cancer Foundation, Society of Gynecologic Oncologists, American Cancer Society. Ovarian Cancer Symptoms Consensus Statement 2007
McGuire WP. Hoskins WJ,Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med.1996; no 334:1-6
Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst.2000; no 92:699-708
Cannistra SA Cancer of the ovary. N Engl J Med.2004; no351:2519-2529
Markman M, Federico M, Liu PY, Hannigan E, Alberts D:Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. Gynecol Oncol 2006, no 103:195-198
Riedinger JM, Bonnetain F, Basuyau JP, et col:Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. Ann Oncol 2007, no 18:881-885.
The serum CA-125 antigen level on overall survival in advanced ovarian cancer. Gynecol Oncol 2006, no 103,195-198.
Petri AL, Hogdall E, Christensen IJ, Kjaer SK, Blaakaer J, Hogdall CK:Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer. APMIS 2006, no 114:359-363.
Mano A, Falcao A, Godinho I, Santos J, Leitao F, de Oliveira C, Caramona M:CA-125 AUC as a predictor for epithelial ovarian cancer relapse. Cancer Biomark 2008, no 4:73-81
Osman N, O'Leary N, Mulcahy E, Barrett N, Wallis F, Hickey K, Gupta R: Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre. Ir Med J 2008,no 101:245-247
Rustin GJ, van der Burg ME:A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials), J Clin Oncol 2009,2728
6. Determining roles of association Carboplatine-Doxorubicine Liposomale/Platinum-
Texane And the Management Of the Cancer Of the Advanced Ovariens Epitheliums At
the teaching hospital Conakry-Jilin 2.
REFERENCES
Jemal A, Siegel R, Ward E, et al:Cancer statistics,2009. CA Cancer J Clin 2009, vol 4 n°59, 225-249.
National Comprehensive Cancer Network:The NCCN Clinical Practice Guidelines in Oncology Ovarian Cancer. Available at: http://www.nccn.org.2eme version 2009, 2010.
Kyrgiou M, Salanti G, Pavlidis N, et al. Survival benefits with diverse chemotherapy regimens for ovarian cancer:meta-analysis of multiple treatments. J Natl Cancer Inst 2006; n°98,1655-1663
Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 2005; n°99,393-399.
Depierre, A. Maintenace chemotherapy in advanced non small cell lung cancer (NCSLC):a randomized study of vinorelbine versus observation in patients responding to induction therapy. Proc Am Soc Clin Oncol,2001, n°20,309a
Smith, I.E., et al., Duration of chemotherapy in advanced non-small-cell lung cancer:A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin.J Clin Oncol,2001, n°19, vol 5,1336-1343
Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer:an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; n°24,4699-4707.
Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J clin Oncol 2010; n°28,3107-3114.
Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010; no 28:3323-3329 Poveda A, Tjulandin S, Kong B, et al. Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr+PLD) versus PLD alone:results from a PPS cohort of a phase III study. J Clin Oncol 2010,28.
Rustin G, van der Burg M, et al. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). J Clin Oncol 2009;27 Suppl.
Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer:the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006; n°13:1702-1710
Sharma R, Graham J, Mitchell H, et al. Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer. Br J Cancer 2009; no 100:707-712.
Fung-Kee-Fung M. Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 2007; n°14:195-208.
Markman M, Blessing J, Rubin SC, et al. Phase Ⅱ trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers:a Gynecologic Oncology Group study. Gynecol Oncol 2006; n°101,436-440.
Kristensen G, Kaern J, Baekelandt M, et al. Chemotherapy versus hormonal treatment in patients with platinum and taxane resistant ovarian cancer: A NSGO study. J Clin Oncol 2008.26.
Tomao F, Panici PB, Frati L, Tomao S. Emerging role of pemetrexed in ovarian cancer. Expert Rev Anticancer Ther 2009; n o 9:1727-1735.
Vergote I, Calvert H, Kania M, et al. A randomised, double-blind, phase Ⅱ study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur J Cancer 2009;no 45:1415-1423.
Larkin JM, Kaye SB. Epothilones in the treatment of cancer. Expert Opin Investig Drugs 2006; n°15,691-702.
De Geest K, Blessing JA, Morris RT, et al. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 2010; n°28: 149-153.
Kumaran GC, Jayson GC, Clamp AR. Antiangiogenic drugs in ovarian cancer. Br J Cancer 2009;n°100:1-7.
Burger RA, Sill MW, Monk BJ, et al. Phase Ⅱ trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer:a Gynecologic Oncology Group study. J Clin Oncol 2007; n°25:5165-5171.
Cannistra SA, Matulonis UA. Penson RT, et al. Phase Ⅱ study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; n°25:5180-5186
Steelman LS, Stadelman KM, Chappell WH, et al. Akt as a therapeutic target in cancer. Expert Opin Ther Targets 2008; 12:1139-1165.
Yap TA, Carden CP, Kaye SB. Beyond chemotherapy:targeted therapies in ovarian cancer. Nat Rev Cancer 2009; 9:167-181.
Eckstein N, Servan K, Hildebrandt B, et al. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res 2009; n°69:2996-3003.
Huang GS, Brouwer-Visser J, Ramirez MJ, et al. Insulin-like growth factor 2 expression modulates taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin Cancer Res 2010; n°16:2999-3010
Ledermann J, Rustin G, Hackshaw A, et al. A randomized phase Ⅱ placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC). J Clin Oncol 2009;27.
Spannuth WA, Sood AK, Coleman RL. Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther 2010; 10:431-437.
Kalli KR, Oberg AL, Keeney GL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 2008; n°108,619-626.
McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition. Cancer Res 2006; n°66,8109-8115.
Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition:frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; n°28:2512-2519.
C. REFERENCES in International Journal Biology and Medical Sciences
7. Critical expression of gelatin-9 in the diagnosis of the uterine cervix carcinogen
tissues precancerous tumors and cancerous
REFERENCES
Aglund K1, Rauvala M1, Puistola U. Angstrom T, Turpeenniemi-Hujanen T,Zackrisson B & Stendahl U.2006. Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer - MMP-9 correlates to the grade and the stage. Gynecol Rauvala, Marita. Matrix metalloproteinases-2 and-9 and tissue inhibitors of metalloproteinases-1 and-2 in gynaecological cancers. Acta Univ.Oul, vo 4, issue 12, pp 1-90
Brem S.1999. Angiogenesis and Cancer control:From concept to therapeutic trial. Cancer Control; issue 6, pp 436-458.
Frisch SM, Ruoslahti E.1997, Integrin and anoikis. Curr Opin Cell Biol issue 9, pp 701-706
Hantz S, Alain S, Denis F.2006. Human papillomavirus prophylactic vaccines:Stakes and perspectives. Gynecol Obstet Fertil, vo 34, issue 78, pp647-55.
Jiangzhong Qing, Zhu Fengchuan,2003, expression MMP-9 of Uterine Cervix and angiogenesis tumoral, the proliferation des cells cancerous, invasion and metastasis. J. Cancer, vo 22, issue 2, pp 178-184.
Kathy Shapiro, Emma Ottolenghi, Patricia Claeys, Janet Petitpierre.2007. Guide essential practices. Overall picture of stages FIGO compared to the assumption of responsibility and forecast in the fight against the cancer of the cervix. Overall picture of stages FIGO compared to the assumption of responsibility and forecast. pp187.
LaFlamme SE, Auer KL.1996. Integrin de signalisation. Semin Cancer Biol, issue 7, pp 111-118
Lin LF, Chuang CH, Li CF, Liao CC, Cheng CP, Cheng TL, Shen MR, Tseng JT, Chang WC, Lee WH, Wang JM. ZBRK1 acts as a metastatic suppressor by directly regulating MMP9 in cervical cancer. Cancer Res:2010; 70(1):192-201.
Li SL, Zhao QM, Liu ZW, Zhao ZH, Gao DL, Zheng XY, Chen KS, Zhang YH.2007. Correlation between the protein expression of reversion inducing cysteine rich protein with Kazal motifs and matrix matalloproteinase-9 in esophageal squamous cell carcinoma and its clinical pathological significance. Shijie Huaren Xiaohua Zazhi; vol5. issue 10, pp 1082-1086
Liotta LA, CN Rao, SH Barsky.1983. Invasion tumoral and matrix extracellular. Lab Invest issue 49, pp 636-649
Lochter A, Bissell MJ.1999. An Odyssey of the chest bone:-control of breast metastasis and matrix Metalloproteinases periprosthetic multi stage. APMIS; issue 107, pp 128-136
Mignatti P, DB Rifkin. Biology and biochemistry of proteases in tumor invasion.1993. Physiol Rev; issue 4, pp 251-258
Mitra A, Chakrabarti J, Banerji A,et al.2006. Cell membrane-associated MT1-MMP dependent activation of MMP-2 in SiHa (human cervical cancer) cells. J Environ Pathol Toxicol Oncol. vo 25, issue 4, pp 655-666.
M Schmitt, Janicke F, N Moniwa, Chucholowski L, H Pache, Graeff H.1992 associated tumor to plasminogen activator urokinase type:and the biological clinical significance. Biol Chem Hoppe Seyler; issue 373, pp 611-622
Nair RR, Solway J, Boyd DD.2006. Expression cloning identifies transgelin (SM22) as a novel repressor of 92-kDa type IV collagenase (MMP-9) expression. JBiol Chem. vo 281, issue 36, pp 26424-6436.
Nicolas Duport.2008. Epidemiological data on cancer cervical-State of knowledge. Health monitoring Institute, pp 1-4.
Noriyuki M, Sumi T, Zhi X, et al.2007. Vascular endothelial growth factor, matrix metalloproteinases, and cyclooxygenase-2 influence prognosis of uterine cervical cancer in young women. Int J Oncol, vo 31, issue 3, pp 531-536
Rundhaug JE. Matrix metalloproteinases and angiogenesis.2005. J Cell Mol Med, issue 9, pp 267-285
Sang-Hyuk Chung and Paul Lambert F.2009. Prevention and treatment of cervical cancer in mice using estrogen receptor antagonists. Medical Science, vo.106, issue 46,pp 19467-19472.
Sheu BC, Lien HC, Ho HN,et al.2007. Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. J.Cancer Res, vo 63, issue 19, pp 6537-6542.
Shusterman S, Maris JM.2005. Prospects for therapeutic inhibition of neuroblastoma angiogenesis. Cancer Lett; issue 228, pp 171-279.
Tamakoshi K., Kikkawa F., A. Nawa, Ishikawa H., Mizuno K., A. Tamakoshi, Yamagata S., N. Suganuma, Y. Tomoda 1995. Characterization of degrading extracellular matrix and its proteinase inhibitor in gynaecological cancer with clinically different metastatic form tissues. Cancer (Phila.), issue 76, pp 2565-2571
van der Stappen JW, AC Williams, Maciewicz RA, Paraskeva C.1996. Activation of cathepsin B, secreted by a colorectal cancer cells line requires a low pH and is mediated cathepsin D. Int J Cancer; issiue 67, pp 547-554
Yoshida S, Kajitani N, Satsuka A, Nakamura H, Sakai H.2008. Ras modifies proliferation and invasiveness of cells expressing human papillomavirus oncoproteins. J Virol vo 82, issue 17, pp 8820-8827
Yu J, Qian H, Li Y, et al.2007. Arsenic trioxide (As2O3) reduces the invasive and metastatic properties of cervical cancer cells in vitro and in vivo. J. Gynecol Oncol, vol06, issue 2, pp 400-406.
Yu W, Liu J, Xiong X, Ai Y, Wang H.2009. Expression of MMP9 and CD147 in invasive squamous cell carcinoma of the uterine cervix and their implication. Pathol Res; vo 205, issue 10, pp 709-715.
[2]Canadian Cancer Statistics. What is ovarian cancer? Canadian society cancer. In Canadian Cancer Society Public Health Agency logo.2009,3-13.
[3]Hoimes CJ, et al. JOP. J Panc0000000000000reas (Online). Cancer Facts & Figures. 2010; 10(4):352-356
[4]Cancer Care Center. What is ovarian cancer? Metro Health Drive Cleveland.2009, OH 44109(216)778-7800
[5]Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer:defining the target for early detection. PLoS Med.2009; 6(7),2-29
[6]Kurman RJ, Shih Ie-M:The origin and pathogenesis of epithelial ovarian cancer:a proposed unifying theory. Am. J. Surg. Pathol.2010,34(3),433-443
[7]Ferlay J, Bray F, Pisani P, and et al. GLOBOCAN 2002:cancer incidence, mortality and prevalence worldwide. IARC Press Cancer Base.2004(5) 2,4-18.
[8]American Joint Committee on Cancer. Ovary. In: AJCC Cancer Staging Manual. Springer.2002,6th ed,275-279.
[9]American Cancer Society Cancer Facts and Figures 2008. American Cancer Society. 2008.1-70
[10]Menon U, Gentry-Mahara J A, Mallett T and et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clin. Chem.2008,54(12): 11-79
[11]Ovarian Cancer Antigen(CA-125) Enzyme Immunassay Tests Kit. Enzyme Immunoassay for the Quantitative Measurement of Ovarian Cancer Antigen CA-12-5. 2008,2-5
[12]Chan JK, Cheung MK, Husain A, and et al. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 2006,108:521-528.
[13]Jemal A, Siegel R,Ward E, et al. Cancer statistics,2006. CA CancerJClin 2006; 56:106-130.
[14]Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol. Biol.2009, 472:413-437.
[15]Mabika B and et al. Cancers of the ovary in children in Gabon:A retrospective study over 20 years. Doctor of Black Africa.2004,51 (11):571-574
[16]Hoskins KF, Stopfer JE, Calzone KA, et al. Assessment and counseling for women with a family history of breast cancer:a guide for clinicians. JAMA.1995;273:577585.
[17]Australian Institute of Health and Welfare and National Breast and Ovarian Cancer Centre 2010 in Ovarian cancer in Australia: An overview. CAN. Canberra:AIHW. Cancer series.2010,48; 136
[18]Tracey Edgell, G. Martin-Roussety, G. Barker, D. J. Autelitano, D. Allen, P. Grant, and G. E. Rice Phase II biomarker trial of a multimarker diagnostic for ovarian cancer Cancer Res Clin Oncol.2010; 136(7):1079-1088.
[19]National Cancer Institute (NCI). Anatomy:the cervix and nearby organs, NCI visuals online. Bethesda, MD:National Institutes of Health, United States Department of Health and Human Services.2009,1-2
[20]American Cancer Society. Cancer Facts & Figures 2009. American Cancer Society.2010.1-8
[21]Kim K, Zang R, Choi SC, Ryu SY, Kim JW. Current status of gynecological cancer in China. J Gynecol Oncol.2009; 20(2):72-76.
[22]Body G et al, tumor and cyst of the ovary. B Hedon, PMadelnat in D. Dargent, S Fridman. Gynecology Ellipses.1998,3-16.
[23]Descamps Ph and neck, ultrasound screening of ovarian cancer is it possible in 1998? J. Gynecol. Midwifery, biol.1998,27 (5):76-480.
[24]Koulibaly M, Kabba IS, Cisse A et al. Cancer incidence in Conakrt. Guinea:Fist results from the cancer Registry. In Etiology of urethral discharge in West Africa:the role of Mycoplasma genitalium and Ghana (5 in Accra), Guinea (18 in Conakry and 1 in Kamsar). Bulletin of the World Health Organization - Etiology of urethral.1992-1995. Int J Cancer.1997; 70; 39-45.
[25]Kazadi Buanga J and neck surgery of ovarian cancer in a precarious situation. The observation at St John of God about 21 cases. Black African Medicine.2005,52 (2): 126-128.
[26]Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics,2002. CA Cancer J Clin.2005,55(2):74-108.
[27]American Joint Committee on Cancer. Ovary. In:AJCC Cancer Staging Manual. Springer; 6th Ed.2002:275-279.
[28]Landen CN, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008;26:995-1005.
[29]Karen A. Johnson. The Standard of Perfection:Thoughts about the Laying Hen Model of Ovarian Cancer. In Perspective on Hakim et al. Cancer Prevention Research,2009 2: 97,114
[30]Kathleen R. Cho. Ming Shih. Pathology:Mechanisms of Disease Annual Review.2009, (4)287-313
[31]Feng Su, Jennifer Lang, Ashutosh Kumar, Carey Ng, Brian Hsieh, Marc A. Suchard, Srinivasa T. Reddy, Robin Farias-Eisner. Validation of Candidate Serum Ovarian Cancer Biomarkers for Early Detection. Biomarker Insights 2007, (2)369-375
[32]Ries, LAG., Harkins, D., Krapcho, M. et al. SEER Cancer Statistics Review,1975-2003, National Cancer Institute.2008,3-4.
[33]Hermsen BBJ, von Mensdorff-Pouilly S, Berkhof J, et al:Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer. J Clin Oncol 2007,25:1383-1389
[34]Urban N, McIntosh MW, Andersen M, et al:Ovarian cancer screening. Hematol Oncol Clin North Am 2003.17,989-1005
[35]Skates SJ, Xu FJ, Yu YH, et al:Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 1995:2004-2010.76
[36]McIntosh MW, Urban N, Karlan B:Generating longitudinal screening algorithms using novel biomarkers for disease. Cancer Epidemiol Biomarkers Prev 2002,11,159-166
[37]Crump C, McIntosh MW, Urban N, et al:Ovarian cancer tumor marker behavior in asymptomatic healthy women:Implications for screening. Cancer Epidemiol Biomarkers Prev.2000.9,1107-1111,
[38]Santillan A, Garg R, Zahurak ML, et al:Risk of epithelial ovarian cancer recurrence in patients with rising serum CA125 levels within the normal range. J Clin Oncol 2005,23, 9338-9343
[39]Friedman LC, Kramer RM:Reproductive issues for women with BRCA mutations. J Natl Cancer Inst Monogr 2005,34,83-86
[40]Petricoin EF, Ardekani AM, Hitt BA, et al:Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002,359.572-577
[41]Ransohoff DF:Lessons from controversy:Ovarian cancer screening and serum proteomics. J Natl Cancer Inst 2005,97,315-319
[42]myDr, Ovarian cancer test (CA125). UBM Medica Australia,2000-2010.2008,2
[43]Carcangiu ML, Radice P, Manoukian S, et al:Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol 23:35-40,2004
[44]Colgan TJ, Murphy J, Cole DEC, et al:Occult carcinoma in prophylactic oophorectomy specimens. Am J Surg Pathol 25:1283-1289,2001
[45]Hermsen BBJ, van Diest PJ, Berkhof J, et al:Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and fallopian tube in women at hereditary high risk of breast and ovarian cancer. Int J Cancer 2006.119:1412-1418
[46]Crawford SM, Peace J:Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann Oncol 2005,16:47-50.
[47]Gynecologic Cancer Foundation, Society of Gynecologic Oncologists, American Cancer Society. Ovarian Cancer Symptoms Consensus Statement 2007
[48]Data interpretation in ovarian cancer in Australia, Australian Institute of Health and Welfare and National Breast and Ovarian Cancer, Centre Australian Institute of Health and Welfare Canberra CAN 48,2010,52,2
[49]Incidence of ovarian cancer in ovarian cancer in Australia, Australian Institute of Health and Welfare and National Breast and Ovarian Cancer, Centre Australian Institute of Health and Welfare Canberra CAN 48.2010.52,5
[50]Tang Taylor. Questions answers on the ovarian cancer test CA-125. Information inspiration & community.2003,1-4
[51]Rossing, M. A., Wicklund, K. G., Cushing-Haugen, K. L., Weiss, N. S. Predictive Value of Symptoms for Early Detection of Ovarian Cancer. J Natl Cancer Inst.2010.102: 222-229
[52]RUFFORD BD, JACOBS IJ, MENON U. Feasability of screening for ovarian cancer using symptoms as selection criteria. BJOG,2007; 114:59-64.
[53]Twombly R:Cancer killer may be'silent'no more. J. Natl Cancer Inst.2007,99(18), 1359-1361
[54]Dawn Dorsey. Ovarian Cancer Symptoms Are Not Silent. CancerWise.2007,1.
[55]Goff BA, Mandel LS, Melancon CH, et al. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA.2004; 291 (22):2705-2712.
[56]Andreson N & Y, Urinary levels of Bcl-2 are elevated in ovarian cancer patients. Gynecol Oncol,2009; 112:60-67.
[57]Chambers, A. F., Vanderhyden, B. C. Ovarian Cancer Biomarkers in Urine. Clin. Cancer Res.2006,12:323-327
[58]Winter-Roach BA, Kitchener HC, Dickinson HO. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev.2009; 21,2-10
[59]Chobanian N, Dietrich CS. Ovarian Cancer. Surgical Clinics of North America.2008; 88,285-99
[60]Cass, I., Karlan, B. Y. Ovarian Cancer Symptoms Speak Out--But What Are They Really Saying?. JNCI J Natl Cancer Ins.(2010).102:211-212.
[61]Ovarian Cancer. What is it? American Association for Clinical Chemistry,2010,1
[62]Goff BA, Matthews BJ, Larson EH et al.:Predictors of comprehensive surgical treatment in patients with ovarian cancer. Cancer 2007,109(10),2031-2042.
[63]Prognostic Significance of CA-125 in the Management of Patients with Recurrent Epithelial Ovarian Carcinoma Selected for Secondary Cytoreduction Anticancer Res. 2009,29(7):2817-2821
[64]Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels Ann Oncol (2009) 20(2):294-297
[65]Ovarian Cancer. Detection In early detection techniques. The National Ovarian Cancer Association (NOCA),2010,6-20.
[66]Kurian AW, Balise RR, McGuire V, Whittemore AS. Histologic types of epithelial ovarian cancer:have they different risk factors? Gynecol Oncol 2005; 96,520-530.
[67]Juretzka MM, Barakat RR, Chi DS et al. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol 2007; 104:176-180
[68]Ozols RF, Bundy BN, Greer BE et al. Phase Ⅲ trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage Ⅲ ovarian cancer:a Gynecologic Oncology Group Study. J Clin Oncol 2003; 21:3194-3200.
[69]The ICON Group. Paclitaxel plus carboplatin versus standard chemotherapy with single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer:the ICON3 randomised trial. Lancet 2002; 360:505-515.
[70]Tung CS, Wong KK, Mok SC. Biomarker discovery in ovarian cancer. Womens Health (Lond Engl).2008,4:27-40
[71]Markman M, Liu PY, Rothenberg ML et al. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol 2006; 24:1454-1458
[72]Liu P-Y Alberts DS, Monk BJ et al. An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol 2007; 25:3615-3620.
[73]Mann JR, Gray ES, Thornton C, Raafat F, Robinson K, Collins GS, Gornall P, Huddart SN, Hale JP, Oakhill A. Mature and immature extracranial teratomas in children:the UK Children's Cancer Study Group Experience. Journal of Clinical Oncology:Official Journal of the American Society of Clinical Oncology.2008,26 (21):3590-3597
[74]Pauler DK, Menon U, McIntosh M, et al:Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev 10:489-493,2001
[75]Tracey Edgell, G. Martin-Roussety, G. Barker, D. J. Autelitano, D. Allen, P. Grant, G. E. Rice. Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J Cancer Res Clin Oncol.2010,136:1079-1088
[76]Lo Curto M. D'Angelo P, Cecchetto G, and et al. Mature and immature teratomas: results of the first paediatric Italian study. Pediatric Surgery International 2007,23 (4): 315-322
[77]Ries LAG, Melbert D, Krapcho M, and et al. SEER cancer statistics review 1975-2005 Institute. NC, Bethesda, MD.2006,3-20
[78]Hess LM, Benham-Hutchins M, Herzog TJ, Hsu CH, Malone DC, Skrepnek GH. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer. May-Jun 2007;17(3):561-570.
[79]Elit L, Oliver TK, Covens A, Kwon J, Fung MF, Hirte HW. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer:a systematic review with metaanalyses. Cancer.2007;109(4):692-702
[80]Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer. Primary care clinics. JAMA. 2004;291(22):2705-2712.
[81]Riedinger JM, Bonnetain F, Basuyau JP et al. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. Ann Oncol 2007; 18:881-885.
[82]Riedinger JM, Wafflart J, Ricolleau G et al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome:results of a French multicentric studv. Ann Oncol 2006; 17:1234-1238.
[83]MEDEIROS LR, ROSA DD, DA ROSA MI. Accuracy of Ca 125 in the diagnosis of ovarian tumors:a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol, 2009; 142:99-105.
[84]Munkarah A, Chatterjee M, Yainski MA. Update on ovarian cancer sreening curr. Opin Obstet Gynecol,2007; 19:22-26
[85]Comparison of CA-125 and Standard Definitions of Progression of Ovarian Cancer in the Intergroup Trial of Cisplatin and Paclitaxel Versus Cisplatin and Cyclophosphamide JCO (2006) 24(1):45-51
[86]Coates RRJ, Kolor K, Stewart SL, Richardsonha LC. Diagnostic markers for ovarian cancer screening:not ready for routine clinical use. Clin Cancer Res,2008; 14,7 575-7576
[87]Moore, R. G., Bast, R. C. Jr. How Do You Distinguish a Malignant Pelvic Mass From a Benign Pelvic Mass? Imaging, Biomarkers, or None of the Above. JCO 2007,25: 4159-4161
[88]Symptoms of Ovarian Cancer in Gynecologic Cancer Symptoms. Facts About Gynecologic Cancer.2010,1-2
[89]Van Nagell JR, De Priest PD, Ueland FR. Ovarian cancer screening with annual transvaginal sosnography:findings of 25 000 women screened. Cancer,2007; 109:1 887-1896.
[90]Fleischer AC, Lyshchick A, Jones HW JR. Contrast enhanced transvaginal sonography of benign versus malignant ovarian masses:preliminar findings. J Ultrasound Med, 2008; 27,1011-1018.
[91]Basal E, Eghbali-Fatourechi GZ, Kalli KR, and et al. Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. PLoS One.2009,20;4(7):6292.
[92]Jacobs I, Davies AP, Ponts J, and et al. Prevalence de depistage pour le cancer de l'ovaire-chez les femmes menopausees par CA 125 de mesure et de l'echographie. BMJ. 1993; 306(6884):1030-1034.
[93]Jacobs IJ, patins S, Davies AP, RP Woolas, Jeyerajah A DH, Oram P Weidemann, K Sibley. Le risque de diagnostic de cancer de l'ovaire apres soulevees serum CA 125 concentration:une etude prospective de cohorte. BMJ.1996:313(7069):1355-1358]
[94]Jacobs IJ, Skates SJ, N MacDonald, and et al. Le depistage du cancer de l'ovaire:un pilote randomisee et controlee. Lancet.1999; 353(9160),1207-1210.
[95]Zurawski VR, Orjaseter H, Andersen A, Jellum E. elevation des taux seriques de CA-125 niveaux avant le diagnostic de la neoplasie-pertinence de l'ovaire pour la detection precoce de l'ovaire et le cancer. Int J Cancer.1988;42(5):677-680.
[96]Bast Jr RC, Klug TL, John St E, and et al. Un dosage radio-immunologique utilisant un anticorps monoclonal de surveiller l'evolution du cancer epithelial de l'ovaire. N Engl J Med.13 octobre 1983; 309 (15):883-7.
[97]Lan Jacobs et al. Ovarian cancer:early detection tests developer. Journal of Pathology 2009,1-2.
[98]H. Martelli[2003]and neck tumor of the gonads in children. Vol lo, (3) 246-250.
[99]Houlston RS, Boume TH, Davies A, Whitehead MI, Campbell S, Collins WP, et al. Use of family history in a screening clinic for familial ovarian cancer. Gynecol Oncol 1992;(42)247-252.
[100]Bell DA, Scully RE. Early de novo ovarian carcinoma. A study of fourteen cases. Cancer.1994, (73) 1859-1864.
[101]Olivier RI, Lubsen-Brandsma MA, Verhoef S, van BeurdenM. CA125 and transvaginal ultrasoundmonitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol.2006; (100)20-2 6.
[102]Mandic A, Nincic D, Vujkov T. Ovarian epithelial carcinoma--a malignant disease sparing no age group. Med Pregl.2003; 56(3-4),157-61.
[103]Coombes KR, Morris JS, Hu J, Edmonson SR, Baggerly KA. Serum proteomics profiling--a young technology begins to mature. Nat. Biotechnol.2005,(3) 291-292.
[104]Armstrong, D. Ovaries and fallopian tubes. In Abeloff MD ed. Abeloffs Clinical Oncology,4th ed. Philadelphia:Churchill Livingstone,2008,1827-1850.
[105]Nelson Guerreiro, Baltazar Gomez-Mancilla and Stephane Charmont. Optimization and evaluation of surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry for protein profiling of cerebrospinal fluid. Proteome Science.2006, (4)7. 1477-5956
[106]Zhang H, Kong B, Qu X, Jia L, Deng B, Yang Q.2006. Biomarker discovery for ovarian cancer using SELDI-TOF-MS. Gynecol. Oncol.2006, (1) 61-66.
[107]Whiteley GR, Colantonio S, Sacconi A, Saul RG. Analytical considerations for mass spectrometry profiling in serum biomarker discovery. Clin.2009, Lab. Med., (1)57-69.
[108]Keith AB, Jeffrey, SM, Sarah RE, Kevin RC. Signal in noise:evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J. Nat. Cancer Inst., 2005,(4) 307-309.
[109]Kristina G, Radomir P, Eva B, Lenka D, Radek L, Rostislav V. When one chip is not enough:augmenting the validity of SELDITOF proteomic profiles of clinical specimens. Lab. Chip.2009, (7) 1014- 1017.
[110]Josep Villanueva, David RS, John P. Differential exoprotease activities confer tumour-specific serum peptidome patterns. J. Clin. Invest.2006,1:271-284
[111]Sven B, Uta C, Georg MF, Jan L, Alexander L, Joachim T. Standardized approach to proteome profiling of human serum based on magnetic bead separation and Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry. Clin. Chem. 2005,(6) 973-980
[112]Cheng AJ, Chen LC, Chien KY, Chen YJ, Chang JT, Wang HM, Liao CT, Chen IH. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin. Chem.2005,12:2236-2244.
[113]Goreliket E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, Bigbee WL, Herberman RB, Lokshin AE. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol.2005,6-18
[114]Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE, Mor G. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res.2008,14(4):1065-1072.
[115]Park IS, Lee YS, Kim JC, Hwang SG. Serum neopterin levels in ovarian tumors. Int J Gynaecol Obstet.1995,51(3),229-234.
[116]Saraswathi A, Malait T. Superiority of CA 125 over CA 19-9 and CES for epithelial ovarian malignancies. Indian J Clin Biochem. (1995,10,23-28.
[117]Mandic A, Nincic D, Vujkov T. Ovarian epithelial carcinoma--a malignant disease sparing no age group. Med Pregl.2003; 56(3-4),157-61.
[118]Argueso P, Spurr-Michaud S, Russo CL, and et al. MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope. Invest Ophthalmol Vis Sci.2003;44(6):2487-95.
[119]Bhan V, Amso N, Whitehead MI, Campbell S, and et al. Characteristics of persistent ovarian masses in asymptomatic women. Br J Obstet Gynaecol.1989; 96:1384-91
[120]Vladimir Nossov,AffiliationDepartment of Obstetrics and Gynecology, University of California, Los Angeles, Medical Center, Los Angeles, CA Malaika Amneus, Feng Su, and et alAffiliations Department of Obstetrics and Gynecology, University of California, Los Angeles, Medical Center, Los Angeles, CA. Affiliation Atherosclerosis Research Unit, Department of Medicine/Cardiology, University of California, Los Angeles. CADepartment of Molecular and Medical Pharmacology. University of California. Los Angeles. CA Farias Robin-Eisner The early detection of ovarian cancer:from traditional methods to proteomics. Can we really do better than serum CA-125? American Journal of Obstetrics & Gynecology 2008(199),3,215-223Affiliations
[121]Berchuck A, Elbendary A, Havrilesky L, Rodriguez GC, Bast RC, Jr. Pathogenesis of ovarian cancers. J Soc Gynecol Investig 1994;(1)181-190.
[122]Karst AM, Drapkin R. Ovarian cancer pathogenesis:a model in evolution. J Oncol. 2010;(93)23-71.
[123]Nossov V, Amneus M, Su F, Lang J, Janco JMT, Reddy ST, Farias-Eisner R. The early detection of ovarian cancer:from traditional methods to proteomics. Can we really do better than serum CA-125? 2008, Am J Obstet Gynecol 199(3):215-223.
[124]Badgwell D, Bast RC Jr. Early detection of ovarian cancer. Dis Markers.2007,23(5-6)397-410
[125]Jackson D, Craven RA, Hutson RC, Graze I, Lueth P, Tonge RP. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin. Cancer Res.2007, 24:7370-7379.
[126]Fields MM, Chevlen E. Ovarian cancer screening:a look at the evidence. Clin. J. Oncol. Nurs.2006, (1)77-81.
[127]Best Evidence Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med.2006; 354(1):34-43.
[128]Dong-Mei Fan, Hui-Rong Shi, Zhi-Min Chen, and et al. Early detection of ovarian carcinoma by proteome profiling based on magnetic bead separation and matrix-assisted laser desorption/ionization time of flight mass spectrometry. African Journal of Microbiology Research.2010, Vol.4(10),940-951
[129]Ries LAG, Melbert D, Krapcho M, and et al. SEER Cancer Statistics Review,1975-2004. National Cancer Institute Bethesda, MD based on November 2006 SEER data submission, posted to the SEER web site,2007.
[130]Buamah P (2000) Benign Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol 75:264-265.
[131]Miralles C, Orea M, Espana P, Provencio M, Sanchez A, et al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol,2003,10: 150-154，
[132]Oei AL, Massuger LF, Bulten J, and et al. Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Br J Cancer,2006,94:814-819.
[133]Greene MH, Piedmonte M, Alberts D, and et al A Prospective Study of Risk-Reducing Salpingo-oophorectomy and Longitudinal CA-125 Screening among Women at Increased Genetic Risk of Ovarian Cancer:Design and Baseline Characteristics:A Gynecologic Oncology Group Study. Cancer Epidemiol Biomarkers Prev,2008,17: 594-604
[134]Skates SJ, Menon U, MacDonald N, Rosenthal AN, and et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol,2003,21:206s-210s.
[135]Fung ET, Hogdall C, EEngelholm SA, and et al. Novel biomarkers to aid in the differential diagnosis of a pelvic mass. Santa, Monica, CA.2006 14-18
[136]Skates SJ, Horick N, Yu Y and et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125Ⅱ, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol.2004.22:4059-4066.
[137]Lee-Jones L. Ovarian tumours:an overview. Atlas Genet Cytogenet Oncol Haematol. 2003
[138]Bast, Jr., R.C., Xu, and et al.. CA125:the past and the future. Int. J. Biol. Markers,1998, 13(4):179-187
[139]Amer K. Karam & Beth Y. Karlan. Ovarian cancer:the duplicity of CA125 measurement. Nature Reviews Clinical Oncology 2010(7).335-339.
[140]Bertenshaw GP, Yip P, Seshaiah P, and et al. (2008) Multi-Analyte Profiling of Serum Antigens, Autoimmune and Infectious Disease Molecules to Identify Biomarkers Dysregulated in Epithelial Ovarian Cancer. Cancer Epidemiol Biomarkers Prev 17: 2872-2881
[141]The above story is reprinted (with editorial adaptations by Science Daily staff) from materials provided by. New Blood Test shows promise as screening tool for Early Detection of Ovarian Cancer. ScienceDaily University of Texas M. D. Anderson Cancer Center. Science News.2010,1
[142]New Hope for Early Detection of Ovarian Cancer with CA-125 Protein Monitoring Over Time Health & Medicine for Senior Citizens.2010,2
[143]Lan Jacobs, Ann Prys Davies, Jane Bridges, and et al Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography BMJ 1993(306) 17
[144]Smith CA, Sinclair AH. Sex determination:insights from the chicken. BioEssays 2004;26:120-32
[145]Fredrickson TN. Ovarian tumors of the hen. Environ Health Perspect 1987;73:35-51.
[146]Piek JMJ, van Diest PJ, Zweemer RP, et al:Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001.195:451-456,
[147]Joyner AB, Runowicz CD. Ovarian cancer screening and early detection. In Carole & Ray Neag Comprehensive Cancer Center, University of Connecticut Health Center, Obstetrics & Gynecology, Farmington, CT 05030, USA. Womens Health (Lond Engl). 2009;5(6):693-696.
[148]Yin, B. W. T.; Lloyd, K. O. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J. Biol. Chem.2001,276(29),2732.
[149]Argueso, P.; Spurr-Michaud, S.; Russo, and et al. MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope. Invest. Ophthal. Vis. Sci.2003,44(6)::2485-2493
[150]Moszynski R, Szpurek D, Michalak S, and et al. The role of endothelin-1 and its correlation with CA125 levels, grayscale ultrasonography and doppler findings in differential diagnoses of ovarian tumors. In Division of Gynecological Surgery, Department of Gynecology, Obstetrics and Gynecological Oncology, University of Medical Sciences, Poznan, Poland. Eur J Gynaecol Oncol.2009;30(5):552-553.
[151]Rinker-Schaeffer C. W., O'Keefe J. P., Welch D. R., and et al. Theodorescu, Metastasis suppressor proteins:discovery, molecular mechanisms, and clinical application. Clinical Cancer Research,2006,(12)13,3882-3889.
[152]Julang Li, Qiang Feng, Jong-Min Kim, and et al. Human Ovarian Cancer and Cisplatin Resistance:Possible Role of Inhibitor of Apoptosis Proteins. Endocrinology.2001, 142(1),370
[153]Jinsong Liu, Gong Yang,l Jennifer A and et al. A Genetically Defined Model for Human Ovarian Cancer. CANCER RESEARCH,2004 64,1655.
[154]William G. Kaelin Jr The von Hippel-Lindau tumour suppressor protein:02 sensing and cancer Nature Reviews Cancer 2008,8,865-873
[155]Ingegerd Hellstro"m, John Raycraft, Martha Hayden-Ledbetter, Jeffrey A. Ledbetter, Miche, Schummer, Martin McIntosh, Charles Drescher, Nicole Urban, and Karl Erik Hellstro m
[156]I. H., J. R., M. H-L., and et al. Pacific Northwest Research Institute, Institute for Systems Biology[M. S.], Fred Hutchinson Cancer Research Center[M. M., C. D., N. U.]. and Swedish Hospital and Medical Center[C. D.], The HE4 (WFDC2) Protein Is a Biomarker for Ovarian Carcinoma. CANCER RESEARCH 2003,63,3695-3700
[157]Berek, J. S., Bast, R. C, and et al. Ovarian cancer screening The use of serial complementary tumor markers to improve sensitivity and specificity for early detection.Cancer,1995,76:2092-2089.
[158]Maggino, T., Gadducci, A., D'Addario, and et al. Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol. Oncol.,1994,54:117-119,
[159]Chang, K., Pai, L. H., Batra, J. K., and et al. Characterization of the antigen (CAK1) recognized by monoclonal antibody Kl present on ovarian cancers and normal mesothelium. Cancer Res.,1992,52:181-178.
[160]Scholler, N., Fu, N., Yang, and et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc. Natl. Acad. Sci. USA,1999,96:11531-11526,.
[161]Schummer, M., Ng, W., Bumgarner, R., and et al. Comparative hybridization of an array of 21500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene,1999,238:375-381.
[162]Ono, K., Tanaka, T., Tsunoda, T., and et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis Cancer Res.,2000,60:5007-5009.
[163]Welsh, J. B., Zarrinkar, P. P., Sapinoso, and et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Natl. Acad. Sci. USA,2001,98:1176-1178,
[164]Kirchhoff, C., Habben, I., Ivell, R., and et al. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol. Reprod.,1991,45:350-348.
[165]Kirchhoff, C. Molecular characterization of epididymal proteins. Rev. Reprod.,1998,3: 86-95.
[166]Dandekar, A. M., Robinson, E. A., Appellla, E., and et al. Complete sequence analysis of cDNA clones encoding rat whey phosphoprotein:homology to a protease inhibitor. Proc. Natl. Acad. Sci. USA,1982,79:3987-3989.
[167]Heinzel, R., Appelhans, H., Gassen, G., and et al. Molecular cloning and expression of cDNA for human antileukoprotease from cervix uterus. Eur. J. Biochem.,1986,160: 63-65.
[168]Wiedow, O., Schroder, J. M., Gregory, H., and et al. An elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J. Biol. Chem.,1990,265:14791-14792.
[169]Bingle, L., Singleton, V., and Bingle, C. D. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene,2002,21:2768-2773.
[170]Hayden, M. S., Gilliland, L. K., and Ledbetter, J. A. Antibody engineering. Curr. Opin. Immunol.,1997,9:201-212.
[171]Davidson NG, Khanna S, Kirwan PH, Bircumshaw D:Prechemotherapy serum CA125 level as a predictor of survival outcome in epithelial carcinoma of the ovary. Clin Oncol (R Coll Radiol) 1991,3:32-26.
[172]Rustin GJ, Gennings JN, Nelstrop AE, and et al. Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group. J Clin Oncol 1989, 7:1667-1667.
[173]Burger RA, Darcy KM, DiSaia PJ, and et al. Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy:a gynecologic oncology group study. Cancer 2004 101:106-109.
[174]Kim HS, Park NH, Chung HH, and et al. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer. Onkologie 2008,31:315-312.
[175]Juretzka MM, Barakat RR, Chi DS. and et al. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol 2007,104:176-178. [176]Riedinger JM, Bonnetain F, Basuyau JP, and et al. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. Ann Oncol 2007,18:881-875.
[177]Badulescu F, Badulescu A, Schenker M, Popescu CF, Stoica Z:The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma. Rom J Morphol Embryol 2005 46:329-328.
[178]Fisken J, Leonard RC, Stewart M, Beattie GJ, Sturgeon C, Aspinall L, Roulston JE:The prognostic value of early CA125 serum assay in epithelial ovarian carcinoma. Br J Cancer 1993,68:140-135.
[179]Redman CW, Blackledge GR, Kelly K, Powell J, Buxton EJ, Luesley DM:Early serum CA125 response and outcome in epithelial ovarian cancer. Eur J Cancer 1990,26:593- 586
[180]Colakovic S, Lukic V, Mitrovic L, Jelic S, Susnjar S, Marinkovic J:Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer. Int J Biol Markers 2000, 15:147-149.
[181]Yedema CA, Kenemans P, Voorhorst F, Bon G, Schijf C, Beex L, Verstraeten A, Hilgers J, Vermorken J:CA 125 half-life in ovarian cancer:a multivariate survival analysis. Br J Cancer 1993,67:1361-1357.
[182]Osman N, O'Leary N, Mulcahy E, Barrett N, Wallis F, Hickey K, Gupta R:Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre. Ir Med J 2008,101:245-237.
[183]Van Dalen A, Favier J, Burges A, and et al. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol 2000, 79:444-445.
[184]Cooper BC, Sood AK, Davis CS, and et al. Preoperative CA 125 levels:an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol 2002,100:59-54.
[185]Buller RE, Vasilev S, DiSaia PJ:CA 125 kinetics:a cost-effective clinical tool to evaluate clinical trial outcomes in the 1990. Am J Obstet Gynecol 1996,174:1241-1243.
[186]Nagele F, Petru E, Medl M, and et al. Preoperative CA 125:an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1995,86:259-264.
[187]Makar AP, Kristensen GB, Kaern J, and et al. Prognostic value of pre-and postoperative serum CA 125 levels in ovarian cancer:new aspects and multivariate analysis. Obstet Gynecol 1992,79:1002-1008.
[188]Sevelda P, Schemper M, Spona J:CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1989, 161:1213-1206.
[189]Moebus V:KRCGWHCHKH:Evaluation of CA125 as a prognostic and predictive factor in ovarian cancer. J Tumor Marker Oncol 1988,3:251-248.
[189]Cruickshank DJ, Fullerton WT, Klopper A:The clinical significance of pre-operative serum CA 125 in ovarian cancer. Br J Obstet Gynaecol 1987,94:692-685
[190]Hunter VJ, Daly L, Helms M, and et al. The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol 1990,163:1164-1157.
[191]Hawkins RE, Roberts K, Wiltshaw E, Mundy J, Fryatt IJ, McCready VR:The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol 1989,96:1395-1389.
[192]Gard GB, Houghton CR:An assessment of the value of serum CA 125 measurements in the management of epithelial ovarian carcinoma. Gynecol Oncol 1994,53:283-259.
[193]Frasci G, Conforti S, Zullo F, and et al. A risk model for ovarian carcinoma patients using CA 125:time to normalization renders second-look laparotomy redundant. Cancer 1996,77:1122-1120.
[194]Mano A, Falcao A, Godinho I, Santos J, Leitao F, de Oliveira C, Caramona M:CA-125 AUC as a predictor for epithelial ovarian cancer relapse. Cancer Biomark 2008,4:73-78.
[195]Mano A, Falcao A, Godinho I, and et al. CA-125 AUC as a new prognostic factor for patients with ovarian cancer. Gynecol Oncol 2005,97:529-524.
[196]Riman T, Persson I, Nilsson S:Hormonal aspects of epithelial ovarian cancer:review of epidemiological evidence. Clin Endocrinol (Oxf) 1998,49:695-702.
[197]Hermsen BBJ, von Mensdorff-Pouilly S, Berkhof J, et al:Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk ovarian cancer. J Clin Oncol 2007,25,1386
[198]Olsen CM, Green AC, Nagle CM, et al.; Australian Cancer Study Group (Ovarian Cancer) and the Australian Ovarian Cancer Study Group. Epithelial ovarian cancer: testing the'androgens hypothesis'. Endocr Relat Cancer.2008;15:1061-1060.
[199]Bidart JM, Thuillier F, Augereau C, Chalas J, Daver A, Jacob N, Labrousse F, Voitot H: Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 1999,45:1695-1701.
[200]Tamakoshi K, Kikkawa F, Hasegawa N, and et al. Clinical value of a new serum tumor marker, CA125II, in gynecologic disease:comparison with CA125. Gynecol Obstet Invest.1995; 39(2),125-129.
[201]Bets Davis, Ovarian cancer. Obstetrics and Gynecology,2009.
[202]Christine Wendt. Protein Diabetes Educator,2009
[203]U.S. Preventive Services Task Force. Screening for ovarian cancer,2004,6.
[204]Finegan J, Bartleman B, Wong PY:A window for the study of prenatal sex hormone influences on postnatal development. J Genet Psychol 1988; 150:101-112
[205]Rubinow DR, Schmidt PJ:Androgens, brain, and behavior. Am J Psychiatry 1996; 153:974-984
[206]Caswell H, Weeks DE:Two-sex models:chaos, extinction, and other dynamic consequences of sex. American Naturalist 1986; 128:707-735
[207]Bachman DL, Wolf PA, Linn R, and et al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology 1992; 42:115-119
[208]Finegan J, Bartleman B, Wong PY:A window for the study of prenatal sex hormone influences on postnatal development. J Genet Psychol 1988; 150:101-112
[209]Rubinow DR, Schmidt PJ:Androgens, brain, and behavior. Am J Psychiatry 1996; 153:974-984
[210]Caswell H, Weeks DE:Two-sex models:chaos, extinction, and other dynamic consequences of sex. American Naturalist 1986; 128:707-735
[211]Bachman DL, Wolf PA, Linn R, and et al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology 1992; 42:115-119
[212]Bachman DL, Wolf PA, Linn RT, and et al. Incidence of dementia and probable Alzheimer's disease in a general population:the Framingham Study. Neurology 1993; 43:515-519
[213]Canadian Study of Health and Aging Working Group:Canadian study of health and aging:study methods and prevalence of dementia. Can Med Assoc J 1994; 150:899-8913
[214]Tang MX, Jacobs D, Stern Y, and et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348:429-432
[215]Henderson VW, Buckwalter JG:Cognitive deficits of men and women with Alzheimer's disease. Neurology 1994; 44:90-96
[216]Hafner H, an der Heiden W:Epidemiology of schizophrenia. Can J Psychiatry 1997; 42:139-151
[217]Lewine RJR, Seeman MV. Gender, brain, and schizophrenia:anatomy of differences/differences of anatomy, in Gender and Psychopathology. Edited by Seeman MV. Washington, DC, American Psychiatric Press,1995
[218]Jablensky A, Cole SW:Is the earlier age at onset of schizophrenia in males a confounded finding? Br J Psychiatry 1997; 170:234-240
[219]Ciompi L The influence of aging on schizophrenia. Triangle 1993; 32:25-31
[220]Wong DF, Wagner HN Jr, Dannals RF and et al. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 1984; 226:1393-1396
[221]Seeman MV:Sex differences in predicting neuroleptic response, in The Prediction of Neuroleptic Response. Edited by Gaebel W, Awad AG. Vienna, Springer-Verlag,1995, pp 51-64
[222]Blum M, McEwen BS, Roberts JL:Transcriptional analysis of tyrosine hydroxylase gene expression in the tuberoinfundibular dopaminergic neurons of the rat arcuate nucleus after estrogen treatment. J Biol Chem 1987; 262:817-821
[223]DiPaolo T:Modulation of brain dopamine transmission by sex steroids. Rev Neurosci 1994; 5:27-42
[224]Toran-Allerand CD:The estrogen/neurotrophin connection during neural development: is co-localization of estrogen receptors with the neurotrophins and their receptors biologically relevant? Dev Neurosci 1996; 18:36-41
[225]Seeman MV, Lang M:The role of estrogens in schizophrenia gender differences. Schizophr Bull 1990; 16:185-194
[226]Bast RC Jr. Klug TL, St John E, and et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983 309:883-882.
[227]Nustad K, Bast RC Jr. Brien TJ, and et al. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen:first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumour Biol 1996,17:196-212.
[228]Markman M:Optimizing primary chemotherapy in ovarian cancer. Hematol Oncol Clin North Am 2003.17:957-958.
[229]Kenemans P. van Kamp GJ, Oehr P, Verstraeten RA:Heterologous double-determinant immunoradiometric assay CA 125 II:reliable second-generation immunoassay for determining CA 125 in serum. Clin Chem 1993,39:2509-2510.
[230]Hogdall EV, Christensen L, Kjaer SK, and et al. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. Gynecol Oncol 2007,104:508-509.
[231]Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE:Defining progression of ovarian carcinoma during follow-up according to CA 125:a North Thames Ovary Group Study. Ann Oncol 1996,7:361-344.
[232]Rustin GJ, Marples M, Nelstrop AE, Mahmoudi M, Meyer T:Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 2001,19:4054-4027.
[233]Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB:CA 125:the past and the future. Int J Biol Markers 1998,13:179-187.
[234]Menon U, Jacobs IJ:Ovarian cancer screening in the general population. Curr Opin Obstet Gynecol 2001,13:61-60.
[235]Verheijen RH, Mensdorff-Pouilly S, van Kamp GJ, Kenemans P:CA 125:fundamental and clinical aspects. Semin Cancer Biol 1999,9:117-114.
[236]Yin BW, Lloyd KO:Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001,276:27371-27370.
[237]Skates SJ, Menon U, MacDonald N, Rosenthal AN, Oram DH, Knapp RC, Jacobs IJ: Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003,21:206-205.
[238]Rustin GJ, Bast RC Jr, Kelloff GJ, and et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 2004,10:3919-3916.
[239]Gronlund B, Dehn H, Hogdall CK, and et al. Cancer-associated serum antigen level:a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma. Int J Gynecol Cancer 2005,15:836-833.
[240]Kang WD, Choi HS, Kim SM. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer. In Department of Obstetrics and Gynecology, Chonnam National University Medical School,8 Hakdong, Dong-gu, Gwangju, Republic of Korea. Gynecol Oncol.2010 Jan;116(1):57-55.
[241]Zurawski VR Jr, et al. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia:relevance for early detection of ovarian cancer. Int J Cancer 1988; (42)677-648.
[242]Agustin A Garcia, Samina Ahmed. Ovarian Cancer. Contributor Information and Disclosures.2010
[243]Kojima. T., Oh-eda, M., Hattori, and et al. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J. Biol. Chem.,1995,270:21984-21987.
[244]Chang, K.; Pastan, I.:Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Nat. Acad. Sci.93,1996, 138.
[245]Scholler, N.; Fu, N.; Yang, Y.; and et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from
[246]Bera, T. K.; Pastan, I. Mesothelin is not required for normal mouse development or reproduction. Molec. Cell. Biol.2000,20,2905.
[247]Campbell, I. G.; Nicolai, H. M.; Foulkes, W. D.; and et al. A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1. Hum. Molec. Genet.3:1994,589-579.
[248]Lange, S.; Xiang, F.; Yakovenko, A.; and et al. The kinase domain of titin controls muscle gene expression and protein turnover. Science,2005,308,1599-1601.
[249]Brown, M. A.; Nicolai, H.; Xu, C.-F.; and et al. Regulation of BRCA1. (Letter) Nature 1994,372,730.
[250]Brown, M. A.; Xu, C.-F.; et al. The 5-prime end of the BRCA1 gene lies within a duplicated region of human chromosome 17q21. Oncogene 1996,12,2511.
[251]Santillan A, Garg R, Zahurak ML, et al Risk of epithelial ovarian cancerrecurrence in patients with rising serum CA125 levels within the normal range.J Clin Oncol 2005, 23:9338-9339
[252]Friedman LC, Kramer RM:Reproductive issues for women with BRCA mutations. J Natl Cancer Inst Monogr 2005,34,85
[253]Ransohoff DF:Lessons from controversy:Ovarian cancer screening and serum proteomics. J Natl Cancer Inst 2005,97:315-317
[254]Hermsen BBJ, van Diest PJ, Berkhof J, et al:Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and fallopian tube in women at hereditary high risk of breast and ovarian cancer. Int J Cancer.2006 119:1412-1409
[255]Kirtly Jones, Female reproductive system. Obstetrics and Gynecology Medicine.2008
[256]Maria Essig. DNA (deoxyribonucleic acid). Reproductive Genetics,2009
[257]Sandy Jocoy, A pelvic exam Obstetrics and Gynecology.2009
[258]Monica Rhodes. Biopsy Medical Toxicology.2009
[259]Ovarian cancer. NCCN Practice Guidelines in Oncology, National Comprehensive Cancer Network.2009.
[260]Sendahl M, Ernst E, Rasmussen PE, Yding Andersen C.2008.
[261]Fertil. Steril. True ovarian volume is underestimated by two-dimensional transvaginal ultrasound measurement.2008
[262]Steven Vasilev, M.D., Ovarian Cancer Stage & Grade:Two Critical Factors. Health's Disease and Condition content.2008.
[263]Berchuck A, Elbendary A, Havrilesky L, and et al. Pathogenesis of ovarian cancers. J Soc Gynecol Investig 1994;(1)181-190.
[264]Karst AM, Drapkin R. Ovarian cancer pathogenesis:a model in evolution. J Oncol. 2010;(93)23-71.
[265]Markman M, Liu PY, Rothenberg ML et al. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer J Clin Oncol 2006; 24:1454-1458
[266]Liu P-Y, Alberts DS, Monk BJ et al An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy J Clin Oncol 2007; 25:3615-3620
[267]Medeiros LR, Rosa DD, DA Rosa MI. Accuracy of Ca 125 in the diagnosis of ovarian tumors:a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol,2009; 142:99-105.
[268]Comparison of CA-125 and Standard Definitions of Progression of Ovarian Cancer in the Intergroup Trial of Cisplatin and Paclitaxel Versus Cisplatin and Cyclophosphamide JCO (2006) 24(1):45-51
[269]Coates RRJ, Kolor K, Stewart SL, and et al. Diagnostic markers for ovarian cancer screening:not ready for routine clinical use. Clin Cancer Res,2008; 14,7575-7576
[270]Pauler DK, Menon U, McIntosh M, et al:Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev 10:489-493,2001
[271]Lo Curto M, D'Angelo P, Cecchetto G, and et al. Mature and immature teratomas: results of the first paediatric Italian study. Pediatric Surgery International.2007,23 (4): 315-322
[272]Ries LAG, Melbert D, Krapcho M, and et al. SEER cancer statistics review 1975-2005 Institute. NC, Bethesda. MD.2006,3-20
[273]Hess LM, Benham-Hutchins M, Herzog TJ, and et al. A meta-analysis of the efficacy of intrapexitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer.2007;17(3):561-570.
[274]Elit L, Oliver TK, Covens A, and et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer:a systematic review with metaanalyses. Cancer.2007;109(4):692-702
[275]Goff BA, Mandel LS, Melancon CH, and et al Frequency of symptoms of ovarian cancer. Primary care clinics. JAMA.2004;291(22):2705-2712.
[276]Riedinger JM, Wafflart J, Ricolleau G et al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome:results of a French multicentric study. Ann Oncol 2006; 17:1234-1238.
[277]Vladimir Nossov, AffiliationDepartment of Obstetrics and Gynecology, University of California, Los Angeles, Medical Center, Los Angeles, CA Malaika Amneus, and et al. The early detection of ovarian cancer:from traditional methods to proteomics. Can we really do better than serum CA-125? American Journal of Obstetrics & Gynecology 2008(199),3,215-223 Affiliations
[278]Amer K. Karam & Beth Y. Karlan. Ovarian cancer:the duplicity of CA125 measurement. Nature Reviews Clinical Oncology,2010,7,335-339
[279]Louis Dubeau MD The cell of origin of ovarian epithelial tumors. The Lancet Oncology. 2008, (9)12,1191-1197
[280]Victorian, Brande. Questioning the Role of CA125 as a Biomarker in Ovarian Cancer. Oncology Times,2010, (32)24,9-10
[281]Jankovic M.M, Milutinovic. B S. Pregnancy-associated CA125 antigen associated CA125 antigen as mucin:evaluation of ferning morphology. Mol Hum Reprod,2007 (13)405-408
[282]McLemore MR, Aouizerat B. Introducing the MUC16 gene:implications for prevention and early detection in epithelial ovarian cancer. Biol Res Nurs.2005 6(4):262-7.
[283]Monica R. McLemore, Bradley Aouizerat. Introducing the MUC16 Gene:Implications for Prevention and Early Detection in Epithelial Ovarian Cancer. Biol Res Nurs April 2005,(6)4,262-267
[284]Jankovic M.M, Milutinovic. B S.Pregnancy-associated CA125 antigen associated CA125 antigen as mucin:evaluation of ferning morphology. Mol Hum Reprod,2007, (13)405-408
[285]McGuire WP. CA-125 and Early Ovarian Cancer. J Natl Cancer Inst,2005,95,105-112
[286]Richard R. Barakat, Maurie Markman, Marcus E. Randall. Principles and Practice of Gynecologic Oncology.-2009-Medical-1072
[287]James L. Wilder, Edward Pavlik, John M. Straughn and et al. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecologic Oncology,2003, (89) 2,233-235
[288]Victorian, Brande. Questioning the Role of CA125 as a Biomarker in Ovarian Cancer. Oncology Times,2010, (32)24,9-10
[289]Louis Dubeau MD The cell of origin of ovarian epithelial tumors. The Lancet Oncology. 2008, (9)12,1191-1197
[290]Tiss, Ali, Timms, John F and et al. Highly Accurate Detection of Ovarian Cancer Using CA125 but Limited Improvement With Serum Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Profiling. International Journal of Gynecological Cancer:2010, (20) 9,1518-1524
[291]Merrill Goozner. Personalizing Ovarian Cancer Screening. JNCI J Natl Cancer Inst (2010) doi:10.1093/jnci/djq296
[292]Digant Gupta, Christopher G Lis. Role of CA125 in predicting ovarian cancer survival-a review of the epidemiological literature. Journal of Ovarian Research 2009, (2),13,1757-2215
[293]Menon, U., Gentry-Maharaj, A., Ryan, and et al. Recruitment to multicentre trials lessons from UKCTOCS:descriptive study. BMJ.2008,337,2079-2079
[294]Fang CY, Cherry C, Devarajnk. A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynaecologic screening for ovarian cancer. Gynecol Oncol,2009; 112:594-600.
[295]Jacobs I, Bast RC Jr:The CA 125 tumour-associated antigen:a review of the literature. Hum Reprod 1989,4(1):1-12.
[296]Kurman R. Malignant germ cell ovarian cancer. Hum Pathol.1997,8.5; 551-564
[297]Odicino F, Pecorelli S. Zigliani L & Creasman WT. History of the FIGO cancer staging system. International Journal of Gynecology and Obstetrics.2008;(101)205-210.
[298]Pecorelli S, Ngan HY & Hacker NF (eds). Staging classification and clinical practice guidelines for gynaecological cancers. International Journal of Gynecology & Obstetrics.2000,10(2),207-312.
[299]Survival rates for ovarian cancer in Early Detection, Diagnosis, and Staging. ACS Cancer Facts & Figures,2007
[300]Rio de Janeiro. Survival rates for ovarian cancer in Familial aggregation of breast/ovarian cancer:age of onset along subsequent generations in Brazil. Cadernos de Saude Publica.14(3),1998
[301]Abenhaim, H. A., Titus-Ernstoff, L., Cramer, D. W. Ovarian cancer risk in relation to medical visits, pelvic examinations and type of health care provider. CMAJ.2007,176: 941-947
[302]National Cancer Institute. Anatomy:the cervix and nearby organs, NCI visuals online. Bethesda, MD:National Institutes of Health, United States Department of Health and Human Services.2009,1-2
[303]Mor QVisintin I, Lai Y, et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci US A.2005; 102,7677-768236.
[304]Ovarian Cancer, CA-125 Addiction, and Informed Confusion:Much Ado About Less JCO (2007) 25(24):3570-3571
[305]Agarwal R, Alvero A, Visintin I, et al. Macrophage migration inhibitory factor expression in ovarian cancer. Am J Obstet Gynecol 2007; 196,348,1-537
[306]Kruskal WH, Wallis WA. Use of ranks in one-criterion variance analysis. J Am Stat Assoc.1952,47:583-621
[307]Kindelberger DW, Lee Y, Miron A, and et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma:Evidence for a causal relationship. Am J Surg Pathol. 2007,31:161-169
[308]Huhtinen K, Suvitie P, Hiissa J, and et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. In.Br J Cancer.2009,100(8):1315-1319.
[309]Tanaka YO, Okada S, Yagi T, and et al. MRI of endometriotic cysts in association with ovarian carcinoma. AJR Am J Roentgenol.2010;194(2):355-361
[310]Kane Gueye SM, in retrospective analysis of 93 cases of 018. ML.SD. L 5115 Ovarian tumors in Julio Curie Institute in Dakar (Senegal) results and therapeutic implications. Medicine in Africa. Black.2003 50 (12):556-560
[311]Paw C a Paw. C and neck malignant germinal tumors of the ovary in girls and adolescent:about 82 cases treated in protocols of the French society of pediatric oncology. Ann. Pediatr.1998,(45) 4.210-217
[312]Bast RC Jr, Badgwell D, Lu Z, and et al. New tumor markers:CA125 and beyond. Int J Gynecol Cancer 2005,15(Suppl 3):274-81
[313]Arioz DT, Tokyol C, Sahin FK, et al. Squamous cell carcinoma arising in a mature cystic teratoma of the ovary in young patient with elevated carbohydrate antigen 19-9. Eur. J. Gynaecol. Oncol.2008,29 (3):282-284.
[314]Muscatello L, Giudice M, Feltri M (2005). "Malignant cervical teratoma:report of a case in a newborn". European archives of oto-rhino-laryngology:official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS):affiliated with the German Society for Oto-Rhino-Laryngology-Head and Neck Surgery 262 (11): 899-904
[315]Arlikar JD, Mane SB, Dhende NP, and et al. Fetus in fetus:two case reports and review of literature. Pediatric Surgery International.2009,25 (3):289-292.
[316]Ukiyama E, Endo M, Yoshida F, and et al., Hata Recurrent yolk sac tumor following resection of a neonatal immature gastric teratoma. Pediatr. Surg. J,2005. Int.21 (7): 585-8.
[317]Tumor in baby's brain contained tiny foot.2008,1.
[318]Talmadge (Ted) Cooper. Orbital dermoid cyst at eMedicine.2010,1-5.
[319]Heintz APM, Odicino F, Maisonneuve P, and et al. Carcinoma of the ovary. International Journal of Gynecology & Obstetrics 2006,95(0):161-192.
[320]National Breast and Ovarian Cancer Centre (NBOCC). Population screening and early detection of ovarian cancer in asymptomatic women:NBOCC position statement. Surry Hills, NSW:NBOCC.2009
[321]Malkasian GD Jr, Knapp RC, Lavin PTand et al. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988, 159(2):341-346.
[322]Dixia Chen DX, Schwartz PE, Li XG, Yang Z:Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol 1988,72(1):23-27.
[323]Nolen B, et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol in press.[321]Skates SJ, Singer DE. Quantifying the potential benefit of CA 125 screening for ovarian cancer. J Clin Epidemiol.1991;44(4-5):365.
[324]Ruibal A, Encabo G, Martinez-Miralles E, and et al. CA 125 seric levels in non malignant pathologies. Bull Cancer 1984,71(2):145-146.
[325]Einthorn. N, MD, R. C. and et al. Prospective evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer.1986.67(3),414-416
[326]Stenman UH, Seppala M:Ovarian cancer antigen CA 125 levels in pelvic inflammaroy disease and pregnancy. Cancer 1986,57(7):1327-1329.
[327]Irene Visintin, Ziding Feng, Gary Longton,and et al. Diagnostic Markers for Detection of Ovarian Cancer 2007 Clin Cancer Res.2008; 14(4),1065
[328]Paavonen J, Miettinen A, Heinonen PK, and et al. Serum CA 125 in (?) inflammatory disease Br J Obstet Gynaecol 1989,96(5):574-579
[329]Saito K, Katsumata Y, Hirabuki T, and et al. Fetus-in-fetus:parasite or (?) study of two cases. Fetal. Diagn. Ther.2007,22 (5):383-388. [330]Chua JH, Chui CH, Sai Prasad TR, Jabcobsen AS. Meenakshi A. Hwang W5.(?) in-fetu in the pelvis:report of a case and literature review. Ann. Acad. Med. Singap. 2005,34 (10):646-649
[331]Kajbafzadeh AM, Baharnoori M. Fetus in fetu. Teratoma also occurs, rarely, in non-human animals.Can J Urol.2006,13 (5):3277-8.
[332]Harms D, Zahn S, Gobel U, and et al. Pathology and molecular biology of teratomas in childhood and adolescence. Klinische Padiatrie.2006,218 (6):296-302.
[333]Utsuki S, Oka H, Sagiuchi T, and et al.Malignant transformation of intracranial mature teratoma to yolk sac tumor after late relapse. Case report. J. Neurosurg.2007,106 (6): 1067-1069.
[334]Chen YH. Chang CH, Chen KC, and et al. Malignant transformation of a well-organized sacrococcygeal fetiform teratoma in a newborn male. J. Formos. Med. Assoc.2007.106 (5):400-402
[335]Biskup W, Calaminus G, Schneider DT, and et al. Teratoma with malignant transformation:experiences of the cooperative GPOH protocols MAKEI.2006,1.
[336]Diallo Ramatoulaye and associated and ovarian teratoma:Etude anatomo-clinical pathology department of the National Hospital Donka. Thesis of doctorate in medicine. 2008,1108,41-43.
[337]Chechia Abdellatif[2002]and et al, Struma ovarii, about a case a smart and Benin:Tunis Med.2002, (80) 1,53-56.
[338]Kocaoglu M, Frush DP (2006). Pediatric presacral masses Radiographics 26 (3):833-857.
[339]Lefebvre R, Theoret C, Dore M, and et al. Ovarian teratoma and endometritis in a mare Can. Vet. J.2005,46 (11):1029-1033.
[340]Chan JK, Urban R, Cheung MK, and et al. Ovarian cancer in younger vs older women: a population-based analysis. British Journal of Cancer 2006, (95)1314-1320.
[341]Maas HAAM, Kruitwagen RFPM, Lemmens VEPP, and et al. The influence of age and co-morbidity on treatment and prognosis of ovarian cancer:a population-based study. Gynecologic Oncology 2005,97:104-109.
[342]McMurdo ME, Witham MD & Gillespie ND. Including older people in clinical research. British Medical Journal.2005, (331)1036-1037.
[343]Petignat P, Fioretta G, Verkooijen HM, and et al.2004. Poorer survival of elderly patients with ovarian cancer:a population-based study. Surgical Oncology 2004, (13)181-186.
[344]South Australia Cancer Registry. Epidemiology of cancer in South Australia. Incidence, mortality and survival 1977 to 1999. Incidence and mortality 1999 analysed by type and geographical location. Twenty-three years of data. Adelaide:South Australia Cancer Registry, Epidemiology Branch, Statewide Division, Department of Human Services.2000,2-4
[345]Uyar D, Frasure HE, Markman M and et al. Treatment patterns by decade of life in elderly women (≥ 70 years of age) with ovarian cancer. Gynecologic Oncology.2005, (98),403-408.
[346]Iyer VR, Lee SI, MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization. AJR Am J Roentgenol.2010; 194(2):311-21
[347]Clare Turnbull, Elizabeth A Rapley, Sheila Seal, and et al. Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer. Nature Genetics.2010,42, 604-607
[348]Cancer Research[http://info.cancerresearchuk.org]. United Kingdom(2005)
[349]DeVita VTHS, Rosenberg SA:Principles and Practice of Oncology.1982 edition. Edited by:KR Perez CA. Young RC. Philadelphia:JB Lippioncott; 1982.
[350]Westhoff C:Ovarian cancer. Annu Rev Public Health 1996,17:85-96.
[351]Culton LK, Deavers MT, Silva EG, and et al. Endometrioid Carcinoma Simultaneously Involving the Uterus and the Fallopian Tube:A Clinicopathologic Study of 13 Cases. Uterine Carcinoma. Am J Surg Pathol.2006,30(7):844-849.
[352]Incidence of ovarian cancer, Incidence in 2006. In An overview. Ovarian cancer, Australia. Australian Institute of Health and Welfare and National Breast and Ovarian Cancer Centre, Australian Institute of Health and Welfare Canberra 2010,48,136
[353]An overview. In Ovarian cancer, Australia. Australian Institute of Health and Welfare and National Breast and Ovarian Cancer Centre, Australian Institute of Health and Welfare Canberra 2010,48,5
[354]AIHW & CA. Cancer Australia. Non-melanoma skin cancer: general practiceconsultations, hospitalisation and mortality. Cancer series. Canberra: AIHW.2008, (43), Cat. (39).
[355]Incidence in 2006 in Introduction Ovarian cancer, Australia. Australian Institute of Health and Welfare and National Breast and Ovarian Cancer Centre, Australian Institute of Health and Welfare Canberra 2010,48,1-65
[356]Ahmedin Jemal, Rebecca Siegel, Elizabeth Ward, Yongping Hao, Jiaquan Xu and Michael J. Thun. Cancer Statistics,2009. CA Cancer J Clin 2009;59;225
[357]Tracey EA, Roder D, Francis J, Zorbas HM, Hacker NF & Bishop J. Reasons for improved survival from ovarian cancer in New South Wales, Australia, between 1980 and 2003:implication for cancer control. International Journal of Gynecological Cancer 2009,19(4),591-599.
[358]Morris CR, Rodriquez AO, Epstein J & Cress RD. Declining trends of epithelial ovarian cancer in California. Gynecologic Oncology 2008, (108),207-213.
[359]FDH (Florida Department of Health). Ovarian cancer in Florida. Tallahassee:Bureau of Epidemiology.2009,1.
[360]Kjaerbye-Thygesen A, Huusom LD, Frederiksen K & Kjaer SK. Trends in the incidence and mortality of ovarian cancer in Denmark 1978-2002:comparison with other Nordic countries. Acta Obstetricia et Gynecologica Scandinavica 2005, (84),1006-1012
[361]Grossi M. Quinn MA. Thursfield VJ. Francis PA, Rome RM, Planner RS et al. Ovarian cancer:patterns of care in Victoria during 1993-1995. Medical Journal of Australia. 2002,177(1),11-16.
[361]Kosary CL. Cancer of the ovary. In:Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD & Horner MJ (eds). SEER survival monograph:cancer survival among adults:US SEER Program,1998-2001, patient and tumour characteristics. NIH pub. Bethesda, MD:National Cancer Institute.2007,(07).6215.
[363]WHC (Women's Health Council) & NCRI (National Cancer Registry Ireland). Women and cancer in Ireland 1994-2001. Dublin:The Women's Health Council,2006,7
[364]Bast RC Jr, Feeney M, Lazarus H. Nadler LM, Colvin RB, Knapp RC:Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981,68(5):1331-1337.
[365]Bast RC Jr, Klug TL, St John E, and et al:A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983, 309(15):883-887.
[366]Alice Park. Ovarian Cancer Screening:Hope for Early Detection. Health & Science. 2010,1-9
[367]Dolson Laura. The Truth About CA 125 Have you seen the Infamous Email? Here's the Whole Story. CA125 Test Facts and Myth.2001,1,5
[368]Granberg S., Wikland M, Friberg L.-G. Tumor marker CA 125 level and ovarian volume at different cycle day periods and in postmenopause. International Journal of Gynecology & Obstetrics.,1990, (33)2,149-152
[369]Ferlay, J, Bray, F, Psiani, P,and et al. Cancer Incidence, Mortality and Prevalence Worldwide IARC Cancer Base. IARCH Press; 2004,5(2),3
[370]Duffy M.J., Bonfrer J.M, Kulpa J., and et al. CA125 in ovarian cancer:European Group on Tumor Markers guidelines for clinical use.2005,15(5),679-691
[371]Louis Dubeau MD The cell of origin of ovarian epithelial tumours. The Lancet Oncology.2008, (9)12,1191-1197
[372]Daniel G. Rosen, Lin Wang, J. Neeley Atkinson, and et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecologic Oncology, 2005(99),267-277
[373]Robert C Past. Early Detection of Ovarian Cancer:New Technologies in Pursuit of a Disease that is Neither Common nor Rare. Trans Am Clin Climatol Assoc. Transactions of the American Clinical and Climatological Association.2004; 115,115-233
[374]Jacobs I, Bast RC, Jr. L'antigene CA 125 associe a la tumeur:une revue de la litterature. Hum Reprod,1989,4,1-9
[375]McIntosh M.W., Drescher C., Karlan B., and et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma Gynecol Oncol 2004 October; 95(1):9-15
[376]Yang L, Klint A, Lambe M, Bellocco R, Riman T, Bergfeldt K et al. Predictors of ovarian cancer survival:a population-based prospective study in Sweden. International Journal of Cancer 2008,(123),672-679
[377]Stany MP, Maxwell GL, Rose GS. Clinical decision making using ovarian cancer risk assessment. AJR Am J Roentgenol. Feb 2010;194(2):337-42
[378]Fourati H. et al. Goitre ovarian aspects anatomo-clinical and therapeutic About 6 cases: Tunis. Med.1998, (76)3,42-45
[379]Aggarwal A, Lucco KL, Lacy J, and et al. Ovarian epithelial tumors of low malignant potential:a case series of 5 adolescent patients. J Pediatr Surg.2009; 44(10):2023.
[380]Kurman R[1997], malignant germ cell ovarian cancer. Hum Pathol.1997,8(5); 551-564
[381]Caroline Munzer, Florence Menegaux, Brigitte Lacour, and et al. Birth-related characteristics, congenital malformation, maternal reproductive history and neuroblastoma:the ESCALE study (SFCE) Int J Cancer.2008; 122(10):2315.
[382]Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N et al. (ed. SEER cancer statistics review,1975-2006. Bethesda, MD:National Cancer Institute. 2009,1-4
[383]Cancer Research UK 2006. Cancer Stats:ovarian cancer survival statistics. London: Cancer Research UK.2009.
[384]WCRF (World Cancer Research Fund) & AICR (American Institute for Cancer Research) Food, nutrition, physical activity and the prevention of cancer:a global perspective. Washington:AIRC.2007,2-4.
[385]Yin BW, Lloyd KO Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001,276:27371-27375
[386]O'Brien TJ, Beard JB, Underwood LJ, and et al. The CA 125 gene:an extracellular superstructure dominated by repeat sequences. Tumour Biol 2001,22:348-366.
[387]Burger RA, Darcy KM, DiSaia PJ, and et al. Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy:a gynecologic oncology group study. Cancer 2004, 101:106-115
[388]Tuxen MK, Soletormos G, Dombernowsky P:Serum tumour marker CA 125 in monitoring of ovarian cancer during firstline chemotherapy. Br J Cancer 2001, 84:1301-1307.
[389]Franco Odicino, Sergio Pecorelli, Lucia Zigliani,William T. Creasman. History of the FIGO cancer staging system. International Journal of Gynecology and Obstetrics (2008) 101,205-210
[390]Makar AP, Kristensen GB, Kaern J, Bormer OP, Abeler VM, Trope CG:Prognostic value of pre-and postoperative serum CA 125 levels in ovarian cancer:new aspects and multivariate analysis. Obstet Gynecol 1992,79:1002-1010
[391]Gadducci A, Zola P, Landoni F, and et al. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer:results of a multicentric Italian study. Gynecol Oncol 1995, 58:42-47.
[392]Burg ME van der, Lammes FB, van Putten WL, and et al. Ovarian cancer:the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecol Oncol 1988,30:307-312.
[393]Colakovic S, Lukic V, Mitrovic L, and et al. Prognostic alue of CA125 kinetics and half-life in advanced ovarian cancer. Int J Biol Markers 2000,15:147-152.
[394]Hunter VJ, Daly L, Helms M, and et al The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction Am J Obstet Gynecol 1990,163:1164-1167.
[394]Hawkins RE, Roberts K, Wiltshaw E, and et al The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol 1989,96:1395-1399.
[395]Mano A, Falcao A, Godinho I, Santos J, Leitao F, Oliveira C, Caramona M:CA-125 AUC as a new prognostic factor for patients with ovarian cancer. Gynecol Oncol 2005, 97:529-534.
[396]Van Dalen A, Favier J, Burges A, and et al Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol 2000, 79:441-448.
[397]Peters-Engl C, Obermair A, Heinzl H, and et al. CA 125 regression after two completed cycles of chemotherapy:lack of prediction for long-term survival in patients with advanced ovarian cancer. Br J Cancer 1999,81:662-666
[398]Badgwell D, Bast RC Jr. Early detection of ovarian cancer. Dis Markers.2007; 23(5-6):397.
[399]Das PM, Bast RC Jr. Early detection of ovarian cancer. Biomark Med.2008 Jun:2(3):291
[400]Zhen Zhang, Robert C. Bast Jr., Yinhua Yu, and et al. Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer. Cancer Res.2004.64; 5882-5890
[401]Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer Mol Cell Proteomics 2004; 3,355-366.
[402]Yu B, Xu PZ, Wang QW, and et al. Clinical value of tumour specific growth factor (TSGF) and carbohydrate antigen-125 (CA-125) in carcinoma of the endometrium. J Int Med Res.2009,37(3):878-883.
[403]Kolwijck E, Thomas CM, Bulten J,and et al. Preoperative CA-125 levels in 123 patients with borderline ovarian tumors:a retrospective analysis and review of the literature. Int J Gynecol Cancer.2009; 19(8):1335-1336.
[404]Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, and et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer. 2005;15(5):679-689.
[405]Huhtinen K, Suvitie P, Hiissa J, and et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. In.Br J Cancer.2009 4(101),3
[406]Parera M, Adamo B, Peralta S, and et al. Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels. Ann Oncol.2009,20(2):294-297.
[407]Camlica H, Duranyildiz D, Tas F, Yasasever V. Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer. Am J Clin Oncol.2008, 31(6),585-588.
[408]Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem.2004,5; 279(10),9190-9198.
[409]Khan Y, Haq AN, Nasar R. Primary fallopian tube carcinoma presenting with a sinus in the posterior portion of cervix. Int J Gynecol Cancer.2004;14(1):166-168.
[410]Pardeshi SP, Kulkarni MM, Hishikar VA. Primary fallopian tube carcinoma. J Postgrad Med.1996; 42(2),59-61.
[411]Ovarian cancer. How is ovarian cancer staged? in Early Detection, Diagnosis, and Staging Topic. American Cancer Society.2010,20-27
[412]Asher et al., Pelvic mass associated with raised CA 125 for benign condition:a case report World Journal of Surgical Oncology 2010,8:28
[413]Ron IG, Inbar M, Gelernter I, and et al. Use of CA-125 response to predict survival parameters of patients with advanced ovarian carcinoma. Acta Obstet Gynecol Scand 1994,73:658-662.
[414]Cruickshank DJ. Fullerton WT, Klopper A. The clinical significance of pre-operative serum Cancer antigen 125 and prognosis. Curr Opin Obstet Gynecol 2008,20:4-6
[415]Kurman RJ, Visvanathan K, Roden R, and et al. Early detection and treatment of ovarian cancer:shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am. J. Obstet. Gynecol.2008,198(4):351-354.
[416]Goonewardene TI, Hall MR, Rustin GJS. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol 2007; 8: 813-821
[417]Ryerson AB, Eheman C, Burton J, et al. Symptoms, diagnoses, and time to key diagnostic procedures among older U.S. women with ovarian cancer. Obstet Gynecol. 2007 109(5):1053-1059.
[418]Bankhead CR, Kehoe ST, Austoker J. Symptoms associated with diagnosis of ovarian cancer:a systematic review. BJOG.2005,112 (7):857-65
[419]Hogdall E:Cancer antigen 125 and prognosis. Curr Opin Obstet Gynecol 2008,20,4-8.
[420]Gadducci A, Cosio S, Tana R, Genazzani AR:Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol 2009.69(1):12-27
[421]Liu J, Xu Y, Wang J:Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis of ovarian carcinoma. Eur J Radiol 2007,62(3):328-334
[422]Consesus Development Program. Ovarian Cancer:Screening, Treatment, and Followup. National Institutes of Health Consensus Development Conference Statement,1994 in OvarianCancer.2005,2.
[423]Togashi K:Ovarian cancer:the clinical role of US, CT, and MRI. Eur Radiol.2003, 13(4):87-104.
[424]Jeong YY, Outwater EK, Kang HK:Imaging evaluation of ovarian masses. Radiographics 2000,20(5):1445-1470.
[425]Balan P:Ultrasonography, computed tomography and magnetic resonance imaging in the assessment of pelvic pathology. Eur J Radiol 2006,58(1):147-1455.
[426]Risum S, Hφgdall C, Loft A, and et al. The diagnostic value of PET/CT for primary ovarian cancer--a prospective study Gynecol Oncol 2007,105(1):145-149
[427]Boubacar Siddi Diallo FB[1997]and neck, ovarian tumor, incidence, pathology and therapy at the Clinic for Gynecology and Obstetrics University Hospital of Donka. Thesis of doctor of medicine. University of Conakry.1997,46,54-57
[428]Chambers, A. F., Vanderhyden, B. C. Ovarian Cancer Biomarkers in Urine. Clin. Cancer Res.2006,12:323-327
[429]Cancer Council Victoria. Canstat:ovarian cancer. Carlton:Cancer Council Victoria. 2007,1.
[430]Katsumata N, Yasuda M, Takahashi F, and et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer:a phase 3, open-label, randomised controlled trial. Lancet.2009;374(9698):1331-1336.
[431]Markman M, Liu PY, Moon J, and et al. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel:follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol.2009;114(2):195-197.
[432]Riman T, Persson I, Nilsson S:Hormonal aspects of epithelial ovarian cancer:review of epidemiological evidence. Clin Endocrinol (Oxf) 1998,49:695-704
[433]Survival by stage at diagnosis. Australia. Australian Institute of Health and Welfare and National Breast and Ovarian Cancer Centre, Australian Institute of Health and Welfare Canberra 2010,48,38
[434]Emily Jackson, Ken Anderson, Chris Ashwell, James Petitte and Paul E. Mozdziak CA125 expression in spontaneous ovarian adenocarcinomas from laying hens. Gynecologic Oncology.2007, (104) 1,192-198
[435]Jacobs IJ, Skates S, Davies AP, Woolas RP, Jeyerajah A, Weidemann P, Sibley K, Oram DH:Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration:a prospective cohort study. BMJ 1996.313(7069):1355-1358.
[436]Bast RC, Brewer M, Zou C, et al. Prevention and early detection of ovarian cancer: mission impossible?. Recent Results Cancer Res.2007,174:91-98
[437]Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N. Engl. J. Med. 2009,361 (2):170-174
[438]Wylam Fought and et al. Journal of Obstetrics Gynecology/Cancer.2009,31(4),300-302
[439]Piek JM, van Diest PJ, Verheijen RH. Ovarian carcinogenesis:an alternative hypothesis. Adv. Exp. Med. Biol.2008,622:79-87
[440]Fazal Hussain, MBBS, Hamed Homoud Al Husainia Gynecologic Tumor Marker Contributor Information and Disclosures.2010,1-6
[441]Liu YN, Ye X, Cheng HY, and et al. Measurement of serum human epididymis secretory protein 4 combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian benign and malignant tumors. Zhonghua Fu Chan Ke Za Zhi. 2010;45(5):363-364.
[442]Barbosa CP, Souza AM, Bianco B, and et al. Frequency of endometriotic lesions in peritoneum samples from asymptomatic fertile women and correlation with CA125 values. Sao Paulo Med J.2009 Nov;127(6):342-5.
[443]Nabeta M, Abe Y, Haraguchi R, and et al. Serum anti-PDIKIL autoantibody as a novel marker for endometriosis. Fertil Steril.2010,2
[444]Penninx J, Brandes M, de Bruin JP, and et al. Prediction of pelvic pathology in subfertile women with combined Chlamydia antibody and CA-125 tests. Eur J Obstet Gynecol Reprod Biol.2009; 147(2):178-82.
[445]Pfisterer J, Plante M, Vergote I, and et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer:an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol.2006;24(29):4699-707.
[446]Evans, J., Ziebland, S., McPherson, A. Minimizing delays in ovarian cancer diagnosis: an expansion of Andersen's model of total patient delay. Fam Pract.2007,24:48-53
[447]Hydzik C. Treatment of ovarian cancer with intraperitoneal chemotherapy. Oncology. 2009;23(11):15-18.
[448]Jemal A, Siegel R, Ward E, and et al. Cancer statistics J. CA Cancer J Clin,2009,59: 225-238.
[449]Duan ZF, Ames RY, Ryan M, et al. CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells J. Cancer Chemoth Pharm,2009,63(4):681-684.
[450]Odening KE, Li W, Rutz R, et al. Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells J. Clin Exp Immunol,2009,155(2):239-244.
[451]Vandersickel V, Mancini M, Marras E, et al. Lentivirus-mediated RNA interference of Ku70 to enhance radiosensitivity of human mammary epithelial cells. J. Int J Radiat Biol,2010,86(2):114-120.
[452]Sankpal NV, Fleming TP, Gillanders, WE. Dual Expression Lentiviral Vectors for Concurrent RNA Interference and Rescue. J Surg Res,2009,156(1):50-56.
[453]Greenlee RT, Hill-Harmon MB, Murray T, and et al. Cancer statistics,2001.CA Cancer J Clin 2001:51:15-29.
[454]Oehler VG, Yeung KY, Choi YE. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data J. Blood,2009,114(15):3292-3295.
[455]Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med.2006; 354,34-35.
[456]Christine S. Walsh and Beth Y. Karlan Contemporary progress in ovarian cancer screening Current Oncology Reports.2007,(9) 6,484
[1]Joyner AB. Runowicz CD. Ovarian cancer screening and early detection. In Carole & Ray Neag Comprehensive Cancer Center, University of Connecticut Health Center, Obstetrics & Gynecology, Farmington, CT 05030, USA. Womens Health (Lond Engl). 2009;5(6):693-696.
[2]Yin, B. W. T.; Lloyd, K.O. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J. Biol. Chem.2001,276(29),2732.
[3]Argueso, P.; Spurr-Michaud, S.; Russo, and et al. MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope. Invest. Ophthal. Vis. Sci.2003,44(6)::2485-2493
[4]Moszynski R, Szpurek D, Michalak S, and et al. The role of endothelin-1 and its correlation with CA125 levels, grayscale ultrasonography and doppler findings in differential diagnoses of ovarian tumors. In Division of Gynecological Surgery, Department of Gynecology, Obstetrics and Gynecological Oncology, University of Medical Sciences, Poznan, Poland. Eur J Gynaecol Oncol.2009;30(5):552-553.
[5]Rinker-Schaeffer C. W., O'Keefe J. P., Welch D. R., and et al. Theodorescu, Metastasis suppressor proteins:discovery, molecular mechanisms, and clinical application. Clinical Cancer Research,2006,(12)13,3882-3889.
[6]Julang Li, Qiang Feng, Jong-Min Kim, and et al. Human Ovarian Cancer and Cisplatin Resistance:Possible Role of Inhibitor of Apoptosis Proteins. Endocrinology.2001, 142(1),370
[7]Jinsong Liu, Gong Yang.1 Jennifer A and et al. A Genetically Defined Model for Human Ovarian Cancer. CANCER RESEARCH,2004 64,1655.
[8]William G. Kaelin Jr The von Hippel-Lindau tumour suppressor protein:O2 sensing and cancer Nature Reviews Cancer 2008,8,865-873
[9]Ingegerd Hellstrom, John Raycraft, Martha Hayden-Ledbetter, Jeffrey A. Ledbetter, Miche, Schummer, Martin McIntosh, Charles Drescher, Nicole Urban, and Karl Erik Hellstrom
[10]I. H., J. R., M. H-L., and et al. Pacific Northwest Research Institute, Institute for Systems Biology [M. S., Fred Hutchinson Cancer Research Center [M. M., C. D.,N. U., and Swedish Hospital and Medical Center [C. D., The HE4 (WFDC2) Protein Is a Biomarker for Ovarian Carcinoma. CANCER RESEARCH.2003,63,3695-3700
[11]Berek, J. S., Bast, R. C, and et al. Ovarian cancer screening The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer,1995.76:2092-2089.
[12]Maggino, T., Gadducci, A., D'Addario, and et al. Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol. Oncol.,1994,54:117-119,
[13]Chang, K., Pai, L. H., Batra, J. K., Pastan, I., and Willingham, M. C. Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res.,1992,52:181-178.
[14]Scholler, N., Fu, N., Yang, and et al. Soluble member(s) of the mesothelin/ megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc. Natl. Acad. Sci. USA,1999,96:11531-11526,.
[15]Schummer, M., Ng, W., Bumgarner, R., and et al. Comparative hybridization of an array of 21 500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene,1999,238:375-381.
[16]Ono, K., Tanaka, T., Tsunoda, T., and et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis Cancer Res.,2000,60:5007-5009.
[17]Welsh, J. B., Zarrinkar, P. P., Sapinoso, and et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Natl. Acad. Sci. USA,2001,98:1176-1178,
[18]Kirchhoff, C, Habben, I., Ivell, R., and et al. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol. Reprod.,1991,45:350-348.
[19]Kirchhoff, C. Molecular characterization of epididymal proteins. Rev. Reprod.,1998, 3:86-95.
[20]Dandekar, A. M., Robinson, E. A., Appellla, E., and et al. Complete sequence analysis of cDNA clones encoding rat whey phosphoprotein:homology to a protease inhibitor. Proc. Natl. Acad. Sci. USA,1982,79:3987-3989.
[21]Heinzel, R., Appelhans, H., Gassen, G., and et al. Molecular cloning and expression of cDNA for human antileukoprotease from cervix uterus. Eur. J. Biochem.,1986,160: 63-65.
[22]Wiedow, O., Schroder, J. M., Gregory, H., and et al. An elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J. Biol. Chem.,1990,265:14791-14792.
[23]Bingle, L., Singleton, V., and Bingle, C. D. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene,2002,21:2768-2773.
[24]Hayden, M. S., Gilliland, L. K., and Ledbetter, J. A. Antibody engineering. Curr. Opin. Immunol.,1997,9:201-212.
[25]Davidson NG, Khanna S, Kirwan PH. Bircumshaw D:Prechemotherapy serum CA125 level as a predictor of survival outcome in epithelial carcinoma of the ovary. Clin Oncol (R Coll Radiol) 1991,3:32-26.
[26]Rustin GJ, Gennings JN, Nelstrop AE, and et al. Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group. J Clin Oncol 1989,7:1667-1667.
[27]Burger RA, Darcy KM, DiSaia PJ, and et al. Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy:a gynecologic oncology group study. Cancer 2004, 101:106-109.
[28]Kim HS, Park NH, Chung HH, and et al. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer. Onkologie 2008,31:315-312.
[29]Juretzka MM, Barakat RR, Chi DS, and et al. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol 2007,104:176-178.6 Riedinger JM, Bonnetain F, Basuyau JP, and et al. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. Ann Oncol 2007,18:881-875.
[30]Badulescu F, Badulescu A, Schenker M, Popescu CF, Stoica Z:The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma. Rom J Morphol Embryol 2005 46:329-328.
[31]Fisken J, Leonard RC, Stewart M, Beattie GJ, Sturgeon C, Aspinall L, Roulston JE: The prognostic value of early C A125 serum assay in epithelial ovarian carcinoma. Br J Cancer 1993,68:140-135.
[32]Redman CW, Blackledge GR, Kelly K, Powell J, Buxton EJ, Luesley DM:Early serum CA125 response and outcome in epithelial ovarian cancer. Eur J Cancer 1990. 26:593-586
[33]Colakovic S, Lukic V, Mitrovic L, Jelic S, Susnjar S, Marinkovic J:Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer. Int J Biol Markers 2000, 15:147-149.
[34]Yedema CA, Kenemans P, Voorhorst F, Bon G, Schijf C, Beex L, Verstraeten A, Hilgers J, Vermorken J:CA 125 half-life in ovarian cancer: a multivariate survival analysis. Br J Cancer 1993,67:1361-1357.
[35]Osman N, O'Leary N, Mulcahy E, Barrett N, Wallis F, Hickey K, Gupta R:Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre. Ir Med J 2008,101:245-237.
[36]Van Dal en A, Favier J, Burges A, and et al. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol 2000,79:444-445.
[37]Cooper BC, Sood AK, Davis CS, and et al. Preoperative CA 125 levels:an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol 2002 100:59-54.
[38]Buller RE, Vasilev S, DiSaia PJ:CA 125 kinetics:a cost-effective clinical tool to evaluate clinical trial outcomes in the 1990. Am J Obstet Gynecol 1996,174:1241-1243.
[39]Nagele F, Petru E, Medl M, and et al. Preoperative CA 125:an independent prognostic factor in patients with stage Ⅰ epithelial ovarian cancer. Obstet Gynecol 1995,86:259-264.
[40]Makar AP, Kristensen GB, Kaern J, and et al. Prognostic value of pre-and postoperative serum CA 125 levels in ovarian cancer:new aspects and multivariate analysis. Obstet Gynecol 1992.79:1002-1008.
[41]Sevelda P, Schemper M, Spona J:CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1989 161:1213-1206.
[42]Moebus V:KRCGWHCHKH:Evaluation of CA125 as a prognostic and predictive factor in ovarian cancer. J Tumor Marker Oncol 1988,3:251-248.
[43]Cruickshank DJ. Fullerton WT. Klopper A:The clinical significance of pre-operative serum CA 125 in ovarian cancer. Br J Obstet Gynaecol 1987,94:692-685
[44]Hunter VJ, Daly L, Helms M, and et al. The prognostic significance of CA 125 half- life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol 1990,163:1164-1157.
[45]Hawkins RE, Roberts K, Wiltshaw E, Mundy J, Fryatt IJ, McCready VR:The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol 1989,96:1395-1389.
[46]Gard GB, Houghton CR:An assessment of the value of serum CA 125 measurements in the management of epithelial ovarian carcinoma. Gynecol Oncol 1994,53:283-259.
[47]Frasci G, Conforti S, Zullo F, and et al. A risk model for ovarian carcinoma patients using CA 125:time to normalization renders second-look laparotomy redundant. Cancer 1996,77:1122-1120.
[48]Mano A, Falcao A, Godinho I, Santos J, Leitao F, de Oliveira C, Caramona M:CA-125 AUC as a predictor for epithelial ovarian cancer relapse. Cancer Biomark 2008, 4:73-78.
[49]Mano A, Falcao A, Godinho I, and et al. CA-125 AUC as a new prognostic factor for patients with ovarian cancer. Gynecol Oncol 2005,97:529-524.
[50]Riman T, Persson I, Nilsson S:Hormonal aspects of epithelial ovarian cancer:review of epidemiological evidence. Clin Endocrinol (Oxf) 1998,49:695-702.
[51]Hermsen BBJ. von Mensdorff-Pouilly S, Berkhof J, et al:Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk ovarian cancer. J Clin Oncol 2007,25,1386
[52]Olsen CM, Green AC, Nagle CM, et al.; Australian Cancer Study Group (Ovarian Cancer) and the Australian Ovarian Cancer Study Group. Epithelial ovarian cancer: testing the'androgens hypothesis'. Endocr Relat Cancer.2008;15:1061-1060.
[53]Bidart JM, Thuillier F, Augereau C, Chalas J, Daver A, Jacob N, Labrousse F, Voitot H:Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 1999,45:1695-1701.
[54]Tamakoshi K, Kikkawa F, Hasegawa N, and et al. Clinical value of a new serum tumor marker, CA125II, in gynecologic disease:comparison with CA125. Gynecol Obstet Invest.1995; 39(2),125-129.
[55]Bets Davis, Ovarian cancer. Obstetrics and Gynecology,2009.
[56]Christine Wendt. Protein Diabetes Educator.2009
[57]U.S. Preventive Services Task Force. Screening for ovarian cancer,2004.6.
[58]Finegan J, Bartleman B, Wong PY:A window for the study of prenatal sex hormone influences on postnatal development. J Genet Psychol 1988; 150:101-112
[59]Rubinow DR, Schmidt PJ:Androgens, brain, and behavior. Am J Psychiatry 1996; 153:974-984
[60]Caswell H, Weeks DE:Two-sex models:chaos, extinction, and other dynamic consequences of sex. American Naturalist 1986; 128:707-735
[61]Bachman DL, Wolf PA, Linn R, and et al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology 1992; 42:115-119
[62]Finegan J, Bartleman B, Wong PY:A window for the study of prenatal sex hormone influences on postnatal development. J Genet Psychol 1988; 150:101-112
[63]Rubinow DR, Schmidt PJ:Androgens, brain, and behavior. Am J Psychiatry 1996; 153:974-984
[64]Caswell H, Weeks DE:Two-sex models:chaos, extinction, and other dynamic consequences of sex. American Naturalist 1986; 128:707-735
[65]Bachman DL, Wolf PA, Linn R, and et al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology 1992; 42:115-119
[66]Bachman DL, Wolf PA, Linn RT, and et al. Incidence of dementia and probable Alzheimer's disease in a general population:the Framingham Study. Neurology 1993; 43:515-519
[67]Canadian Study of Health and Aging Working Group:Canadian study of health and aging:study methods and prevalence of dementia. Can Med Assoc J 1994; 150:899-8913
[68]Tang MX, Jacobs D, Stern Y, and et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348:429-432
[69]Henderson VW, Buckwalter JG:Cognitive deficits of men and women with Alzheimer's disease. Neurology 1994; 44:90-96
[70]Hafner H, an der Heiden W:Epidemiology of schizophrenia. Can J Psychiatry 1997; 42:139-151
[71]Lewine RJR, Seeman MV. Gender, brain, and schizophrenia:anatomy of differences/differences of anatomy, in Gender and Psychopathology. Edited by Seeman MV. Washington, DC, American Psychiatric Press,1995
[72]Jablensky A, Cole SW:Is the earlier age at onset of schizophrenia in males a confounded finding? Br J Psychiatry 1997; 170:234-240
[73]Ciompi L The influence of aging on schizophrenia. Triangle 1993; 32:25-31
[74]Wong DF, Wagner HN Jr, Dannals RF and et al. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 1984; 226:1393-1396
[75]Seeman MV:Sex differences in predicting neuroleptic response, in The Prediction of Neuroleptic Response. Edited by Gaebel W, Awad AG. Vienna, Springer-Verlag,1995, pp 51-64
[76]Blum M, McEwen BS, Roberts JL:Transcriptional analysis of tyrosine hydroxylase gene expression in the tuberoinfundibular dopaminergic neurons of the rat arcuate nucleus after estrogen treatment. J Biol Chem 1987; 262:817-821
[77]DiPaolo T:Modulation of brain dopamine transmission by sex steroids. Rev Neurosci 1994; 5:27-42
[78]Toran-Allerand CD:The estrogen/neurotrophin connection during neural development: is co-localization of estrogen receptors with the neurotrophins and their receptors biologically relevant? Dev Neurosci 1996; 18:36-41
[79]Seeman MV, Lang M:The role of estrogens in schizophrenia gender differences. Schizophr Bull 1990; 16:185-194
[80]Bast RC Jr, Klug TL, St John E, and et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983 309:883-882.
[81]Nustad K, Bast RC Jr, Brien TJ, and et al. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen:first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumour Biol 1996,17:196-212.
[82]Markman M:Optimizing primary chemotherapy in ovarian cancer. Hematol Oncol Clin North Am 2003,17:957-958.
[83]Kenemans P, van Kamp GJ, Oehr P, Verstraeten RA:Heterologous double-determinant immunoradiometric assay CA 125 II:reliable second-generation immunoassay for determining CA 125 in serum. Clin Chem 1993,39:2509-2510.
[84]Hogdall EV, Christensen L., Kjaer SK, and et al. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. Gynecol Oncol 2007,104:508-509.
[85]Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE:Defining progression of ovarian carcinoma during follow-up according to CA 125:a North Thames Ovary Group Study. Ann Oncol 1996,7:361-344.
[86]Rustin GJ, Marples M, Nelstrop AE. Mahmoudi M, Meyer T:Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 2001,19:4054-4027.
[87]Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB:CA 125:the past and the future. Int J Biol Markers 1998,13:179-187.
[88]Menon U, Jacobs IJ:Ovarian cancer screening in the general population. Curr Opin Obstet Gynecol 2001,13:61-60.
[89]Verheijen RH, Mensdorff-Pouilly S, van Kamp GJ, Kenemans P:CA 125: fundamental and clinical aspects. Semin Cancer Biol 1999,9:117-114.
[90]Yin BW, Lloyd KO:Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001,276:27371-27370.
[91]Skates SJ, Menon U, MacDonald N, Rosenthal AN, Oram DH, Knapp RC, Jacobs IJ: Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003,21:206-205.
[92]Rustin GJ, Bast RC Jr, Kelloff GJ, Barrett JC, Carter SK, Nisen PD, Sigman CC, Parkinson DR, Ruddon RW:Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 2004,10:3919-3916.
[93]Gronlund B, Dehn H, Hogdall CK, Engelholm SA, Jorgensen M, Norgaard-Pedersen B, Hogdall EV:Cancer-associated serum antigen level:a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma. Int J Gynecol Cancer 2005, 15:836-833.
[94]Kang WD, Choi HS, Kim SM. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer. In Department of Obstetrics and Gynecology, Chonnam National University Medical School,8 Hakdong, Dong-gu, Gwangju, Republic of Korea. Gynecol Oncol.2010 Jan;116(1):57-55.
[95]Zurawski VR Jr, et al. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia:relevance for early detection of ovarian cancer. Int J Cancer 1988; (42)677-648
[96]Agustin A Garcia, Samina Ahmed. Ovarian Cancer. Contributor Information and Disclosures.2010
[97]3 Kojima, T., Oh-eda, M., Hattori, and et al. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J. Biol. Chem.,1995,270:21984-21987.
[98]4 Chang, K.; Pastan, I.:Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas. and ovarian cancers. Proc. Nat. Acad. Sci.93, 1996,138.
[99]Scholler, N.; Fu, N.; Yang, Y.; and et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc. Nat. Acad. Sci.1999,96:11531-11535.
[100]Bera, T. K.; Pastan, I. Mesothelin is not required for normal mouse development or reproduction. Molec. Cell. Biol.2000,20,2905.
[101]Campbell, I. G.; Nicolai, H. M.; Foulkes, W. D.; and et al. A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1. Hum. Molec. Genet.3:1994,589-579.
[102]Lange, S.; Xiang, F.; Yakovenko, A.; and et al. The kinase domain of titin controls muscle gene expression and protein turnover. Science,2005,308,1599-1601.
[103]Brown, M. A.; Nicolai, H.; Xu, C.-F.; and et al. Regulation of BRCA1. (Letter) Nature 1994,372,730.
[104]Brown, M. A.; Xu, C.-F.; et al. The 5-prime end of the BRCA1 gene lies within a duplicated region of human chromosome 17q21. Oncogene 1996,12,2511.
[105]Santillan A, Garg R, Zahurak ML, et al:Risk of epithelial ovarian cancerrecurrence in patients with rising serum CA125 levels within the normal range.J Clin Oncol 2005, 23:9338-9339
[106]Friedman LC, Kramer RM:Reproductive issues for women with BRCA mutations. J Natl Cancer Inst Monogr 2005,34,85
[107]Ransohoff DF:Lessons from controversy:Ovarian cancer screening and serum proteomics. J Natl Cancer Inst 2005,97:315-317
[108]Hermsen BBJ, van Diest PJ, Berkhof J, et al:Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and fallopian tube in women at hereditary high risk of breast and ovarian cancer. Int J Cancer.2006 119:1412-1409
[109]Kirtly Jones, Female reproductive system. Obstetrics and Gynecology Medicine.2008
[110]Maria Essig. DNA (deoxyribonucleic acid). Reproductive Genetics,2009
[111]Sandy Jocoy, A pelvic exam Obstetrics and Gynecology.2009
[112]Monica Rhodes. Biopsy Medical Toxicology.2009
[113]Ovarian cancer. NCCN Practice Guidelines in Oncology, National Comprehensive Cancer Network.2009.
[114]Sendahl M, Ernst E, Rasmussen PE, Yding Andersen C.2008.
[115]Fertil. Steril. True ovarian volume is underestimated by two-dimensional transvaginal ultrasound measurement.2008
[116]Steven Vasilev, M.D., Ovarian Cancer Stage & Grade:Two Critical Factors. Health's Disease and Condition content.2008.
[117]Berchuck A, Elbendary A, Havrilesky L, and et al. Pathogenesis of ovarian cancers. J Soc Gynecol Investig 1994;(1)181-190.
[118]Karst AM, Drapkin R. Ovarian cancer pathogenesis:a model in evolution. J Oncol. 2010; (93)23-71.
[119]Markman M, Liu PY, Rothenberg ML et al. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer J Clin Oncol 2006; 24:1454-1458
[120]Liu P-Y, Alberts DS, Monk BJ et al An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy J Clin Oncol 2007; 25:3615-3620
[121]Medeiros LR, Rosa DD, DA Rosa MI. Accuracy of Ca 125 in the diagnosis of ovarian tumors:a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol,2009; 142:99-105.
[122]Comparison of CA-125 and Standard Definitions of Progression of Ovarian Cancer in the Intergroup Trial of Cisplatin and Paclitaxel Versus Cisplatin and Cyclophosphamide JCO (2006) 24(1):45-51
[123]Coates RRJ, Kolor K, Stewart SL, Richardsonha LC. Diagnostic markers for ovarian cancer screening:not ready for routine clinical use. Clin Cancer Res,2008; 14,7 575-7576
[124]Pauler DK, Menon U, McIntosh M, et al:Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev 10:489-493,2001
[125]Lo Curto M, DA'ngelo P, Cecchetto G, and et al. Mature and immature teratomas: results of the first paediatric Italian study. Pediatric Surgery International.2007,23 (4): 315-322
[126]Ries LAG, Melbert D, Krapcho M, and et al. SEER cancer statistics review 1975-2005 Institute. NC, Bethesda, MD.2006,3-20
[127]Hess LM, Benham-Hutchins M, Herzog TJ. and et al. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer.2007;17(3):561-570.
[128]Elit L, Oliver TK, Covens A, and et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer:a systematic review with metaanalyses. Cancer.2007;109(4):692-702
[129]Goff BA, Mandel LS, Melancon CH. Muntz HG. Frequency of symptoms of ovarian cancer. Primary care clinics. JAMA.2004;291(22):2705-2712.
[130]Riedinger JM, Wafflart J, Ricolleau G et al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome:results of a French multicentric study. Ann Oncol 2006; 17:1234-1238.
[131]Vladimir Nossov, AffiliationDepartment of Obstetrics and Gynecology, University of California, Los Angeles, Medical Center, Los Angeles, CA Malaika Amneus, and et al. The early detection of ovarian cancer:from traditional methods to proteomics. Can we really do better than serum CA-125? American Journal of Obstetrics & Gynecology 2008(199),3,215-223Affiliations
[132]Amer K. Karam & Beth Y. Karlan. Ovarian cancer:the duplicity of CA125 measurement. Nature Reviews Clinical Oncology,2010,7,335-339
[133]Louis Dubeau MD The cell of origin of ovarian epithelial tumors. The Lancet Oncology.2008, (9)12,1191-1197
[134]Victorian. Brande. Questioning the Role of CA125 as a Biomarker in Ovarian Cancer. Oncology Times,2010, (32)24,9-10
[135]Jankovic M.M, Milutinovic. B S. Pregnancy-associated CA125 antigen associated CA125 antigen as mucin:evaluation of ferning morphology. Mol Hum Reprod,2007, (13)405-408
[136]McLemore MR, Aouizerat B. Introducing the MUC16 gene:implications for prevention and early detection in epithelial ovarian cancer. Biol Res Nurs.2005 6(4):262-7.
[137]Monica R. McLemore, Bradley Aouizerat . Introducing the MUC16 Gene: Implications for Prevention and Early Detection in Epithelial Ovarian Cancer. Biol Res Nurs April 2005, (6) 4,262-267
[138]Jankovic M.M, Milutinovic. B S.Pregnancy-associated CA125 antigen associated CA125 antigen as mucin:evaluation of ferning morphology. Mol Hum Reprod,2007, (13)405-408
[139]WP McGuire. CA-125 and Early Ovarian Cancer. J Natl Cancer Inst,2005,95.105- 112
[140]Richard R. Barakat, Maurie Markman, Marcus E. Randall. Principles and Practice of Gynecologic Oncology.-2009-Medical-1072
[141]James L. Wilder, Edward Pavlik, John M. Straughn and et al. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer:a preliminary investigation. Gynecologic Oncology,2003, (89) 2,233-235
[142]Victorian, Brande. Questioning the Role of CA125 as a Biomarker in Ovarian Cancer. Oncology Times,2010, (32)24,9-10
[143]Louis Dubeau MD The cell of origin of ovarian epithelial tumors. The Lancet Oncology.2008, (9)12,1191-1197
[144]Tiss, Ali, Timms, John F and et al. Highly Accurate Detection of Ovarian Cancer Using CA125 but Limited Improvement With Serum Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Profiling. International Journal of Gynecological Cancer:2010, (20) 9,1518-1524
[145]Merrill Goozner. Personalizing Ovarian Cancer Screening. JNCI J Natl Cancer Inst (2010) doi:10.1093/jnci/djq296
[146]Digant Gupta, Christopher G Lis. Role of CA125 in predicting ovarian cancer survival a review of the epidemiological literature. Journal of Ovarian Research 2009, (2),13,1757-2215
[1]Parkin DM et al. (2005) Global cancer statistics,2002. CA Cancer J Clin 55:74-108
[2]Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin M.GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide:IARC CancerBase No.10 [Internet].Lyon, France:International Agency for Research on Cancer; 2010.
[3]Office for National Statistics. Cancer Statistics registrations:Registrations of cancer diagnosed in 2007, England. Series MB1 no.38.2010
[4]Cancer Intelligence and Surveillance Unit. Cancer Incidence in Wales.2010.
[5]Stirling D et al. (2005) Screening for familial ovarian cancer:failure of current protocols to detect ovarian cancer at an early stage according to the International Federation of Gynecology and Obstetrics system. J Clin Oncol 23:5588-5596
[6]Evans, J., Ziebland, S., McPherson, A. Minimizing delays in ovarian cancer diagnosis: an expansion of Andersen's model of total patient delay. Fam Pract.2007,24:48-55
[7]Hydzik C. Treatment of ovarian cancer with intraperitoneal chemotherapy. Oncology. 2009; 23(11):15-20.
[8]Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics [J]. CA Cancer J Clin,2009,59:225-249.
[9]Duan ZF, Ames RY, Ryan M, et al. CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells [J]. Cancer Chemoth Pharm,2009.63(4):681-689.
[10]Odening KE, Li W, Rutz R, et al. Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells [J]. Clin Exp Immunol,2009,155(2):239-248.
[11]Vandersickel V, Mancini M, Marras E, et al. Lentivirus-mediated RNA interference of Ku70 to enhance radiosensitivity of human mammary epithelial cells [J]. Int J Radiat Biol,2010,86(2):114-124.
[12]Sankpal NV. Fleming TP, Gillanders, WE. Dual Expression Lentiviral Vectors for Concurrent RNA Interference and Rescue [J]. J Surg Res,2009,156(1):50-56.
[13]Greenlee RT, Hill-Harmon MB, Murray T, Thum M. Cancer statistics,2001.CA Cancer J Clin 2001:51:15-36.
[14]Oehler VG, Yeung KY, Choi YE. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data [J]. Blood,2009,114(15):3292-3298.
[15]Gynecologic Cancer Foundation, Society of Gynecologic Oncologists, American Cancer Society. Ovarian Cancer Symptoms Consensus Statement 2007
[16]Odicino F, Pecorelli S, Zigliani L & Creasman WT. History of the FIGO cancer staging system. International Journal of Gynecology and Obstetrics.2008;(101)205-210.
[17]Menon, U., Gentry-Maharaj, A., Ryan, A. and et al. Recruitment to multicentre trials lessons from UKCTOCS:descriptive study. BMJ.2008,337,2079-2079
[18]Ries LAG, Melbert D, Krapcho M, and et al (eds). SEER cancer statistics review 1975-2005 Institute. NC, Bethesda, MD.2006,3-20
[19]Tracey Edgell, G. Martin-Roussety, G. Barker, and et al. Phase Ⅱ biomarker trial of a multimarker diagnostic for ovarian cancer. J Cancer Res Clin Oncol.2010,136:1079-1088
[20]Mann JR, Gray ES, Thornton C, Raafat F, and et al. Mature and immature extracranial teratomas in children:the UK Children's Cancer Study Group Experience. Journal of Clinical Oncology:Official Journal of the American Society of Clinical Oncology.2008, 26 (21):3590-3597
[21]Moore, R. G., Bast, R. C. Jr. How Do You Distinguish a Malignant Pelvic Mass From a Benign Pelvic Mass? Imaging, Biomarkers, or None of the Above. JCO 2007,25:4159-4161
[22]Kurman RJ. Shih Ie-M:The origin and pathogenesis of epithelial ovarian cancer:a proposed unifying theory. Am. J. Surg. Pathol.2010,34(3),433-443
[23]American Cancer Society Cancer Facts and Figures 2008 American Cancer Society. 2008,1-70
[24]Prof Louis Dubeau MD The cell of origin of ovarian epithelial tumors. The Lancet Oncology.2008, (9)12,1191-1197
[25]Jemal A, Siegel R,Ward E, et al. Cancer statistics,2006. CA CancerJClin 2006; 56:106-130.
[26]Winter-Roach BA, Kitchener HC, Dickinson HO. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev.2009; 21,2-10
[27]myDr, Ovarian cancer test (CA125). UBM Medica Australia,2000-2010.2008,2
[28]Nossov V, Amneus M, Su F, Lang J, and et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? 2008, Am J Obstet Gynecol 199(3):215-223.
[29]Tung CS, Wong KK, Mok SC. Biomarker discovery in ovarian cancer. Womens Health (Lond Engl).2008,4:27-40
[30]Abenhaim, H. A., Titus-Ernstoff. L., Cramer, D. W. Ovarian cancer risk in relation to medical visits, pelvic examinations and type of health care provider. CMAJ.2007,176: 941-947
[31]Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer:defining the target for early detection. PLoS Med.2009; 6(7),2-29
[32]Markman M, Liu PY, Rothenberg ML et al. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol 2006; 24:1454-1458
[33]Dong-Mei Fan, Hui-Rong Shi, Zhi-Min Chen, Qing-Hua Wu, Hui-Na Liu and Rui-Tao Zhang. Early detection of ovarian carcinoma by proteome profiling based on magnetic bead separation and matrix-assisted laser desorption/ionization time of flight mass spectrometry. African Journal of Microbiology Research.2010, Vol.4(10),940-951
[34]Hess LM, Benham-Hutchins M, Herzog TJ, and et al. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer. May-Jun 2007; 17(3):561-570.
[35]Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer:an intergroup trial of the AGO-OVAR, the NCIC CTG and the EORTC GCG. J Clin Oncol.2006;24(29):4699-7070
[36]Bookman M (2006) GOG0182-ICON5:5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs. combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma [abstract#5002]. J Clin Onco
[37]Elit L, Oliver TK, Covens A, and et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer:a systematic review with metaanalyses. Cancer.2007;109(4):692-702
[38]Riedinger JM, Bonnetain F, Basuyau JP et al. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. Ann Oncol 2007; 18:881-885.
[39]Emily Jackson, Ken Anderson, Chris Ashwell, James Petitte and Paul E. Mozdziak CA125 expression in spontaneous ovarian adenocarcinomas from laying hens. Gynecologic Oncology.2007, (104) 1,192-198
[40]American Cancer Society of Gynecologic Oncologists. Ovarian Cancer Symptoms, Cancer Facts & Figures, Consensus Statement 2007
[41]Agustin A Garcia (2007). Ovarian cancer in eMedecine specialties. Gynecologic oncology
[42]Karen A. Johnson. The Standard of Perfection:Thoughts about the Laying Hen Model of Ovarian Cancer. In Perspective on Hakim et al. Cancer Prevention Research,2009 2: 97,114
[43]Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih Ie M. Early detection and treatment of ovarian cancer:shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am. J. Obstet. Gynecol.2008,198(4):351-356.
[44]Asher et al., Pelvic mass associated with raised CA 125 for benign condition:a case report World Journal of Surgical Oncology 2010,8:28
[45]Kathleen R. Cho, Ming Shih. Pathology:Mechanisms of Disease Annual Review.2009, (4)287-313
[46]Hermsen BBJ, von Mensdorff-Pouilly S, Berkhof J, et al:Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer. J Clin Oncol 2007.25:1383-1389
[47]Ries, LAG, Harkins, D., Krapcho, M. et al. SEER Cancer Statistics Review,1975-2003, National Cancer Institute.2008,3-4.
[48]Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer Methods Mol. Biol.2009, 472:413-437.
[49]Fang CY, Cherry C, Devarajnk. A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynaecologic screening for ovarian cancer. Gynecol Oncol,2009; 112:594-600
[50]Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem.2001;20:27371-27375
[51]Chan, Tian, Monk, et al. Prognostic factors for high-risk early-stage epithelial ovarian cancer:a Gynecologic Oncology Group study. Cancer.2008;112:2202-2210
[52]Peter W. Kujtan. Why Did You Not Do the CA-125 Test? Health & Wellness, Doctor's Corner.2003,22,27-28.2003
[53]Tiss, Ali, Timms, John F and et al. Highly Accurate Detection of Ovarian Cancer Using CA125 but Limited Improvement With Serum Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Profiling. International Journal of Gynecological Cancer:2010, (20) 9,1518-1524
[54]Merrill Goozner. Personalizing Ovarian Cancer Screening. JNCI J Natl Cancer Inst (2010) doi:10.1093/jnci/djq296
[55]Van Dalen A, Favier J, Burges A, Hasholzner U, de Bruijn HW, Dobler-Girdziunaite D, Dombi VH, Fink D, Giai M, McGing P, Harlozinska A, Kainz C, Markowska J, Molina R, Sturgeon C, Bowman A, Einarsson R:Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol 2000, 79:444.450
[56]Gadducci A, Cosio S, Tana R, Genazzani AR:Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol 2009,69(1):12-27
[57]Digant Gupta, Christopher G Lis. Role of CA125 in predicting ovarian cancer survival-a review of the epidemiological literature. Journal of Ovarian Research 2009, (2),13.1757-2215
[58]William P. McGuire. CA-125 and Early Ovarian Cancer:Does This Help the Clinician or Further Muddy the Water? Journal of Clinical Oncology,2005, (23) 25,5862-586
[59]Hydzik C. Treatment of ovarian cancer with intraperitoneal chemotherapy. Oncology. 2009;23(11):15-18.
[60]Jemal A. Siegel R, Ward E, and et al. Cancer statistics J. CA Cancer J Clin,2009,59: 225-238.
[61]Duan ZF, Ames RY, Ryan M, et al. CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells J. Cancer Chemoth Pharm,2009,63(4):681-684.
[62]Odening KE, Li W, Rutz R, et al. Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells J. Clin Exp Immunol,2009,155(2):239-244.
[63]Vandersickel V, Mancini M, Marras E, et al. Lentivirus-mediated RNA interference of Ku70 to enhance radiosensitivity of human mammary epithelial cells. J. Int J Radiat Biol,2010,86(2):114-120.
[64]Sankpal NV, Fleming TP, Gillanders, WE. Dual Expression Lentiviral Vectors for Concurrent RNA Interference and Rescue. J Surg Res,2009,156(1):50-56.
[65]Greenlee RT, Hill-Harmon MB, Murray T, and et al. Cancer statistics,2001.CA Cancer J Clin 2001:51:15-29.
[66]Oehler VG, Yeung KY, Choi YE. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data J. Blood,2009.114(15):3292-3295.
[67]Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med.2006; 354,34-35.
[68]Jacobs I, Bast RC, Jr. L'antigene CA 125 associe a la tumeur:une revue de la litterature. Hum Reprod,1989,4,1-12
[69]The electronic version of this article is the complete one and can be found online at: http://www.ovarianresearch.com/content/2/1/13
[70]http://creativecommons.org/licenses/by/2.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
A.REFERENCES in Journal Medical of Guinea
1. Importance of hematoxylin-eosin in diagnosis of cervical neoplasia
REFERENCES
Adenomyosis with severe inflammation in the uterine cervix in a dog. Hiromichi Tamada, Noritoshi Kawate, Toshio Inaba, Mitsuru Kuwamura, Masaya Maeda, Taketsugu Kajikawa, and Tsutomu Sawada.2005. Can Vet J. April; 46(4):333-334.
Agosti JM, Goldie SJ.2007. Introducing HPV vaccine in developing countries. Key challenges and issues [archive], New Eng J Med,356:1908-1910.
Boyle P, Ferlay J.2004. Cancer incidence et de mortalite en Europe. Ann Oncol 2005; 16:481-488.
Castapeda-Ipiguez MS, Toledo-R Cisneros, Aguilera-Delgadillo M.1998. Facteurs de risque de cancer de l'uterus cervico-vaginales chez les femmes dans Zacalecos. Salud Publica de Mexico 40:330-8
Danielle MARTEL (IFTAB-PARIS. Hemalun, Eosine (HE).2005, Fiches techniques Bioimage His-Image.1-2
da Silva Cardeal LB, Brohem CA, Correa TC, et al.2006. Higher expression and activity of metalloproteinases in human cervical carcinoma cell lines is associated with HPV presence[J]. Biochem Cell Biol.84(5):713-719.
Fonn S, B Bloch, Mabina M, S Carpenter, Cronje H, Maise C. et al.2002. Prevalence des lesions precancereuses et le cancer du col de l'uterus en Afrique du Sud:Une etude multicentrique. Afr Med S.92:148-156
Lawson JSHW, R Henson, Bobo JK, MK Kaeser.2000. Application de la recommandation pour la detection precoce du cancer du sein et du col uterin chez le groupe a faible revenu. Rep Recomm MMWR 49:37-55
Llewellyn BD. Nuclear staining with alum-hematoxylin. Biotech. Histochem.2009,84:159-177.
Misra JS, K Das, Chandrawati.1998. Resultats de la clinique downstaging cancer du col uterin dans un programme de depistage cytologique. Diag Cytopathol.19:344-348
Misra JS, Gupta HP, Das V.2004. Evaluation de la faisabilite devaluation du temps de vie de celibataire frottis entre 41-50 ans de la strategic de l'age pour le controle du cancer du col dans les pays en developpement de nos 32 annees d'experience de 1'hopital en fonction de routine de depistage cytologique. Diag Cytopathol; 31:376-379.
Mitkas P, Koutkias V, Symeonidis A, et al.2008. Association studies on cervical cancer facilitated by inference and semantic technologies:the assist approach [J].Stud Health Technol Inform,136:241-246.
Murthy NS, Chaudhary K, Saxena Tendances S.2005. L'incidence du cancer du col uterin: scenario indien. Eur J Cancer Prev 14:513-8
Organisation mondiale de la Sante, de la cytologie du tractus genital feminin.1995. Geneve: OMS; 1973 8- Systeme de Bethesda pour la declaration col de l'uterus/diagnostic cytologique vaginal:Acta cytologie 37:115-120
Peko J.F; Buambo S.; Diafouka M; Nsonde-Malanda J.2009. LESIONS PRECANCEREUSES DU COL UTERIN ET INFECTION A VIH A BRAZZAVILLE (56)10,532-536
Rauvala M, Aglund K, Puistola U, et al.2006. Matrix metalloproteinases-2 and -9 in cervical cancer:different roles in tumor progression[J].Int J Gynecol Cancer,16(3):1297-1302COL
Roberts CC, Tadesse AS, Sands J, et al.2006. Detection of HPV in Norwegian cervical biopsy specimens with type-specific PCR and reverse line blot assays. J Clin.36 (4):277-282.
Schiffman M, Castle PE, Jeronimo J, Rodriguez AC,Wacholder S.2007. Human Papilloma virus and cervical cancer. Lancet.370:890-907.
Shanta V, S Krishnamurthi, Gajalakshmi CK, Swaminathan R, Ravichandran K.2000. Epidemiologie du cancer du col de l'uterus:perspective mondiale et nationale. Indian J Med Assoc; 98:49-52
Wei YC, Chou YS, Chu TY.2007. Detection and typing of minimal human Papilloma virus DNAin plasma. Int J Gynaecol Obstet; 96 (2):112-116.
Woodman CB, Collins SI, Young LS.2007. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 7(1):11-22.
Wu RF, Dai M, Qiao YL, Clifford GM, Liu ZH, Arslan A, Li N, Shi JF, Snijders PJ, Meijer CJ, Franceschi S.2007. Human papillomavirus infection in women in Shenzhen City, People's Republic of China, a population typical of recent Chinese urbanisation Int J Cancer 121:1306-1311
2. Importance of hematoxylin-eosin in diagnosis of cervical neoplasia
REFERENCES
Aglund Kl, Rauvala Ml. Puistola U, Angstrom T, Turpeenniemi-Hujanen T.Zackrisson B & Stendahl U. Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer MMP-9 correlates to the grade and the stage. Gynecol Rauvala, Marita. Matrix metalloproteinases-2 and-9 and tissue inhibitors of metalloproteinases-1 and-2 in gynaecological cancers. Acta Univ. Oul.2006,4,12,1-90,
Bor-Ching Sheu, Huang-Chun Lien, Hong-Nerng Ho, Ho-Hsiung Lin, Song-Nan Chow, Su-Cheng Huang, and Su-Ming Hsu. Increased Expresomie sion and Activation of Gelatinolytic Matrix Metalloproteinases Is Associated with the Progression and Recurrence of Human Cervical CancerCancer Res,2003 63; 6537
Brooks R, Kizer N, Nguyen L, Jaishuen A, Wanat K, Nugent E, Grigsby P, Allsworth JE, Rader JS. Polymorphisms in MMP9 and SIPA1 are associated with increased risk of nodal metastases in early-stage cervical cancer. Gynecol Oncol.2010 Mar; 116(3):539-43.
Coussens L. M., Fingleton B., Matrisian L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (Wash. DC),295:2387-2392,2002.
Cuzick J, M Arbyn, Sankaranarayanan R, V Tsu, Ronco G, MH Mayrand, et al. Vue d'ensemble des ressources humaines en fonction et d'autres nouvelles options-papillomavirus pour le depistage du cancer du col uterin dans les pays developpes et en developpement. Vaccine 2008; 26:29-41
Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev. (Lond.),2:163-176,2002.
Garzetti G. G, Ciavattini A., Lucarini G., Goteri G., Nictolis M. D., Biagini G Microinvasive cervical carcinoma and cervical intraepithelial neoplasia:biologic significance and clinical implications of 72-kDa metalloproteinase immunostaining. Gynecol. Oncol., 61:97-203,1999.
Gilles C.. Polette M., Piette J., Munaut C., Thompson E. W., Birembaut P., Foidart J-M. High level of MT-MMP expression is associated with invasiveness of cervical cancer cells. Int. J. Cancer,65:209-213,1996.Liotta L. A.. Kohn E. C. The microenvironment of the tumor-host interface. Nature (Lond.),411:375-379,2001.
Hantz S, Alain S, Denis F. Human papillomavirus prophylactic vaccines:stakes and perspectives. Gynecol Obstet Fertil 2006 Jul:34(78):647-55.
Johansson N., Vaalamo M., Grenman S., Hietanen S., Klemi P., Saarialho-Kere U., Kahari V-M. Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas. Am. J. Pathol.,154:469-480,1999.
Kato Y, T Yamashita, Ishikawa Entre ce qui concerne l'expression de M. de la metalloproteinase matricielle-2 et la matrice metalloproteinase-9 et la Capacite d'invasion des Cellules cancereuses du col uterin. Oncol Rep 2002; 9:565-569
Lin LF, Chuang CH, Li CF, Liao CC, Cheng CF, Cheng TL, Shen MR, Tseng JT, Chang WC, Lee WH, Wang JM. ZBRK1 acts as a metastatic suppressor by directly regulating MMP9 in cervical cancer. Cancer Res.2010 Jan 1; 70(1):192-201.
Li Sheng Lei, Liu Zongwen, Zhaoqiu Min, et al. Esophageal squamous cell carcinoma RECKmRNA and protein expression and its significance. Chinese Journal of Clinical Oncology,2007,34:1280-1286.
McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Histoire naturelle des neoplasies cervicales intraepitheliales et risque de cancer invasif chez les femmes presentant une neoplasie intraepitheliale cervicale 3:une etude de cohorte retrospective. Lancet Oncol 2008; 9:425-434
M Iwasaki, Nishikawa A, T Fujimoto, N Akutagawa, K Manase, T Endo, et al. Effet anti-invasive du L'MMI-166 Selectif inhibiteur de metalloproteinase matrice nouvelle, col uterin Dans Le lignees de carcinome CELLULAIRES. Gynecol Oncol.2002; 85:103-107.
Moss M. L., Jin S-L. C., Milla M. E., Burkhart W., Carter H. L., Chen W-J., Clay W. C. Didsbury J. R., Hassler D., Hoffman C. R., Kost T. A., Lambert M. H., Leesnitzer M. A., McCauley P., McGeehan G., Mitchell J., Moyer M., Pahel G., Rocque W., Overton L. K., Schoenen F., Seaton T., Su J-L., Warner J., Willard D., Becherer J. D. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-a. Nature (Lond.),385:733-736,1997.
Nakamura H., Ueno H., Yamashita K., Shimada T., Yamamoto E., Noguchi M., Fujimoto N., Sato H., Seiki M., Okada Y. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res.,59:467-473,1999.
Noriyuki M, Sumi T, Zhi X, et al.Vascular endothelial growth factor, matrix metalloproteinases, and cyclooxygenase-2 influence prognosis of uterine cervical cancer in young women[J].Int J Oncol,2007.31(3):531-6.
Nuovo G. J., MacConnell P. B., Simsir A., Valea F., French D. L. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res.,55: 267-275,1995.
Rauvala,Marita. Matrix metalloproteinases-2 and-9 and tissue inhibitors of metalloproteinases-1 and-2 in gynaecological cancers. Acta Univ. Oul.2006,4.12, 1-90,
Rundhaug JE Matrix metalloproteinases and angiogenesis. J Cell Mol Med,2005,9:267-285
Sang-Hyuk Chung and Paul F. Lambert Prevention and treatment of cervical cancer in mice using estrogen receptor antagonists. Medical Science, November 17,2009, vol.106, no.46,19467-19472
Sheu B-C., Hsu S-M., Ho H-N., Lien H-C., Huang S-C., Lin R-H. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res.,61:237-242, 2001
Schiffman M, S. Wacholder De l'Inde au monde:une meilleure facon de prevenir le cancer du col de 1'uterus. N Engl J Med 2009;360:1453-512.
Ueno H., Yamashita K., Azumano I., Inoue M., Okada Y. Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas. Int. J. Cancer (Pred. Oncol.),84:470-477,1999.
Yamashita K., Azumano I., Mai M., Okada Y. Expression and tissue localization of matrix metalloproteinase-7 (matrilysin) in human gastric carcinomas.Implications for vessel invasion and metastasis. Int. J. Cancer (Pred. Oncol.),79:187-194,1998.
Yang SF, Wang PH, Lin LY, et al.A significant elevation of plasma A significant elevation of plasma level of matrix metalloproteinase-9 in patients with high-grade intraepithelial neoplasia and early squamous cell carcinoma of the uterine cervix [J].Reprod Sci, 2007,14(7):710-718.
Yoshida S, Kajitani N, Satsuka A, Nakamura H, Sakai H. Ras modifies proliferation and invasiveness of cells expressing human papillomavirus oncoproteins. J Virol.2008 Sep; 82(17):8820-7.
Yu J, Qian H, Li Y, et al.Arsenic trioxide (As2O3) reduces the invasive and metastatic properties of cervical cancer cells in vitro and in vivo[J].Gynecol Oncol, 2007,106(2):400-6.
Wang, Qin Tianjie, Ruan Zhi-ping, Ma Jinlu. Expressions and significance of PCNA and MMP9 in cervix cancer tissueExpressions and significance of PCNA and MMP-9 in cervix cancer tissue.journal.shouxi.net,13:15:42,2006,364
Wang PH, Yang SF, Chen GD, et al. Human non metastatic clone 23 type 1 gene suppresses migration of cervical cancer cells and enhances the migration inhibition of fungal immunomodulatory protein from Ganoderma tsugae[J].Reprod Sci,2007,14(5):475-485.
3. Colposcopic aspects of cervix vaginal lesions condylomatosis of the Center Donka Hospital University
REFERENCES
Almonte M, Ferreccio C, Winkler JL. Cuzick J, Tsu V, Robles S, Takahashi R, Sasieni P Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. Int J Cancer 2007,121:796-802
CEDEF. Item 149-Tumeurs cutanees epitheliales et melaniques:tumeurs a papillomavirus humain (HPV). Annales de dermatologie et de venereologie 2008,135S,141-14
Derrien J. les papillomavirus dans la genese des cancers du col Uterin. Concours medical 2000,165-172
Ferlay J, Bray F, DM Parkin P Pisani,. GLOBOCAN 2002:l'incidence du cancer, de mortalite et de prevalence dans le monde. Base de cancer du CIRC N°5, Version 2.0. IARC Press,2004:Lyon
Goldie S, Gaffikin L, Goldhaber-Fiebert J, Gordillo-Tobar A, Levin C. Mahe C, Wright T. Cost effectiveness of cervical screening in five developing countries. The New England Journal of Medicine.2005; 353:2158-2168.
Isabelle Navarria. Martine Jacot-Guillarmod. Depistage, traitement et surveillance. In Recommandations pour la prise en charge des pathologies cervicales. Societe Suisse de Gyn Obst,,6-17,2010
Koulibaly M. Ibrahim Sidiki, Amara Cisse, Sory Baillo, Diallo, Mamadou Diallo，Mamadou Bobo Diallo, Namory Keita, Naby Daouda Camara, cancer Indicence in conakry, Guinea:First Results From the cancer Registry. Int. Cancer.1997,70,39-45
Kurman RJ, Malkasian GD Jr，Sedlis A, Salomon D. De Papanicolaou a Bethesda:La justification d'une classification cytologique du col de nouvelles. Obstet Gynecol 1991; 77:779-82
LS Massad, YC Collins. Resistance des correlations entre l'impression colposcopique et histologie de la biopsie. Gynecol Oncol 2003; 89:424-8
Li. J-F Shi, S Franceschi, W-H Zhang M Dai, B Liu, Y-Z Zhang, L-K Li, R-F Wu, H De Vuyst1, M Plummer. Y-L Qiao, and G Clifford. Different cervical cancer screening approaches in a Chinese multicentre study. British Journal of Cancer 2009,100,532-537
Lynette Denny, Rengaswamy Sankaranarayanan. Secondary prevention of cervical cancer. International Journal of Gynecology and Obstetrics.2006,94 (Supplement 1),6.
Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutle'e F, Franco EL. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.2007, N Engl J Med 357:1579-1588
Mitchell MF, Schottenfeld D, Tortolero-Luna D, Cantor SB, Richrds-Kortum R. Colposcopie Pour le diagnostic des lesions intra-epithieles:Une meta-analyse. Obstet Gynecol 1998; 91:626-31
Pimple S, Muwonge R, Amin G, Goswami S, Sankaranarayanan R, Shastri SS. Cytology versus HPV testing for the detection of high-grade cervical lesions in women found positive on visual inspection in Mumbai, India. Int J Gynaecol Obstet.; 2010, 108(3):236-239.
Pretorius RG, Bao YP, Belinson JL, Burchette RJ, Smith JS, Qiao YL Inappropriate gold standard bias in cervical cancer screening studies. Int J Cancer 2007,121:2218— 2224cervical cancer.2007, N Engl J Med 357:1579-1588
Rauvala M, Aglund K, Puistola U, et al. Matrix metalloproteinases-2 and-9 in cervical cancer: different roles in tumor progression[J].Int J Gynecol Cancer,2006,16(3):1297-1302
Reid R, P. Scalzi verrues genitales et le cancer du col de l'uterus:VII:un meilleur indice pour differencier les infections colposcopique papillomc benin virale de haut grade neoplasie intraepitheliale cervicale. Am J Obstet Gynecol 1985; 153:611-8
Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, Fayette JM, Cherian J Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India:a cluster-randomised trial.2007, Lancet 370:398-406
Sangwa-Lugoma G, Mahmud S, Nasr SH, Liaras J, Kayembe PK, Tozin RR, Drouin P, Lorincz A, Ferenczy A, Franco EL Visual inspection as a cervical cancer screening method in a primary health care setting in Africa. Int J Cancer 2006,119:1389-1395
Sellors J, Sankaranarayanan R. Colposcopie et traitement des neoplasies cervicales intraepitheliales:manuel pour debutants. Lyon:IARC Press,2003
B. REFERENCES in International Journal of Advanced Studies and Research in Africa
4. Interest of the successive application of acetic acid and lugol in identification lesion
Papilloma virus Cervical
References
Almonte M. Ferreccio C, Winkler JL, Cuzick J, Tsu V, Robles S, Takahashi R, Sasieni P. 2007. Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. Int J Cancer.121:796-802.
Arbyn M, Sankaranarayanan R, Muwonge R, Keita N, Dolo A, Mbalawa CG, et al. 2008;Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer 123:153-158
Aynaud O, Piron D, Barrasso R, Poveda JD.1998. Comparison of clinical, histological, and virological symptoms of HPV in HIV-1 infected men and immunocompetent subjects. Sex Transm Infect.74(1):32-34.
Basu P, Sankaranarayanan R, Mandal R, Roy C, Das P, Choudhury D, et al.2003. The Calcutta Cervical Cancer Early Detection Group. Visual inspection with acetic acid and cytology in the early detection of cervical neoplasia in Kolkata, India. International Journal of Gynecological Cancer; 13:626-632.
Belinson J, Qiao YL, Pretorius R, Zhang WH, Elson P, Li L, Pan QJ, Fischer C, Lorincz A, Zahniser D.2001. Shanxi Province Cervical Cancer Screening Study:a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol.83:439-444
Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV.2002. The causal relation between human papillomavirus and cervical cancer. Journal of Clinical Pathology;55:244-65.
Blumenthal PD, Gaffikin L, Chirenje ZM, McGrath J, Womack S, Shah K.2001. Adjunctive testing for cervical cancer in low resource settings with visual inspection, HPV, and the Pap smear. International Journal of Gynaecology and Obstetrics;72:47-53.
Castellsague X.2008. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol.110:4-.7
CEDEF.2008. Item 149-Tumeurs cutanees epitheliales et melaniques:tumeurs a papillomavirus humain (HPV). Annales de dermatologie et de venereologie 135,141
Cuzick J. Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P. Iftner T.2006. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer.119:1095-1101
Dai M, Bao YP, Li N. Clifford GM, Vaccarella S. Snijders PJF, Huang RD, Sun LX, Meijer CJLM, Qiao YL, Franceschi S.2006. Human papillomavirus infection in Shanxi Province, People's Republic of China:a population-based study. Br J Cancer.95:96-101
da Silva Cardeal LB, Brohem CA, Correa TC, and et al.2006. Higher expression and activity of metalloproteinases in human cervical carcinoma cell lines is associated with HPV presence. J. Biochem Cell Biol,84(5):713-719.
De Vuyst H, Claeys P, Njiru S, Muchiri L, Steyaert S, De Sutter P. Van Marck E, Bwayo J, Temmerman M.2005. Comparison of pap smear, visual inspection with acetic acid, human papillomavirus DNA-PCR testing and cervicography. Int J Gynaecol Obstet.;89:120-126.
Denny L, Kuhn L, De Souza M, Pollack AE, Dupree W, Wright TC., Jr.2005. Screen-and-treat approaches for cervical cancer prevention in low-resource settings:a randomized controlled trial. JAMA.294:2173-2181
Denny L, Kuhn L, Pollack A, Wainwright H, Wright TC, Jr Evaluation of alternative methods of cervical cancer screening for resource-poor settings. Cancer. 2000;89:826-833
Denny L, Kuhn L, Pollack A, Wright TC Jr.2002. Direct visual inspection for cervical cancer screening:an analysis of factors influencing test performance. Cancer; 94:1699-707.
Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2004. Cancer Incidence, Mortality and Prevalence Worldwide. International Agency for Research on Cancer (IARC) Cancer Base.5(2)
Ferreccio C, Bratti MC, Sherman ME, Herrero R, Wacholder S, Hildesheim A, Burk RD, Hutchinson M, Alfaro M, Greenberg MD, Morales J, Rodriguez AC, Schussler J, Eklund C, Marshall G, Schiffman M.2003. A comparison of single and combined visual, cytologic, and virologic tests as screening strategies in a region at high risk of cervical cancer. Cancer Epidemiol Biomarkers Prev.;12:815-823.
Giustranti C.2006. Cancer du col de 1'uterus:MYC, un gene sous influence. J. Inst Curie.68:4
Goldie S, Gaffikin L, Goldhaber-Fiebert J, Gordillo-Tobar A, Levin C, Mahe C, Wright T. 2005. Cost effectiveness of cervical screening in five developing countries. The New England Journal of Medicine.353:2158-2168
IARC IARC.2005. Handbooks of Cancer Prevention Volume 10:Cervix Cancer Screening. IARC Press,311.
International Agency for Research on Cancer Working Group on the Evaluation of Carcinogenic Risks to Humans.1995. Human Papillomaviruses. Lyon:IARCPress; (IARC monographs on the Evaluation of Carcinogenic Risks to Humans.64.
IARC Working Group on Cervical Cancer Screening.1986. Summary chapter. In:Hakama M, Miller AB, Day NE, editors. Screening for cancer of the uterine cervix. Lyon: IARCPress; (IARC Scientific Publications),76,133-142
Jean-Philippe Spano, Anne-Genevieve Marcelin, Guislaine Carcelin,2005. HPV and cancer. Bulletin du Cance.92 (1):59-64
Jeronimo J, Schiffman M.2006. Colposcopy at a crossroads. Am J Obstet Gynecol.,195: 349-353
Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E.2007. Diagnostic accuracy of human papillomavirus testing in primary cervical screening:a systematic review and meta analysis of non-randomized studies. Gynecol Oncol,104: 232-246
Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC.2000. Human papillomavirus testing for cervical cancer screening in low-resource settings. Journal of the National Cancer Institute;92:818-25
Kulasingham SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, et al.2002. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities:comparison of sensitivity, specificity, and frequency of referral. JAMA;288:1749-57.
Li LK, Dai M, Clifford GM, Yao WQ, Arslan A, Li N, Shi JF, Snijders PJ, Meijer CJ, Qiao YL, Franceschi S.2006. Human papillomavirus infection in Shenyang City, People's Republic of China:a population-based study. Br J Cancer.95:1593-1597.
Li N, J-F Shi, S Franceschi, W-H Zhang M Dai, B Liu, Y-Z Zhang, L-K Li, R-F Wu, H De Vuystl, M Plummer, Y-L Qiao, and G Clifford.2009. Different cervical cancer screening approaches in a Chinese multicentre study. British Journal of Cancer 100: 532-537
Lynette Denny 2006. Rengaswamy Sankaranarayanan. Secondary prevention of cervical cancer. International Journal of Gynecology and Obstetrics.,94 (Supplement 1),65-70
Mahboobeh Safaeian, Mohammad Kiddugavu,Patti E. Gravitt,Stephen J. Gange, Joseph Ssekasanvu. Dan Murokora.Marc Sklar, David Serwadda, Maria J. Wawer.Keerti V. Shah and Ron Gray.2008. Determinants of Incidence and Clearance of High-Risk Human Papillomavirus Infections in Rural Rakai, Uganda. Cancer Epidemiol Biomarkers Prev;17(6). June 2008
Massad LS, Collins YC.2003; Strength of correlations between colposcopic impression and biopsy histology. Gynecol Oncol 89:424-424
Mayaud P, Gill DK, Weiss HA, Uledi E. Kopwe L, Todd J. ka-Gina G Grosskurth H, Hayes RJ, Mabey DC, Lacey CJ.2001. The interrelation of HIV, cervical human papillomavirus, and neoplasia among antenatal clinic attenders in Tanzania. Sex Transm Infect.77(4):248-254.
Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlee F, Franco EL.2007. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med,357:1579-1588.
Mitchell MF, Schottenfeld D, Tortolero-Luna G Cantor SB, Richards-Kortum R. 1998;Colposcopy for the diagnosis of squamous intraepithelial lesions:A meta-analysis. Obstet Gynecol 91:626-631
Mitkas P, Koutkias V, Symeonidis A, et al.2008. Association studies on cervical cancer facilitated by inference and semantic technologies:the assist approach. J. Stud Health Technol Inform.136:241-246.
Monk BJ, Tewari KS.2007. The spectrum and clinical sequelae of human papillomavirus infection. Gynecol Oncol.107:6-13
Morris BJ.2007. Why circumcision is a biomedical imperative for the 21 (st) century. Bioessays.29(11):1147-58.
Nicolas Duport.2008. Donnees epidemiologiques sur le cancer du col de Tuterus-Etat des connaissanccs-Actualisation In Maladies chroniques et traumatismes. Institut de veille sanitaire:5-27
Ng'andwe C, Lowe JJ, Richards PJ, Hause L, Wood C, Angeletti PC.2007. The distribution of sexually-transmitted Human Papillomaviruses in HIV positive and negative patients in Zambia, Africa. BMC Infect Dis.7:77.
Organisation mondiale de la Sante, de la cytologie du tractus genital feminin.1973, Geneve: OMS
Parkin D, Whelan S, Ferlay J, et al., editors.2002. Cancer Incidence in Five Continents.. IARC Scientific Publications.155(8):418-499
Peto J, Gilham C, Fletcher O, Matthews FE.2004. The cervical cancer epidemic that screening has prevented in the UK. Lancet.364:249—256.
Philip E. Castle, Mark Schiffman, Cosette M. Wheeler, Nicolas Wentzensen and Parti E. Gravitt.2009. Impact of Improved Classification on the Association of Human Papillomavirus With Cervical Vrecancer.Am.Epidemiol. J.172(1):390
Pimple S, Muwonge R, Amin G, Goswami S, Sankaranarayanan R, Shastri SS.2010. Cytology versus HPV testing for the detection of high-grade cervical lesions in women found positive on visual inspection in Mumbai, India. Int J Gynaecol Obstet. 108(3):236-239Expand+
Pretorius RG, Bao YP, Belinson JL, Burchette RJ, Smith JS, Qiao YL.2007. Inappropriate gold standard bias in cervical cancer screening studies. Int J Cancer.121:2218-2224.
Rengaswamy Sankaranarayanan, Ketayun Dinshaw, BhagwanMNene, Kunnambath Ramadas, Pulikattil Okkaru Esmy, Kasturi Jayant, Thara Somanathan, Surendra Shastri.2006. Cervical and oral cancer screening in India. J Med Screen. (Suppl 1):35-38
Safaeian M, Kiddugavu M, Gravitt PE, et al.2007. Comparability of self-collected vaginal swabs and physician-collected cervical swabs for detection of human papillomavirus infections in Rakai, Uganda. Sex Transm Dis;34:429-36.
Safaeian M, Kiddugavu M, Gravitt PE, Gange SJ, Ssekasanvu J, Murokora D, Sklar M, Serwadda D, Wawer MJ, Shah KV, Gray R.2008. Prevalence and risk factors for carcinogenic human papillomavirus infections in rural Rakai, Uganda. Sex Transm Infect.84(4):306-311.
Sangwa-Lugoma G, Mahmud S, Nasr SH, Liaras J, Kayembe PK, Tozin RR, Drouin P. Lorincz A, Ferenczy A, Franco EL.2006. Visual inspection as a cervical cancer screening method in a primary health care setting in Africa. Int J Cancer.;119:1389-1395.
Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, Fayette JM, Cherian J.2007. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India:a cluster-randomised trial. Lancet.370:398-406.
Sankaranarayanan R, Wesley R, Thara S, Dhakad N, Chandralekha B, Sebastian P, et al. 2003;Test characteristics of visual inspection with 4% acetic acid (VIA) and Lugol's iodine (VILI) in cervical cancer screening in Kerala, India. Int J Cancer 106:404-408.
Sankaranarayanan R, Chatterji R, Shastri SS, Wesley RS, Basu P, Mahe C, Muwonge R, Seigneurin D, Somanathan T, Roy C, Kelkar R, Chinoy R, Dinshaw K, Mandal R, Amin G, Goswami S, Pal S, Patil S, Dhakad N, Frappart L, Fontaniere B.2004b. Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: results from a multicenter study in India. Int J Cancer.112:341-347.
Sankaranarayanan R, Wesley R. A Practical Manual on Visual Screening for Cervical Neoplasia 2003. IARC Press:Lyon; IARC technical publication no.41
Sankaranarayanan R, Shastri S, Basu P, Mahe C, Mandal R, Amin G, et al.2004. The role of low-level magnification in visual inspection with acetic acid for the early detection of cervical neoplasia. Cancer Detection and Prevention; 28:245-251.
Sankaranarayanan R, Wesley R, Somanathan T, Dhakad N, Shyamalakumary B, Amma NS, et al.1998. Visual inspection of the uterine cervix after the application of acetic acid in the detection of cervical carcinoma and its precursors, Cancer;83:2150-256
Sankaranarayanan R, et al.,2005;. A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. International Journal of Cancer,116(4):617—623
Sankaranarayanan R et al.2005. A critical assessment of screening methods for cervical neoplasia. International Journal of Gynecology and Obstetrics.(89) 2:4-12
Sankaranarayanan R, Basu P, Wesley R, Mahe C, Keita N, Gombe C, et al.2004. Accuracy of visual screening for cervical neoplasia: Results from an IARC multicentre study in India
and Africa. International Journal of Cancer; 110,907-913
Sankaranarayanan R. Royal Society of Tropical Medicine and Hygiene meeting at Manson House,2002. Cervical cancer in developing countries. Trans R Soc Trop Med Hyg. 96:580-582.
Sankaranarayanan R, Budukh A, Rajkumar R. Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bulletin of the World Health Organization 2001;79:954-962.
Sarian LO, Derchain SF, Naud P, Roteli-Martins C, Longatto-Filho A. Tatti S, Branca M, Erzen M, Serpa-Hammes L, Matos J, Gontijo R, Braganca JF, Lima TP, Maeda MY, Lorincz A, Dores GB, Costa S, Syrjanen S, Syrjanen K.2005. Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) study. J Med Screen.; 12:142-149
Schiffman M.2007. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer; 111:145-53
Sellors JW, Sankaranarayanan R. Colposcopy and Treatment of Cervical Intraepithelial Neoplasia:A Beginner's Manual. International Agency for Research on Cancer:Lyon; 2003.
Sepulveda C, Prado R.2005. Effective cervical cytology screening in middle-income countries:The Chilean experience. Cancer Detect Prev.29:405-411
Shastri SS, Dinshaw K, Amin G, Goswami S, Patil S, Chinoy R, et al.2005;Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical Neoplasia in Mumbai, India. Bull World Health Organ 83:186-191
Steward BW. Kleihues P.2003. World Cancer Report. IARC Press.145-166
Surendra S Shastri.2010. Cervical cancer screening and vaccination in India. Indian Journal of Medical Ethics.7(1):41
Surendra S. Shastri, Ketayun Dinshaw, Geetanjali Amin, Smriti Goswami, Sharmila Patil, Roshini Chinoy, S. Kane, Rohini Kelkar, Richard Muwonge, Cedric Mahe, Dulhan Ajit, & R. Sankaranarayanan.2005. Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India. Bulletin of the World Health Organization.83:186-194.
Systeme de Bethesda pour la declaration col de l'uterus / diagnostic cytologique vaginal. 1995. Acta cytologie.37:115-120
University of Zimbabwe/JHPIEGO Cervical Cancer Project.1999. Visual inspection with acetic acid for cervical cancer screening:test qualities in a primary-care setting. Lancet 353:869-873.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N.1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol.189(1):12-29
Wu R.F., Dai M., Qiao Y.L., Clifford G.M., Liu Z.H., Arslan A., Li N., Shi J.F., Snijders P.J., Meijer C.J., Franceschi S.2007. Human papillomavirus infection in women in Shenzhen City, People's Republic of China, a population typical of recent Chinese urbanisation. Int J Cancer,121:1306- 1311.
5. Interest of CA 125 antigens dosing for the assessment of premature ovarian cancer
REFERENCES
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ:Cancer statistics. CA Cancer J Clin 2008, no 58,71-96.
Edwards BK, Brown ML, Wingo PA, et col:Annual report to the nation on the status of cancer,1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005, no97,1407-1427.
Hartge P, Whittemore AS, Itnyre J, McGowan L. Cramer D:Rates and risks of ovarian cancer in subgroups of white women in the United States The Collaborative Ovarian Cancer Group Obstet Gynecol 1994, no84,760-764.
Lu KH, Patterson AP, Wang L, et col:Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004, no 10,3291-3300
Averette HE, Janicek MF, Menck HR:The National Cancer Data Base report on ovarian cancer. American College of Surgeons Commission on Cancer and the American Cancer Society Cancer 1995, no76,1096-1103
Kosary CL:FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system:an analysis of 1973-1987 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 1994, no 10,31-46.
Fishman DA, Bozorgi K:The scientific basis of early detection of epithelial ovarian cancer: the National Ovarian Cancer Early Detection Program (NOCEDP). Cancer Treat Res 2002, no107,3-28.
Jemal A, Siegel R, Ward E, et al:Cancer statistics,2009. CA Cancer J Clin 2009, vol 4, no 59, 225-249.
van Dalen A, Favier J, Burges A, et col:Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol 2000, no 79, 444-450
Bast RC Jr, Badgwell D, Lu Z, Marquez R, et col:New tumor markers:CA125 and beyond. Int J Gynecol Cancer 2005, no15(Suppl 3),274-281.
Landen CN, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008; no26,995-1005.
Kurman RJ, Visvanathan K, Roden R, et al. Early detection and treatment of ovarian cancer; shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 2008; n o198,351-356.
Heerlein Meinhold-1, Bauerschlag D, Zhou Y, et al. An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. Clin Cancer Res.2007; no13(2 Pt 1),458-466
Abstracts of the first scientific workshop of the Early Detection Research Network Dis Markers 2001,17:3-38
Hogdall E:Cancer antigen 125 and prognosis. Curr Opin Obstet Gynecol 2008, no 20,4-8.
Tuxen MK, Soletormos G, Dombernowsky P:Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev 1995, no 21,215-245.
Karen A. Johnson. The Standard of Perfection:Thoughts about the Laying Hen Model of Ovarian Cancer. In Perspective on Hakim et al. Cancer Prevention Research,2009, vol 2,n o 97,114
Gynecologic Cancer Foundation, Society of Gynecologic Oncologists, American Cancer Society. Ovarian Cancer Symptoms Consensus Statement 2007
McGuire WP. Hoskins WJ,Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med.1996; no 334:1-6
Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst.2000; no 92:699-708
Cannistra SA Cancer of the ovary. N Engl J Med.2004; no351:2519-2529
Markman M, Federico M, Liu PY, Hannigan E, Alberts D:Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. Gynecol Oncol 2006, no 103:195-198
Riedinger JM, Bonnetain F, Basuyau JP, et col:Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome. Ann Oncol 2007, no 18:881-885.
The serum CA-125 antigen level on overall survival in advanced ovarian cancer. Gynecol Oncol 2006, no 103,195-198.
Petri AL, Hogdall E, Christensen IJ, Kjaer SK, Blaakaer J, Hogdall CK:Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer. APMIS 2006, no 114:359-363.
Mano A, Falcao A, Godinho I, Santos J, Leitao F, de Oliveira C, Caramona M:CA-125 AUC as a predictor for epithelial ovarian cancer relapse. Cancer Biomark 2008, no 4:73-81
Osman N, O'Leary N, Mulcahy E, Barrett N, Wallis F, Hickey K, Gupta R: Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre. Ir Med J 2008,no 101:245-247
Rustin GJ, van der Burg ME:A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials), J Clin Oncol 2009,2728
6. Determining roles of association Carboplatine-Doxorubicine Liposomale/Platinum-
Texane And the Management Of the Cancer Of the Advanced Ovariens Epitheliums At
the teaching hospital Conakry-Jilin 2.
REFERENCES
Jemal A, Siegel R, Ward E, et al:Cancer statistics,2009. CA Cancer J Clin 2009, vol 4 n°59, 225-249.
National Comprehensive Cancer Network:The NCCN Clinical Practice Guidelines in Oncology Ovarian Cancer. Available at: http://www.nccn.org.2eme version 2009, 2010.
Kyrgiou M, Salanti G, Pavlidis N, et al. Survival benefits with diverse chemotherapy regimens for ovarian cancer:meta-analysis of multiple treatments. J Natl Cancer Inst 2006; n°98,1655-1663
Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 2005; n°99,393-399.
Depierre, A. Maintenace chemotherapy in advanced non small cell lung cancer (NCSLC):a randomized study of vinorelbine versus observation in patients responding to induction therapy. Proc Am Soc Clin Oncol,2001, n°20,309a
Smith, I.E., et al., Duration of chemotherapy in advanced non-small-cell lung cancer:A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin.J Clin Oncol,2001, n°19, vol 5,1336-1343
Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer:an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; n°24,4699-4707.
Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J clin Oncol 2010; n°28,3107-3114.
Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010; no 28:3323-3329 Poveda A, Tjulandin S, Kong B, et al. Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr+PLD) versus PLD alone:results from a PPS cohort of a phase III study. J Clin Oncol 2010,28.
Rustin G, van der Burg M, et al. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). J Clin Oncol 2009;27 Suppl.
Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer:the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006; n°13:1702-1710
Sharma R, Graham J, Mitchell H, et al. Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer. Br J Cancer 2009; no 100:707-712.
Fung-Kee-Fung M. Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 2007; n°14:195-208.
Markman M, Blessing J, Rubin SC, et al. Phase Ⅱ trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers:a Gynecologic Oncology Group study. Gynecol Oncol 2006; n°101,436-440.
Kristensen G, Kaern J, Baekelandt M, et al. Chemotherapy versus hormonal treatment in patients with platinum and taxane resistant ovarian cancer: A NSGO study. J Clin Oncol 2008.26.
Tomao F, Panici PB, Frati L, Tomao S. Emerging role of pemetrexed in ovarian cancer. Expert Rev Anticancer Ther 2009; n o 9:1727-1735.
Vergote I, Calvert H, Kania M, et al. A randomised, double-blind, phase Ⅱ study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur J Cancer 2009;no 45:1415-1423.
Larkin JM, Kaye SB. Epothilones in the treatment of cancer. Expert Opin Investig Drugs 2006; n°15,691-702.
De Geest K, Blessing JA, Morris RT, et al. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 2010; n°28: 149-153.
Kumaran GC, Jayson GC, Clamp AR. Antiangiogenic drugs in ovarian cancer. Br J Cancer 2009;n°100:1-7.
Burger RA, Sill MW, Monk BJ, et al. Phase Ⅱ trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer:a Gynecologic Oncology Group study. J Clin Oncol 2007; n°25:5165-5171.
Cannistra SA, Matulonis UA. Penson RT, et al. Phase Ⅱ study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; n°25:5180-5186
Steelman LS, Stadelman KM, Chappell WH, et al. Akt as a therapeutic target in cancer. Expert Opin Ther Targets 2008; 12:1139-1165.
Yap TA, Carden CP, Kaye SB. Beyond chemotherapy:targeted therapies in ovarian cancer. Nat Rev Cancer 2009; 9:167-181.
Eckstein N, Servan K, Hildebrandt B, et al. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res 2009; n°69:2996-3003.
Huang GS, Brouwer-Visser J, Ramirez MJ, et al. Insulin-like growth factor 2 expression modulates taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin Cancer Res 2010; n°16:2999-3010
Ledermann J, Rustin G, Hackshaw A, et al. A randomized phase Ⅱ placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC). J Clin Oncol 2009;27.
Spannuth WA, Sood AK, Coleman RL. Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther 2010; 10:431-437.
Kalli KR, Oberg AL, Keeney GL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 2008; n°108,619-626.
McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition. Cancer Res 2006; n°66,8109-8115.
Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition:frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; n°28:2512-2519.
C. REFERENCES in International Journal Biology and Medical Sciences
7. Critical expression of gelatin-9 in the diagnosis of the uterine cervix carcinogen
tissues precancerous tumors and cancerous
REFERENCES
Aglund K1, Rauvala M1, Puistola U. Angstrom T, Turpeenniemi-Hujanen T,Zackrisson B & Stendahl U.2006. Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer - MMP-9 correlates to the grade and the stage. Gynecol Rauvala, Marita. Matrix metalloproteinases-2 and-9 and tissue inhibitors of metalloproteinases-1 and-2 in gynaecological cancers. Acta Univ.Oul, vo 4, issue 12, pp 1-90
Brem S.1999. Angiogenesis and Cancer control:From concept to therapeutic trial. Cancer Control; issue 6, pp 436-458.
Frisch SM, Ruoslahti E.1997, Integrin and anoikis. Curr Opin Cell Biol issue 9, pp 701-706
Hantz S, Alain S, Denis F.2006. Human papillomavirus prophylactic vaccines:Stakes and perspectives. Gynecol Obstet Fertil, vo 34, issue 78, pp647-55.
Jiangzhong Qing, Zhu Fengchuan,2003, expression MMP-9 of Uterine Cervix and angiogenesis tumoral, the proliferation des cells cancerous, invasion and metastasis. J. Cancer, vo 22, issue 2, pp 178-184.
Kathy Shapiro, Emma Ottolenghi, Patricia Claeys, Janet Petitpierre.2007. Guide essential practices. Overall picture of stages FIGO compared to the assumption of responsibility and forecast in the fight against the cancer of the cervix. Overall picture of stages FIGO compared to the assumption of responsibility and forecast. pp187.
LaFlamme SE, Auer KL.1996. Integrin de signalisation. Semin Cancer Biol, issue 7, pp 111-118
Lin LF, Chuang CH, Li CF, Liao CC, Cheng CP, Cheng TL, Shen MR, Tseng JT, Chang WC, Lee WH, Wang JM. ZBRK1 acts as a metastatic suppressor by directly regulating MMP9 in cervical cancer. Cancer Res:2010; 70(1):192-201.
Li SL, Zhao QM, Liu ZW, Zhao ZH, Gao DL, Zheng XY, Chen KS, Zhang YH.2007. Correlation between the protein expression of reversion inducing cysteine rich protein with Kazal motifs and matrix matalloproteinase-9 in esophageal squamous cell carcinoma and its clinical pathological significance. Shijie Huaren Xiaohua Zazhi; vol5. issue 10, pp 1082-1086
Liotta LA, CN Rao, SH Barsky.1983. Invasion tumoral and matrix extracellular. Lab Invest issue 49, pp 636-649
Lochter A, Bissell MJ.1999. An Odyssey of the chest bone:-control of breast metastasis and matrix Metalloproteinases periprosthetic multi stage. APMIS; issue 107, pp 128-136
Mignatti P, DB Rifkin. Biology and biochemistry of proteases in tumor invasion.1993. Physiol Rev; issue 4, pp 251-258
Mitra A, Chakrabarti J, Banerji A,et al.2006. Cell membrane-associated MT1-MMP dependent activation of MMP-2 in SiHa (human cervical cancer) cells. J Environ Pathol Toxicol Oncol. vo 25, issue 4, pp 655-666.
M Schmitt, Janicke F, N Moniwa, Chucholowski L, H Pache, Graeff H.1992 associated tumor to plasminogen activator urokinase type:and the biological clinical significance. Biol Chem Hoppe Seyler; issue 373, pp 611-622
Nair RR, Solway J, Boyd DD.2006. Expression cloning identifies transgelin (SM22) as a novel repressor of 92-kDa type IV collagenase (MMP-9) expression. JBiol Chem. vo 281, issue 36, pp 26424-6436.
Nicolas Duport.2008. Epidemiological data on cancer cervical-State of knowledge. Health monitoring Institute, pp 1-4.
Noriyuki M, Sumi T, Zhi X, et al.2007. Vascular endothelial growth factor, matrix metalloproteinases, and cyclooxygenase-2 influence prognosis of uterine cervical cancer in young women. Int J Oncol, vo 31, issue 3, pp 531-536
Rundhaug JE. Matrix metalloproteinases and angiogenesis.2005. J Cell Mol Med, issue 9, pp 267-285
Sang-Hyuk Chung and Paul Lambert F.2009. Prevention and treatment of cervical cancer in mice using estrogen receptor antagonists. Medical Science, vo.106, issue 46,pp 19467-19472.
Sheu BC, Lien HC, Ho HN,et al.2007. Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. J.Cancer Res, vo 63, issue 19, pp 6537-6542.
Shusterman S, Maris JM.2005. Prospects for therapeutic inhibition of neuroblastoma angiogenesis. Cancer Lett; issue 228, pp 171-279.
Tamakoshi K., Kikkawa F., A. Nawa, Ishikawa H., Mizuno K., A. Tamakoshi, Yamagata S., N. Suganuma, Y. Tomoda 1995. Characterization of degrading extracellular matrix and its proteinase inhibitor in gynaecological cancer with clinically different metastatic form tissues. Cancer (Phila.), issue 76, pp 2565-2571
van der Stappen JW, AC Williams, Maciewicz RA, Paraskeva C.1996. Activation of cathepsin B, secreted by a colorectal cancer cells line requires a low pH and is mediated cathepsin D. Int J Cancer; issiue 67, pp 547-554
Yoshida S, Kajitani N, Satsuka A, Nakamura H, Sakai H.2008. Ras modifies proliferation and invasiveness of cells expressing human papillomavirus oncoproteins. J Virol vo 82, issue 17, pp 8820-8827
Yu J, Qian H, Li Y, et al.2007. Arsenic trioxide (As2O3) reduces the invasive and metastatic properties of cervical cancer cells in vitro and in vivo. J. Gynecol Oncol, vol06, issue 2, pp 400-406.
Yu W, Liu J, Xiong X, Ai Y, Wang H.2009. Expression of MMP9 and CD147 in invasive squamous cell carcinoma of the uterine cervix and their implication. Pathol Res; vo 205, issue 10, pp 709-715.